Novel lipid nanoparticle formulations for delivery of nucleic acids, having a piperidine ring and two chains with two carboxyl groups each

Novel PEG-free lipid nanoparticles with specific ionizable lipids improve mRNA delivery to spleen, lymph nodes, and muscle cells, addressing liver tropism and immune reactions, ensuring effective and safe therapeutic delivery.

WO2026234261A1PCT designated stage Publication Date: 2026-11-12CUREVAC SE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/063477
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2026-01-12
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Traditional mRNA lipid nanoparticle formulations exhibit strong liver tropism, leading to impaired delivery to non-liver tissues, and cause undesired immune reactions such as complement activation-related pseudo allergy and accelerated blood clearance, necessitating higher dosing and limiting clinical translation.

Method used

Development of novel, PEG-free lipid nanoparticles with specific ionizable lipids and optimized ratios to enhance delivery to spleen, lymph nodes, and muscle cells, reducing liver tropism and improving targeting to macrophages and dendritic cells, while maintaining stability and tolerability.

Benefits of technology

The novel nanoparticles achieve enhanced delivery to extrahepatic organs and immune cells, reducing liver accumulation, minimizing immune reactions, and ensuring effective therapeutic index without unacceptable toxicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000010_0001
    Figure IMGF000010_0001
  • Figure IMGF000013_0001
    Figure IMGF000013_0001
  • Figure IMGF000017_0001
    Figure IMGF000017_0001
Patent Text Reader

Abstract

The present invention provides novel ionizable lipids and novel lipid nanoparticles useful for the delivery of nucleic acids, related pharmaceutical compositions or vaccines as defined herein for use as a medicament, preferably a vaccine, for use in the treatment and / or prophylaxis of diseases, preferably cancer diseases.
Need to check novelty before this filing date? Find Prior Art

Description

CureVac SE / P396WO1 08thMay 2026NOVEL LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS, HAVING A PIPERIDINE RING AND TWO CHAINS WITH TWO CARBOXYL GROUPS EACHTECHNICAL FIELDThe present invention provides novel ionizable lipids and novel lipid nanoparticles useful for the delivery of nucleic acids, related pharmaceutical compositions or vaccines as defined herein for use as a medicament, preferably a vaccine, for use in the treatment and / or prophylaxis of diseases, preferably cancer diseases.SEQUENCE LISTINGThe present application is being filed along with a ST.26 sequence listing in XML format conforming to the rules of WIPO Standard ST.26. Said sequence listing has been filed as an electronic document when filing the instant application. The sequence listing information in the ST.26 XML format is incorporated herein by reference in its entirety.BACKGROUNDCancer is a major global health problem and is one of the leading causes of death worldwide. Traditional cancer treatments, such as surgery, chemotherapy, and radiation therapy, have limited efficacy and can cause significant side effects. Immunotherapy, which involves harnessing the power of the immune system to target cancer cells, has emerged as a promising new approach for the treatment of cancer. Despite significant advances in the development of cancer therapies, there remains a need for new and more effective treatments, particularly for those cancers that are resistant to existing therapies or have a poor prognosis.In recent years, mRNA has emerged as a promising therapeutic tool for the treatment of cancer and other diseases, as it can be used to direct the production of proteins that can inhibit or otherwise reduce the growth or survival of cancer cells. The advantages of using mRNA include transient expression and a non-transforming character -mRNA does not need to enter the nucleus to be expressed and moreover cannot integrate into the host genome, thereby eliminating the risk of oncogenesis.Two problems currently face the use of mRNA in therapeutic contexts. First, free RNAs are susceptible to nuclease digestion in plasma. Second, free RNAs have limited ability to gain access to the intracellular compartment where the relevant translation machinery resides. To overcome these challenges, various delivery strategies have been developed, including the provision and use of lipid nanoparticle formulations comprising ionizable lipids and pegylated lipids, encapsulating and thereby protecting the mRNA to block degradation and facilitate its uptake into target cells.Regarding biodistribution, a central limitation of existing traditional mRNA lipid nanoparticle formulations, including clinically validated mRNA lipid nanoparticle formulations, is the presence of a strong liver tropism, meaning high levels of expression are primarily detected in the liver, when administered to a subject in need. That is due to specific uptake mechanisms of clinically validated mRNA lipid nanoparticle formulations and due to the physiology of the liver, which leads to most of those lipid nanoparticles accumulating in liver tissue and cells after intravenous (i.v.) and even after intramuscular (i.m.) administration. As a result, mRNA delivery to non-liver tissue with traditional mRNA lipid nanoparticles is impeded by the natural liver tropism of said traditional mRNA lipid nanoparticle formulations. Moreover, because the liver acts to break down substances delivered to a subject in need, transfectionCureVac SE / P396WO1 2 / 219of non-liver tissue with traditional mRNA lipid nanoparticle formulations requires higher dosing to provide sufficient lipid nanoparticle load to overcome the liver and reach non-liver tissue. All in all, this liver tropism presents a critical bottleneck for the clinical translation of lipid nanoparticle mRNA-mediated therapy.Another disadvantage of traditional mRNA lipid nanoparticle formulations, including clinically validated mRNA lipid nanoparticle formulations, comprising pegylated lipids is the unexpected and undesired immune reactions, hypersensitivity reactions, complement activation-related pseudo allergy (CARPA), and accelerated blood clearance (ABC), caused e.g. by formation of anti-PEG antibodies following first and following repeated administration have been reported (review PMID 3716250, Tenchov, Sasso and Zhou, 2023).Further regarding biodistribution, the spleen is the largest secondary lymphoid organ in the body and is a site for antigen presentation, filtration of blood borne pathogens and activation of cellular immune responses within the bloodstream, making it a promising target for medicines for diseases involving these pathways. Further, lymph nodes, as organs of the lymphatic system and component of the adaptive immune system, housing lymphocytes, including B and T cells, are another promising target for medicines. One cell type within the spleen and lymph nodes of particular interest are macrophages. Macrophages have a broad role in maintaining homeostasis. E.g. dysregulation of macrophages can contribute to the generation of immunosuppressive tumor microenvironment in cancer, chronic inflammation in autoimmune disorders, and antigen presentation in cancer vaccine applications. Further, in this regard, dendritic cells are immune cells of interest in e.g. spleen and lymph nodes for transfection with artificial nucleic acids, preferably mRNA, wherein the artificial nucleic acid comprises at least one coding sequence encoding at least one (i) cancer or tumor antigen or epitope or (ii) therapeutic protein for use in the treatment or prevention of cancer or tumor diseases. Thusly, especially also macrophages and conventional type 1 dendritic cells (cDC1 ) cells are interesting and important immune cell types of interest for transfection with artificial nucleic acids, preferably mRNA, wherein the artificial nucleic acid comprises at least one coding sequence encoding at least one (i) cancer or tumor antigen or epitope or (ii) therapeutic protein for use in the treatment or prevention of cancer or tumor diseases.Accordingly, there is a constant requirement for novel, alternative and / or improved lipid nanoparticles and novel, alternative and / or improved ionizable lipids, for the treatment and / or prophylaxis of infectious diseases, for use in Molecular Therapy approaches providing a therapeutic protein, and also particularly this need is high in the field of cancer treatment and / or prophylaxis. Said novel, alternative and / or improved lipid nanoparticles and novel, alternative and / or improved ionizable lipids should offer one or more of the following properties: improved in vivo efficacy, improved transfection process, improved toxicity, being PEG free, improved costs, improved producibility, improved storage behavior at different temperatures, improved repetitive dosing tolerance for subjects in need, simplicity of design, reduced cell toxicity, better targeting ability, enhanced short-term and / or long-term immunity, better promotion of endosomal escape of mRNA molecule. Preferably, said novel, alternative and / or improved lipid nanoparticles should not show the natural and strong liver tropism of traditional mRNA lipid nanoparticles, but have a higher ratio in favor of spleen, lymph nodes like draining lymph nodes, and / or muscle cells of the injection site, also preferably having a cell tropism for macrophages and / or dendritic cells (preferably cDC1 ), when compared to reference lipid nanoparticle compositions. Thusly macrophages and / or cDC1 cells are interesting and important immune cell types of interest for transfection.With view to the above-mentioned disadvantages or technical problems of traditional lipid nanoparticles (see Background section), it is an object of the present invention to provide novel, alternative and / or improved ionizable lipids and / or novel, alternative and / or improved lipid nanoparticles for introducing artificial nucleic acids, preferablyCureVac SE / P396WO1 3 / 219mRNA into cells of primates, including humans, for the prophylaxis and / or treatment of aforementioned diseases, overcoming at least one of above-mentioned disadvantages or technical problems.It is another object of the present invention to provide improved PEG-free lipid nanoparticles for the delivery of artificial nucleic acids, preferably mRNA, to avoid aforementioned unexpected and undesired negative effects. Preferably, these PEG-free lipid nanoparticles provide optimal druglipid ratios, protect the nucleic acid from degradation and clearance in serum, be suitable for systemic or local delivery, and provide optimal intracellular delivery of the nucleic acid. In addition, these PEG-free lipid nanoparticles comprising artificial nucleic acids, preferably mRNA should be well-tolerated and provide an adequate therapeutic index, such that patient treatment at an effective dose of the nucleic acid is not associated with unacceptable toxicity and / or risk to the patient. It is still another object of the present invention, to provide novel, alternative and / or improved ionizable lipids and / or novel, alternative and / or improved lipid nanoparticles, preferably PEG-free, with a reduced liver tropism, that can effectively target artificial nucleic acid delivery, preferably mRNA delivery, to extrahepatic organs and cells, preferably as the spleen, lymph nodes like draining lymph nodes and / or muscle cells of the injection site, also preferably having also a cell tropism for macrophages and / or dendritic cells (preferably cDC1 ), at an increased ratio than reference lipid nanoparticles or traditional lipid nanoparticles, preferably when administered intravenously or intramuscularly.It is a further object of the invention to provide novel, alternative and / or improved lipid nanoparticles that transfect macrophages and / or cDC1 cells with artificial nucleic acids, preferably mRNA, wherein the artificial nucleic acid comprises at least one coding sequence encoding at least one (i) cancer or tumor antigen or epitope or (ii) therapeutic protein for use in the treatment or prevention of cancer or tumor diseases at a higher level than reference lipid nanoparticles or traditional lipid nanoparticles, preferably when administered intramuscularly.It is a further object of the invention to provide novel, alternative and / or improved lipid nanoparticles that transfect macrophages and / or cDC1 cells with artificial nucleic acids, preferably mRNA, wherein the artificial nucleic acid comprises at least one coding sequence encoding at least one (i) cancer or tumor antigen or epitope or (ii) therapeutic protein for use in the treatment or prevention of cancer or tumor diseases at a higher level than reference lipid nanoparticles or traditional lipid nanoparticles, preferably when administered intravenously.It is still another object of the present invention, to provide novel, alternative and / or improved ionizable lipids and / or novel, alternative and / or improved lipid nanoparticles, with a reduced liver tropism, that can effectively target artificial nucleic acid delivery, preferably mRNA delivery to extrahepatic organs and cells, preferably as the spleen, lymph nodes like draining lymph nodes and / or muscle cells of the injection site, at an increased ratio than reference lipid nanoparticles or traditional lipid nanoparticles, when administered intramuscularly.It is a further object of the invention to provide novel, alternative and / or improved lipid nanoparticles that have a higher ratio of spleen, lymph node (preferably draining lymph node), and / or muscle cell of the injection site delivery, preferably having also a cell tropism for macrophages and / or dendritic cells (preferably cDC1 ), when compared to reference lipid nanoparticles or traditional lipid nanoparticles, preferably when administered intramuscularly. It is yet another object of the invention to provide novel, alternative and / or improved lipid nanoparticles that have a high spleen to liver ratio, preferably after intramuscular injection. A next object of the invention is to provide novel, alternative and / or improved lipid nanoparticles that have a high draining lymph node to liver ratio, preferably afterCureVac SE / P396WO1 4 / 219intramuscular injection. Another object of the invention to provide novel, alternative and / or improved lipid nanoparticles that have a high site of injection muscle to liver ratio, preferably after intramuscular injection. A further object of the invention is the provision of novel lipid nanoparticles having enhanced physiochemical properties including stability upon freezing and thawing. A next object of the invention is the provision of novel lipid nanoparticles having enhanced physiochemical properties including stability upon lyophilization and reconstitution. Another object of the invention is the provision of novel lipid nanoparticles having enhanced physiochemical properties including stability upon short- and long-term storage.CureVac SE / P396WO1 5 / 219SUMMARY OF THE INVENTIONThe above-mentioned objects are solved by the underlying description and the accompanying claims. In particular, the objects of the invention are solved by providing novel, alternative and / or improved ionizable lipids and / or novel, alternative and / or improved lipid nanoparticles comprising said novel ionizable lipids, pharmaceutical compositions, kits or kits of parts, methods for preventing, ameliorating or treating a disease or condition in a subject in need, and methods of reducing or inhibiting tumor growth in a subject in need, methods of inducing an antigen-specific immune response in a subject in need, and ionizable lipids for use as a medicament and / or for use in the prevention or treatment of a cancer disease.The present invention provides novel ionizable lipids (e.g., compound of Formula (I)), lipid nanoparticles comprising said novel ionizable lipids, and related methods of delivering therapeutic and / or prophylactic agents (artificial nucleic acids, preferably mRNA) with the lipid nanoparticles described herein. The inventors surprisingly found that the combination of (i) specific and novel ionizable lipids with (ii) specific and novel ratios lead to lipid nanoparticles having several surprising and unexpected beneficial effects, amongst other a higher tropism to spleen, draining lymph nodes and / or muscle tissue of the injection site.DEFINITIONSFor the sake of clarity and readability, the following scientific background information and definitions are provided. Any technical features mentioned herein or disclosed thereby can be part of or may be read on each and every embodiment of the invention. Additional definitions and explanations can be provided in the context of this disclosure.Unless defined otherwise, or unless the specific context requires otherwise, all technical terms used herein have the same meaning as is commonly understood by a person skilled in the relevant technical field.Unless the context indicates or requires otherwise, the words “comprise”, “comprises” and “comprising” and similar expressions are to be construed in an open and inclusive sense, as “including, but not limited to” in this description and in the claims. It also needs to be understood that for the purposes of the present invention, the term “consisting of’ is considered to be a preferred embodiment of the term “comprising”. If hereinafter a group is defined to comprise at least a certain number of embodiments, this is also meant to encompass a group which preferably consists of these embodiments only.The expressions, “one embodiment”, “an embodiment”, “a specific embodiment” and the like mean that a particular feature, property or characteristic, or a particular group or combination of features, properties or characteristics, as referred to in combination with the respective expression, is present in at least one of the embodiments of the invention. The occurrence of these expressions in various places throughout this description do not necessarily refer to the same embodiment. Moreover, the particular features, properties or characteristics may be combined in any suitable manner in one or more embodiments.The singular forms “a”, “an” and “the” should be understood as to include plural references unless the context clearly dictates otherwise.CureVac SE / P396WO1 6 / 219Percentages in the context of numbers should be understood as relative to the total number of the respective items. In other cases, and unless the context dictates otherwise, percentages should be understood as percentages by weight (wt-%), volume (vol.-%) or percentages by mole (mol.-%).Adjuvant / adjuvant component: An adjuvant or an adjuvant component in the broadest sense is typically a (e.g. pharmacological or immunological) agent or composition that may modify, e.g. enhance, the efficacy of other agents, such as a drug or vaccine. Conventionally the term refers in the context of the invention to a compound or composition that serves as a carrier or auxiliary substance for immunogens and / or other pharmaceutically active compounds. It is to be interpreted in a broad sense and refers to a broad spectrum of substances that are able to increase the immunogenicity of antigens incorporated into or co-administered with an adjuvant in question. In the context of the present invention an adjuvant will preferably enhance the specific immunogenic effect of the active agents of the present invention. Typically, “adjuvant” or “adjuvant component” has the same meaning and can be used mutually. Adjuvants may be divided, e.g., into immunopotentiators, antigenic delivery systems or even combinations thereof. The term “adjuvant” is typically understood not to comprise agents which confer immunity by themselves. An adjuvant assists the immune system unspecifically to enhance the antigen-specific immune response by e.g. promoting presentation of an antigen to the immune system or induction of an unspecific innate immune response. Furthermore, an adjuvant may preferably e.g. modulate the antigen-specific immune response by e.g. shifting the dominating Th2-based antigen specific response to a more Th1-based antigen specific response or vice versa. Accordingly, an adjuvant may favorably modulate cytokine expression / secretion, antigen presentation, type of immune response et cetera.The term “antibody” as used herein, includes both an intact antibody and an antibody fragment. Typically, an intact “antibody” is an immunoglobulin that specifically binds to a particular antigen. An antibody may be a member of any immunoglobulin class, including any of the human classes: IgG, IgM, IgE, IgA and IgD. Typically, an intact antibody is a tetramer. Each tetramer consists of two identical pairs of polypeptide chains, each pair having a “light” chain and a “heavy” chain. An “antibody fragment” includes a portion of an intact antibody, such as the antigen-binding or variable region of an antibody. Examples of antibody fragments include Fab, Fab’, F(ab’) 2 and Fv fragments; triabodies; tetrabodies; linear antibodies; single-chain antibody molecules; and multi specific antibodies formed from antibody fragments. E.g., the antibody fragments comprise isolated fragments, “Fv” fragments consisting of heavy and light chain variable regions, recombinant single chain polypeptide molecules in which the light and heavy chain variable regions are linked together by a peptide linker (“ScFv Proteins”) and minimal recognition units consisting of amino acid residues that mimic the hypervariable region. Examples of antigen-binding fragments of an antibody include, but are not limited to, Fab fragment, Fab’ fragment, F (ab’) 2 fragment, scFv fragment, Fv fragment, dsFv diabody, dAb fragment, fragment Fd’, Fd fragment and an isolated complementarity determining region (CDR). Suitable antibodies that may be encoded by the therapeutic RNA of the invention include monoclonal antibodies, polyclonal antibodies, antibody mixtures or cocktails, human or humanized antibodies, chimeric antibodies, Fab fragments, or bispecific antibodies. In the context of the invention, an antibody may be provided by the at least one therapeutic RNA of the inventive combination / composition.The term “antigen” in the context of the present invention refers typically to a substance which may be recognized by the immune system, preferably by the adaptive immune system, and is capable of triggering an antigen-specific immune response, e.g. by formation of antibodies and / or antigen-specific T cells as part of an adaptive immune response. Typically, an antigen may be or may comprise a peptide or protein which may be presented by the MHC to T-cells. In the sense of the present invention an antigen may be the product of translation of a provided nucleic acid molecule, preferably an mRNA as defined herein. In this context, also fragments, variants and derivatives ofCureVac SE / P396WO1 7 / 219peptides and proteins comprising at least one epitope are understood as antigen. Accordingly, the term “antigen” as used herein will be recognized and understood by the person of ordinary skill in the art, and is e.g. intended to refer to a substance which may be recognized by the immune system, preferably by the adaptive immune system, and is capable of triggering an antigen-specific immune response, e.g. by formation of antibodies and / or antigenspecific T cells as part of an adaptive immune response. Typically, an antigen may be or may comprise a peptide or protein which may be presented by the MHC to T-cells. Also fragments, variants and derivatives of peptides or proteins derived from e.g. cancer antigens comprising at least one epitope may be understood as antigens. In the context of the present invention, an antigen may be the product of translation of a provided therapeutic RNA (e.g. coding RNA, replicon RNA, mRNA). The term “antigenic peptide or protein” will be recognized and understood by the person of ordinary skill in the art, and is e.g. intended to refer to a peptide or protein derived from a (antigenic) protein which may stimulate the body’s adaptive immune system to provide an adaptive immune response. Therefore an “antigenic peptide or protein” comprises at least one epitope or antigen of the protein it is derived from (e.g. a tumor antigen, a viral antigen, a bacterial antigen, a protozoan antigen). In the context of the invention, an antigen may be provided by the at least one therapeutic RNA of the inventive combination / composition.The terms “administration” or “administering” refer to providing a composition to a subject in a manner that permits the composition to have its intended effect. Administration may be performed by intramuscular injection, intravenous injection, intratumoral injection, inhalation, or any other suitable route as indicated herein, preferably intramuscular injection.As used herein, a “compound” means a chemical substance, which is a material consisting of molecules having essentially the same chemical structure and properties. For a small molecular compound, the molecules are typically identical with respect to their atomic composition and structural configuration. For a macromolecular or polymeric compound, the molecules of a compound are highly similar but not all of them are necessarily identical. For example, a segment of a polymer that is designated to consist of 50 monomeric units may also contain individual molecules with e.g. 48 or 53 monomeric units.Derivative of a protein or peptide: A derivative of a protein or peptide is typically understood to be a molecule that is derived from another molecule, such as said peptide or protein. A “derivative” of a peptide or protein also encompasses fusions comprising a peptide or protein used in the present invention. For example, the fusion comprises a label, such as, for example, an epitope, e.g., a FLAG epitope or a V5 epitope. For example, the epitope is a FLAG epitope. Such a tag is useful for, for example, purifying the fusion protein.Any reference to a compound or moiety having a functional group which is ionizable (“ionizable compound” or “ionizable moiety”) under physiological conditions should be understood as including the ionized form of the respective compound or moiety. Vice versa, any reference to a compound or moiety having an ionized functional group which may also exist in the non-ionized form under physiological conditions should be understood as including the non-ionized form of the respective compound or moiety. For example, the disclosure of a compound having a carboxyl group should be interpreted as referring to the respective compound with non-ionized carboxyl group or with the ionized carboxylate group.As used herein, the term “covalently” refers to a linkage or conjugation by a chemical bond, i.e. through direct covalent chemical bonding, i.e. not through electrostatic association or interactions or the like.CureVac SE / P396WO1 8 / 219The term “about” is used when parameters or values do not necessarily need to be identical, i.e. 100% the same. Accordingly, “about” means, that a parameter or values may or may not diverge by 0.1% to 5%, preferably by 0% (i.e. preferably being identical with the value given after “about”) and also preferably by 0.1% to 5%; in particular, by 0.5%, 1%, 2%, 3%, 4%, or 5%. The skilled person will know that e.g. certain parameters or values may slightly vary based on the method how the parameter was determined. For example, if a certain parameter or value is defined herein to have e.g. a length of “about 1000 nucleotides”, the length may diverge by 0.1% to 5%, preferably by 0.1% to 5%; in particular, by 0.5%, 1%, 2%, 3%, 4%, or 5%. Accordingly, the skilled person will know that in that specific example, the length may diverge by 1 to 200 nucleotides, preferably by 1 to 100 nucleotides; in particular, by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 nucleotides. In other words, the term “about” most preferably refers to the exact values or parameters as given after the term “about”, but also preferably to values or parameters diverging as described above (i.e. about 1 mol% most preferably means 1% but the value may also diverge as described above).A “lipid”, as used herein, refers to a group of organic compounds that are derivatives of fatty acids (e.g., esters) and are generally characterized by being insoluble in water but soluble in many organic solvents. Lipids are usually divided in at least three classes: (1 ) “simple lipids” which include fats and oils as well as waxes; (2) “compound lipids” which include phospholipids and glycolipids; and (3) “derived lipids” such as sterols. Regarding glycolipids, in certain embodiments, the LNP comprises glycolipids (e.g., monosialoganglioside GM1). A lipidoid compound, also simply referred to as lipidoid, is a lipid-like compound, i.e. an amphiphilic compound with lipid-like physical properties. In the context of the present invention, the term lipid is considered to encompass lipidoids.In this context, the prefix “poly-” refers to a plurality of atoms or groups having the respective property in a compound. If put in parenthesis, the presence of a plurality is optional. For example, (poly)cationic means cationic and / or polycationic. However, the absence of the prefix should not be interpreted such as to exclude a plurality. For example, a polycationic compound is also a cationic compound and may be referred to as such.The term “molecule” may either be used as a synonym for “compound” or for an individual (i.e. a single) molecule. In the context of the present invention, the term “modification” or “nucleoside modification” refers to nucleic acids such as mRNAs or molecules comprising nucleosides which do not normally occur in native mRNA, preferably nonnatural nucleosides. In particular, the term preferably refers to mRNA nucleosides other than adenine, guanine, cytosine, uracil and thymine.The term “nucleoside” generally refers to compounds consisting of a sugar, usually ribose or deoxyribose, and a purine or pyrimidine base. The term “nucleotide” generally refers to a nucleoside comprising a phosphate group attached to the sugar.Immune system: The immune system may protect organisms from infection. If a pathogen breaks through a physical barrier of an organism and enters this organism, the innate immune system provides an immediate, but non-specific response. If pathogens evade this innate response, vertebrates possess a second layer of protection, the adaptive immune system. Here, the immune system adapts its response during an infection to improve its recognition of the pathogen. This improved response is then retained after the pathogen has been eliminated, in the form of an immunological memory, and allows the adaptive immune system to mount faster and stronger attacks each time this pathogen is encountered. According to this, the immune system comprises the innate and the adaptive immune system. Each of these two parts contains so called humoral and cellular components.CureVac SE / P396WO1 9 / 219Immune response: An immune response may typically either be a specific reaction of the adaptive immune system to a particular antigen (so called specific or adaptive immune response) or an unspecific reaction of the innate immune system (so called unspecific or innate immune response). The invention relates to the core to specific reactions (adaptive immune responses) of the adaptive immune system. Particularly, it relates to adaptive immune responses to infections by viruses like e.g. Influenza viruses. Preferably, it also relates to immune responses after administration of a cancer vaccine to a cancer patient. The specific response can be supported by an additional unspecific reaction (innate immune response). Therefore, the invention also relates to a compound for simultaneous stimulation of the innate and the adaptive immune system to evoke an efficient adaptive immune response. The terms “increased”, “increasing”, “increase”, “improved”, “improvement”, “improving”, “higher” and the like as used herein, are used herein to generally means an increase by a statistically significant amount. In some aspects and embodiments, the terms “increased” or “improved” means an increase or improvement of at least 10% as compared to a reference level, for example an increase or improvement of at least about 10%, at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90% or up to and including a 100% increase or any improvement between 10-100% as compared to a reference level, standard, or control. Other examples of “increased”, “higher” or “improved” includes an increase of at least about 2-fold, at least about 5-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, at least about 30-fold, at least about 35-fold, at least about 40-fold, at least about 45-fold, at least about 50-fold, at least about 55-fold, at least about 60-fold, at least about 65-fold, at least about 70-fold, at least about 75-fold, at least about 80-fold, at least about 85-fold, at least about 90-fold, at least about 95-fold, at least about 100-fold, at least about 125-fold, at least about 150-fold, at least about 175-fold, at least about 200-fold, at least about 225-fold, at least about 250-fold, at least about 275-fold, at least about 300-fold, at least about 325-fold, at least about 350-fold, at least about 375-fold, at least about 400-fold, at least about 425-fold, at least about 450-fold, at least about 475-fold, at least about 500-fold, or more as compared to a reference level.Adaptive immune system: The adaptive immune system is composed of highly specialized, systemic cells and processes that eliminate or prevent pathogenic growth. The adaptive immune response provides the vertebrate immune system with the ability to recognize and remember specific pathogens (to generate immunity), and to mount stronger attacks each time the pathogen is encountered. The system is highly adaptable because of somatic hypermutation (a process of increased frequency of somatic mutations), and V(D)J recombination (an irreversible genetic recombination of antigen receptor gene segments). This mechanism allows a small number of genes to generate a vast number of different antigen receptors, which are then uniquely expressed on each individual lymphocyte. Because the gene rearrangement leads to an irreversible change in the DNA of each cell, all of the progeny (offspring) of that cell will then inherit genes encoding the same receptor specificity, including the Memory B cells and Memory T cells that are the keys to long-lived specific immunity. Immune network theory is a theory of how the adaptive immune system works, that is based on interactions between the variable regions of the receptors of T cells, B cells and of molecules made by T cells and B cells that have variable regions.Adaptive immune response: The adaptive immune response is typically understood to be antigen-specific. Antigen specificity allows for the generation of responses that are tailored to specific antigens, pathogens or pathogen-infected cells. The ability to mount these tailored responses is maintained in the body by “memory cells”. Should a pathogen infect the body more than once, these specific memory cells are used to quickly eliminate it. In this context, the first step of an adaptive immune response is the activation of naive antigen-specific T cells or different immuneCureVac SE / P396WO1 10 / 219cells able to induce an antigen-specific immune response by antigen-presenting cells. This occurs in the lymphoid tissues and organs through which naive T cells are constantly passing. Cell types that can serve as antigen-presenting cells are inter alia dendritic cells, macrophages, and B cells. Each of these cells has a distinct function in eliciting immune responses. Dendritic cells take up antigens by phagocytosis and macropinocytosis and are stimulated by contact with e.g. a foreign antigen to migrate to the local lymphoid tissue, where they differentiate into mature dendritic cells. Macrophages ingest particulate antigens such as bacteria and are induced by infectious agents or other appropriate stimuli to express MHC molecules. The unique ability of B cells to bind and internalize soluble protein antigens via their receptors may also be important to induce T cells. Presenting the antigen on MHC molecules leads to activation of T cells which induces their proliferation and differentiation into armed effector T cells. The most important function of effector T cells is the killing of infected cells by CD8+ cytotoxic T cells and the activation of macrophages by Th1 cells which together make up cell-mediated immunity, and the activation of B cells by both Th2 and Th1 cells to produce different classes of antibody, thus driving the humoral immune response. T cells recognize an antigen by their T cell receptors which do not recognize and bind antigen directly but instead recognize short peptide fragments e.g. of pathogen-derived protein antigens, which are bound to MHC molecules on the surfaces of other cells.Cellular immunity / cellular immune response: Cellular immunity relates typically to the activation of macrophages, natural killer cells (NK), antigen-specific cytotoxic T-lymphocytes, and the release of various cytokines in response to an antigen. In a more general way, cellular immunity is not related to antibodies but to the activation of cells of the immune system. A cellular immune response is characterized e.g. by activating antigen-specific cytotoxic T-lymphocytes that are able to induce apoptosis in body cells displaying epitopes of an antigen on their surface, such as virus-infected cells, cells with intracellular bacteria, and cancer cells displaying tumor antigens; activating macrophages and natural killer cells, enabling them to destroy pathogens; and stimulating cells to secrete a variety of cytokines that influence the function of other cells involved in adaptive immune responses and innate immune responses.Humoral immunity / humoral immune response: Humoral immunity refers typically to antibody production and the accessory processes that may accompany it. A humoral immune response may be typically characterized, e.g., by Th2 activation and cytokine production, germinal center formation and isotype switching, affinity maturation and memory cell generation. Humoral immunity also typically may refer to the effector functions of antibodies, which include pathogen and toxin neutralization, classical complement activation, and opsonin promotion of phagocytosis and pathogen elimination.CureVac SE / P396WO1 11 / 219nucleic acid, an immunostimulatory RNA (isRNA), a CpG-DNA, an antibacterial agent, or an anti-viral agent. Typically a response of the innate immune system includes recruiting immune cells to sites of infection, through the production of chemical factors, including specialized chemical mediators, called cytokines; activation of the complement cascade; identification and removal of foreign substances present in organs, tissues, the blood and lymph, by specialized white blood cells; activation of the adaptive immune system through a process known as antigen presentation; and / or acting as a physical and chemical barrier to infectious agents.In general, the term “ionizable” means, unless a different meaning is clear from the specific context, that the respective structure bears a positive charge, either permanently or not permanently but in response to certain conditions such as e.g. pH. Thus, the term “ionizable” covers both “permanently cationic” and “cationisable” or “cationic” and vice versa. The term “cationisable” as used herein means that a compound, or group or atom, is positively charged at a lower pH and uncharged at a higher pH of its environment. Also, in non-aqueous environments where no pH value can be determined, a cationisable compound, group or atom is positively charged at a high hydrogen ion concentration and uncharged at a low concentration or activity of hydrogen ions. It depends on the individual properties of the cationisable or polycationisable compound, in particular the pKa of the respective cationisable group or atom, at which pH or hydrogen ion concentration it is charged or uncharged. In diluted aqueous environments, the fraction of cationisable compounds, groups or atoms bearing a positive charge may be estimated using the so-called Henderson-Hasselbalch equation which is well-known to a person skilled in the art. E.g., if a compound or moiety is cationisable, it is preferred that it is positively charged ata pH value of about 1 to 9, preferably 4 to 9, 5 to 8 or even 6 to 8, more preferably of a pH value of or below 9, of or below 8, of or below 7, most preferably at physiological pH values, e.g. about 7.3 to 7.4, i.e. under physiological conditions, particularly under physiological salt conditions of the cell in vivo. In preferred embodiments, it is preferred that the cationisable compound or moiety is predominantly neutral at physiological pH values, e.g. about 7.0-7.4, but becomes positively charged at lower pH values. In some embodiments, the preferred range of pKa for the cationisable compound or moiety is about 5 to about 7. In some embodiments, the protonatable lipids have a pKa of the protonatable group in the range of about 5 to about 8, preferably about 6 to about 7. In a most preferred embodiment, the protonatable lipid has a pKa of the protonatable group in the range of about 6.4 to 6.7, preferably 6.582 (CIL86).Unless a different meaning is clear from the specific context, the term “cationic” means that the respective structure bears a positive charge, either permanently, or not permanently but in response to certain conditions such as pH. Thus, the term “cationic” covers both "permanently cationic" and “cationisable”. For example, a compound or moiety with a primary, secondary or tertiary amino group is cationic, and more specifically, cationisable, as it may exist predominantly in the positively charged state under physiological conditions.As used herein, “permanently cationic” means that the respective compound, or group or atom, is positively charged at any pH value or hydrogen ion activity of its environment. Very often, the positive charge results from the presence of a quaternary nitrogen atom. Where a compound carries a plurality of such positive charges, it may be referred to as permanently polycationic, which is a subcategory of permanently cationic.Similarly, the terms “anionic”, “anionizable” and “permanently anionic” are used to have the analog meaning as “cationic”, “cationisable” and “permanently cationic”, except that the charge of the respective compound, group or atom is negative rather than positive.As used herein, the term “ionizable lipid” has its ordinary meaning in the art and may refer to a lipid comprising one or more charged moieties. In some embodiments, an ionizable lipid may be positively charged or negativelyCureVac SE / P396WO1 12 / 219charged. An ionizable lipid may be positively charged, in which case it can be referred to as “ionizable lipid”. Accordingly, the terms “cationic lipid” and “ionizable lipid” may be used herein throughout the whole specification interchangeably. In certain embodiments, an ionizable lipid molecule may comprise an amine group and can be referred to as an ionizable amino lipid. As used herein, a “charged moiety” is a chemical moiety that carries a formal electronic charge, e.g., monovalent (+1, or -1), divalent (+2, or -2), trivalent (+3, or -3), etc. The charged moiety may be anionic (i.e., negatively charged) or cationic (i.e., positively charged). Examples of positively charged moieties include amine groups (e.g., primary, secondary, and / or tertiary amines), ammonium groups, pyridinium group, guanidine groups, and imidazolium groups. In a particular embodiment, the charged moieties comprise amine groups. Examples of negatively- charged groups or precursors thereof, include carboxylate groups, sulfonate groups, sulfate groups, phosphonate groups, phosphate groups, hydroxyl groups, and the like. The charge of the charged moiety may vary, in some cases, with the environmental conditions, for example, changes in pH may alter the charge of the moiety, and / or cause the moiety to become charged or uncharged. In general, the charge density of the molecule may be selected as desired. It should be understood that the terms “charged” or “charged moiety” does not refer to a “partial negative charge" or “partial positive charge" on a molecule. The terms “partial negative charge" and “partial positive charge" are given its ordinary meaning in the art. A “partial negative charge" may result when a functional group comprises a bond that becomes polarized such that electron density is pulled toward one atom of the bond, creating a partial negative charge on the atom. Those of ordinary skill in the art will, in general, recognize bonds that can become polarized in this way. In some embodiments, the ionizable lipid is an ionizable amino lipid, sometimes referred to in the art as an “ionizable cationic lipid” or “cationic ionizable lipid”. In one embodiment, the ionizable amino lipid may have a positively charged hydrophilic head and a hydrophobic tail that are connected via a linker structure.The expression “neutral”, when applied to a compound such as a lipid or a sterol, or to a group or moiety, either means that it is neither cationic nor anionic, such as a compound having no functional groups that are ionizable under physiological conditions as, for example, like a hydrocarbon; or it is both cationic and anionic, i.e. zwitterionic, under typical physiological conditions, such as a typical native phosphatidylcholine.Immunostimulatory RNA: An immunostimulatory RNA (isRNA) in the context of the invention may typically be an RNA that is able to induce an innate immune response itself. It usually does not have an open reading frame and thus does not provide a peptide-antigen or immunogen but elicits an innate immune response e.g. by binding to a specific kind of Toll-like-receptor (TLR) or other suitable receptors. However, of course also mRNAs having an open reading frame and coding for a peptide / protein (e.g. an antigenic function) may induce an innate immune response. The term “delivery”, as used herein, encompasses both local and systemic delivery. For example, delivery of an artificial nucleic acid, preferably a mRNA encompasses situations in which an artificial nucleic acid, preferably mRNA, is delivered to a target tissue and the encoded protein is expressed and retained within the target tissue (also referred to as “local distribution” or “local delivery”), and situations in which an mRNA is delivered to a target tissue and the encoded protein is expressed and secreted into patient’s circulation system (e.g., serum) and systematically distributed and taken up by other tissues (also referred to as “systemic distribution” or “systemic delivery). In other exemplary situations, an artificial nucleic acid, preferably mRNA, is delivered systemically and is taken up in a wide variety of cells and tissues in vivo. In some exemplary situations, the delivery is intravenous, intramuscular or subcutaneous, preferably intramuscular. Typically, an artificial nucleic acid, preferably mRNA, comprised within the lipid nanoparticles of the invention and intended for “delivery”, is also termed a “cargo” sequence. The term “delivery” accordingly encompasses delivery of cargo mRNA to cells, organs, or tissues and the like.CureVac SE / P396WO1 13 / 219The term “derived from” as used throughout the present specification in the context of a nucleic acid, i.e. for a nucleic acid “derived from” (another) nucleic acid, means that the nucleic acid, which is derived from (another) nucleic acid, shares e.g. at least about 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or about 99% sequence identity with the nucleic acid from which it is derived. The skilled person is aware that sequence identity is typically calculated for the same types of nucleic acids, i.e. for DNA sequences or for RNA sequences. Thus, it is understood, if a DNA is “derived from” an RNA or if an RNA is “derived from” a DNA, in a first step the RNA sequence is converted into the corresponding DNA sequence (in particular by replacing U by T throughout the sequence) or, vice versa, the DNA sequence is converted into the corresponding RNA sequence (in particular by replacing the T by U throughout the sequence). Thereafter, the sequence identity of the DNA sequences or the sequence identity of the RNA sequences is determined. Preferably, a nucleic acid “derived from” a nucleic acid also refers to nucleic acid, which is modified in comparison to the nucleic acid from which it is derived, e.g. in order to increase RNA stability even further and / or to prolong and / or increase protein production. In the context of amino acid sequences, the term “derived from” means that the amino acid sequence, which is derived from (another) amino acid sequence, shares e.g. at least about 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or about 99% sequence identity with the amino acid sequence from which it is derived.B cell epitopes are typically fragments located on the outer surface of (native) protein or peptide antigens as defined herein, preferably having 5 to 15 amino acids, more preferably having 5 to 12 amino acids, even more preferably having 6 to 9 amino acids, which may be recognized by antibodies, i.e. in their native form.Such epitopes of proteins or peptides may furthermore be selected from any of the variants of such proteins or peptides mentioned herein. In this context antigenic determinants can be conformational or discontinuous epitopes which are composed of segments of the proteins or peptides as defined herein that are discontinuous in the amino acid sequence of the proteins or peptides as defined herein but are brought together in the three-dimensional structure or continuous or linear epitopes which are composed of a single polypeptide chain.A “tolerogenic composition” is a composition that promotes immune tolerance in cells or cellular systems to an antigen, wherein the antigen may be a self-antigen or a non-self-antigen. In other words, there is no immune response or a reduced immune response to the antigen. Contrary thereto, a vaccine composition according to the present invention induces an immune response to a specific antigen, namely the antigen encoded by the at least one nucleic acid, preferably mRNA. The antigen may also be a self-antigen or a non-self-antigen, and the overall aim of a vaccine composition of the present invention is to create a (strong) immune response to this antigen, wherein the overall aim of a tolerogenic composition is to at least partly, at best completely, suppress an immune response to this antigen.CureVac SE / P396WO1 14 / 219The term “antigen-providing mRNA” in the context of the invention may typically be an mRNA, having at least one open reading frame that can be translated by a cell or an organism provided with that mRNA. The product of this translation is a peptide or protein that may act as an antigen, preferably as an immunogen. The product may also be a fusion protein composed of more than one immunogen, e.g. a fusion protein that consist of two or more epitopes, peptides or proteins derived from the same or different virus-proteins or cancer-proteins, wherein the epitopes, peptides or proteins may be linked by linker sequences.“Isolated”: As used herein, the term “isolated”, in regard to a nucleic acid molecule, preferably an isolated mRNA, a protein, or a polypeptide, means that the nucleic acid molecule, preferably isolated mRNA, a protein, or polypeptide is in a condition other than its native environment, such as apart from blood and / or animal tissue. In some embodiments, an isolated nucleic acid molecule, preferably isolated mRNA, a protein, or polypeptide is substantially free of other nucleic acid molecules, proteins, or other polypeptides, particularly other nucleic acid molecules, proteins or polypeptides of animal origin. In some embodiments, the nucleic acid molecule, preferably isolated mRNA, a protein, or polypeptide can be in a highly purified form, i.e., greater than 95% pure or greater than 99% pure. When used in this context, the term “isolated” does not exclude the presence of the same nucleic acid molecule, protein or polypeptide in alternative physical forms, such as dimers or alternatively phosphorylated or derivatized forms. Isolated substances may also have varying levels of purity in reference to the substances from which they have been associated. Isolated substances and / or entities may also be separated from at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or more of the other components with which they were initially associated. In some embodiments, isolated agents are more than about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more than about 99% pure. As used herein, a substance is “pure” if it is substantially free of other components. In the context of the present invention, aspects, embodiments, description and claims, the term “mRNA” preferably means an “isolated mRNA” and vice versa.The terms “RNA” and “mRNA” will be recognized and understood by the person of ordinary skill in the art and are e.g. intended to be a ribonucleic acid molecule, i.e. a polymer consisting of nucleotides. These nucleotides are usually adenosine-monophosphate, uridine-monophosphate, guanosine-monophosphate and cytidinemonophosphate monomers which are connected to each other along a so-called backbone. The backbone is formed by phosphodiester bonds between the sugar, i.e. ribose, of a first and a phosphate moiety of a second, adjacent monomer. The specific succession of the monomers is called the RNA-sequence. The mRNA (messenger RNA) usually provides the nucleotide sequence that may be translated into an amino-acid sequence of a particular peptide or protein after administration to the subject in need.The terms “artificial nucleic acid” or “nucleic acid” mean any compound comprising, or consisting of, DNA or RNA. The term may be used for a polynucleotide and / or oligonucleotide. Wherever herein reference is made to a nucleic acid or nucleic acid sequence encoding a particular protein and / or peptide, said nucleic acid or nucleic acid sequence, respectively, preferably also comprises regulatory sequences allowing in a suitable host, e.g. a human being, its expression, i.e. transcription and / or translation of the nucleic acid sequence encoding the particular protein or peptide.A “messenger RNA” or “mRNA” in preferred embodiments is an “artificial mRNA”. An “artificial mRNA” in the context of the entire disclosure of the invention herein means an mRNA molecule, that does not occur naturally. A “nucleic acid” of the invention in preferred embodiments is an artificial mRNA molecule i.e. a non-natural occurring mRNA molecule. Such mRNA molecule may be non-natural due to its individual sequence (which does not occur naturally)CureVac SE / P396WO1 15 / 219and / or due to other modifications, e.g. structural modifications of nucleotides which do not occur naturally. Typically, artificial mRNA molecules may be designed and / or generated by genetic engineering methods to correspond to a desired artificial sequence of nucleotides (heterologous sequence). In this context an artificial sequence is usually a sequence that may not occur naturally, i.e. it differs from the wild type sequence by at least one nucleotide. The term “wild type” may be understood as a sequence occurring in nature. Further, none of the terms i.e. the term “artificial nucleic acid” or “artificial mRNA” are restricted to mean “one single molecule” but is, typically, understood to comprise an ensemble of identical molecules. Accordingly, it may relate to a plurality of identical molecules contained in an aliquot.The terms “heterologous” or “heterologous sequence” as used throughout the present specification in the context of a nucleic acid sequence or an amino acid sequence refers to a sequence (e.g. DNA, RNA, amino acid) will be recognized and understood by the person of ordinary skill in the art, and is intended to refer to a sequence that is derived from another gene, from another allele, from another species. Two sequences are typically understood to be “heterologous” if they are not derivable from the same gene or in the same allele. I.e., although heterologous sequences may be derivable from the same organism, they naturally (in nature) do not occur in the same nucleic acid molecule, such as e.g. in the same RNA or protein.Monocistronic mRNA: A monocistronic mRNA may typically be an mRNA, that comprises only one open reading frame (coding sequence or coding region). An open reading frame in this context is a sequence of several nucleotide triplets (codons) that can be translated into a peptide or protein.Bi- / multicistronic mRNA: mRNA, that typically may have two (bicistronic) or more (multicistronic) open reading frames (ORF) (coding regions or coding sequences). An open reading frame in this context is a sequence of several nucleotide triplets (codons) that can be translated into a peptide or protein. Translation of such an mRNA yields two (bicistronic) or more (multicistronic) distinct translation products (provided the ORFs are not identical). For expression in eukaryotes such mRNAs may for example comprise an internal ribosomal entry site (IRES) sequence. The terms "substituted" or “optionally substituted” refer to the replacement of one or more hydrogen radicals in a given structure with the radical of a specified substituent including, but not limited to: halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, thiol, alkylthio, oxo, thioxy, arylthio, alkylthioalkyl, arylthioalkyl, alkylsulfonyl, alkylsulfonylalkyl, arylsulfonylalkyl, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, trifluoromethyl, cyano, nitro, alkylamino, arylamino, alkylaminoalkyl, arylamino alkyl, aminoalkylamino, hydroxy, alkoxyalkyl, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, acyl, aralkoxycarbonyl, carboxylic acid, sulfonic acid, sulfonyl, phosphonic acid, aryl, heteroaryl, heterocyclic, and aliphatic. It is understood that the substituent may be further substituted. Exemplary substituents include amino, alkylamino, dialkylamino, and cyclic amino compounds.5’-Terminal Oligopyrimidine Tract (TOP): The 5’-terminal oligopyrimidine tract (TOP) is typically a stretch of pyrimidine nucleotides located at the 5’-terminal region of a nucleic acid molecule, such as the 5’-terminal region of certain mRNA molecules or the 5’-terminal region of a functional entity, e.g. the transcribed region, of certain genes. The sequence starts with a cytidine, which usually corresponds to the transcriptional start site, and is followed by a stretch of usually about 3 to 30 pyrimidine nucleotides. For example, the TOP may comprise 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or even more nucleotides. The pyrimidine stretch and thus the 5’-TOP ends one nucleotide 5’ to the first purine nucleotide located downstream of the TOP. Messenger RNA that contains a 5’-terminal oligopyrimidine tract is often referred to as TOP mRNA. Accordingly,CureVac SE / P396WO1 16 / 219genes that provide such messenger RNAs are referred to as TOP genes. TOP sequences have, for example, been found in genes and mRNAs encoding peptide elongation factors and ribosomal proteins.TOP motif: In the context of the present invention, a TOP motif is a nucleic acid sequence which corresponds to a 5’-TOP as defined above. Thus, a TOP motif in the context of the present invention is preferably a stretch of pyrimidine nucleotides having a length of 3-30 nucleotides. Preferably, the TOP motif consists of at least 3 pyrimidine nucleotides, preferably at least 4 pyrimidine nucleotides, preferably at least 5 pyrimidine nucleotides, more preferably at least 6 nucleotides, more preferably at least 7 nucleotides, most preferably at least 8 pyrimidine nucleotides, wherein the stretch of pyrimidine nucleotides preferably starts at its 5’-end with a cytosine nucleotide. In TOP genes and TOP mRNAs, the TOP motif preferably starts at its 5’-end with the transcriptional start site and ends one nucleotide 5’ to the first purine residue in said gene or mRNA. A TOP motif in the sense of the present invention is preferably located at the 5’-end of a sequence which represents a 5’-UTR or at the 5’-end of a sequence which codes for a 5’-UTR. Thus, preferably, a stretch of 3 or more pyrimidine nucleotides is called “TOP motif’ in the sense of the present invention if this stretch is located at the 5’-end of a respective sequence, such as the inventive mRNA, the 5’-UTR element of the inventive mRNA, or the nucleic acid sequence which is derived from the 5’-UTR of a TOP gene as described herein. In other words, a stretch of 3 or more pyrimidine nucleotides which is not located at the 5’-end of a 5’-UTR or a 5-UTR element but anywhere within a 5’-UTR or a 5’-UTR element is preferably not referred to as “TOP motif’.TOP gene: TOP genes are typically characterized by the presence of a 5’-terminal oligopyrimidine tract. Furthermore, most TOP genes are characterized by a growth-associated translational regulation. However, also TOP genes with a tissue specific translational regulation are known. As defined above, the 5’-UTR of a TOP gene corresponds to the sequence of a 5’-UTR of a mature mRNA derived from a TOP gene, which preferably extends from the nucleotide located 3’ to the 5’-CAP to the nucleotide located 5’ to the start codon. A 5’-UTR of a TOP gene typically does not comprise any start codons, preferably no upstream AUGs (uAUGs) or upstream open reading frames (uORFs). Therein, upstream AUGs and upstream open reading frames are typically understood to be AUGs and open reading frames that occur 5’ of the start codon (AUG) of the open reading frame that should be translated. The 5’-UTRs of TOP genes are generally rather short. The lengths of 5’-UTRs of TOP genes may vary between 20 nucleotides up to 500 nucleotides, and are typically less than about 200 nucleotides, preferably less than about 150 nucleotides, more preferably less than about 100 nucleotides. Exemplary 5’-UTRs of TOP genes in the sense of the present invention are the nucleic acid sequences extending from the nucleotide at position 5 to the nucleotide located immediately 5’ to the start codon (e.g. the ATG) in the sequences according to SEQ ID NO: 1-1363, SEQ ID NO:1395, SEQ ID NO:1421 and SEQ ID NO:1422 of international patent application W02013143700 or homologs or variants thereof, whose disclosure is incorporated herewith by reference. In this context a particularly preferred fragment of a 5’-UTR of a TOP gene is a 5’-UTR of a TOP gene lacking the 5’-TOP motif. The term “5’-UTR of a TOP gene” preferably refers to the 5’-UTR of a naturally occurring TOP gene.Fragment of a nucleic acid sequence, particularly an mRNA: A fragment of a nucleic acid sequence consists of a continuous stretch of nucleotides corresponding to a continuous stretch of nucleotides in the full-length nucleic acid sequence which is the basis for the nucleic acid sequence of the fragment, which represents at least 20%, preferably at least 30%, more preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, even more preferably at least 70%, even more preferably at least 80%, and most preferably at least 90% of the full-length nucleic acid sequence. Such a fragment, in the sense of the present invention, is preferably a functional fragment of the full-length nucleic acid sequence.CureVac SE / P396WO1 17 / 219Also, the term “fragment” in the context of nucleic acid sequences or genes refers to a continuous subsequence of the full-length reference (or “parent”) nucleic acid sequence or gene. In other words, a “fragment” may typically be a shorter portion of a full-length nucleic acid sequence or gene. Accordingly, a fragment, typically, consists of a sequence that is identical to the corresponding stretch within the full-length nucleic acid sequence or gene. The term includes naturally occurring fragments as well as engineered fragments. A preferred fragment of a sequence in the context of the present invention, consists of a continuous stretch of nucleic acids corresponding to a continuous stretch of entities in the nucleic acid or gene the fragment is derived from, which represents at least 20%, preferably at least 30%, more preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, even more preferably at least 70%, and even more preferably at least 80% of the total (i.e. full-length) nucleic acid sequence or gene from which the fragment is derived. A sequence identity indicated with respect to such a fragment preferably refers to the entire nucleic acid sequence or gene. Preferably, a “fragment” may comprise a nucleic acid sequence having a sequence identity of at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, preferably of at least 70%, more preferably of at least 80%, even more preferably at least 85%, even more preferably of at least 90% and most preferably of at least 95% or even 97%, to a reference nucleic acid sequence or gene that it is derived from.CureVac SE / P396WO1 18 / 219Also, in this context a fragment of a protein may typically comprise an amino acid sequence having a sequence identity of at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, preferably of at least 70%, more preferably of at least 80%, even more preferably at least 85%, even more preferably of at least 90% and most preferably of at least 95% or even 97%, with an amino acid sequence of the respective naturally occurring full-length protein.In the context of the present invention, a “fragment” or a “variant” of a protein or peptide may have at least 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% amino acid identity over a stretch of at least 10, at least 20, at least 30, at least 50, at least 75 or at least 100 amino acids of such protein or peptide. More preferably, a “fragment” or a “variant” of a protein or peptide as used herein is at least 40%, preferably at least 50%, more preferably at least 60%, more preferably at least 70%, even more preferably at least 80%, even more preferably at least 90%, most preferably at least 95% identical to the protein or peptide, from which the variant is derived. Full-length protein: The term “full-length protein” as used herein typically refers to a protein that substantially comprises the entire amino acid sequence of the naturally occurring protein. Nevertheless, substitutions of amino acids e.g. due to mutation in the protein are also encompassed in the term full-length protein.RNA In vitro transcription: The terms “RNA in vitro transcription” or “in vitro transcription” relate to a process wherein RNA is synthesized in a cell-free system (in vitro). DNA, particularly plasmid DNA, is used as template for the generation of mRNA transcripts. RNA may be obtained by DNA-dependent in vitro transcription of an appropriate DNA template, which according to the present invention is preferably a linearized plasmid DNA template. The promoter for controlling in vitro transcription can be any promoter for any DNA-dependent RNA polymerase. Particular examples of DNA-dependent RNA polymerases are the T7, T3, and SP6 RNA polymerases. A DNA template for in vitro RNA transcription may be obtained by cloning of a nucleic acid, in particular cDNA corresponding to the respective RNA to be in vitro transcribed and introducing it into an appropriate vector for in vitro transcription, for example into plasmid DNA. In a preferred embodiment of the present invention the DNA template is linearized with a suitable restriction enzyme before it is transcribed in vitro. The cDNA may be obtained by reverse transcription of mRNA or chemical synthesis. Moreover, the DNA template for in vitro RNA synthesis may also be obtained by gene synthesis. Methods for in vitro transcription are known in the art (see, e.g., Geall et al. (2013) Semin. Immunol. 25(2): 152-159; Brunelle et al. (2013) Methods Enzymol. 530:101-14). Reagents used in said method typically include:1 ) a linearized DNA template with a promoter sequence that has a high binding affinity for its respective RNA polymerase such as bacteriophage-encoded RNA polymerases;2) ribonucleoside triphosphates (NTPs) for the four bases (adenine, cytosine, guanine and uracil);3) optionally, a CAP analogue as defined above (e.g. m7G(5’)ppp(5’)G (m7G));4) a DNA-dependent RNA polymerase capable of binding to the promoter sequence within the linearized DNA template (e.g. T7, T3 or SP6 RNA polymerase);5) optionally, a ribonuclease (RNase) inhibitor to inactivate any contaminating RNase;6) optionally, a pyrophosphatase to degrade pyrophosphate, which may inhibit transcription;7) MgCl₂, which supplies Mg2+ions as a co-factor for the polymerase;8) a buffer to maintain a suitable pH value, which can also contain antioxidants (e.g. DTT), and / or polyamines such as spermidine at optimal concentrations.CureVac SE / P396WO1 19 / 219Identity of a sequence: In order to determine the percentage to which two sequences are identical, e.g. nucleic acid sequences or amino acid sequences as defined herein, preferably the amino acid sequences encoded by a nucleic acid sequence as defined herein or the amino acid sequences themselves, the sequences can be aligned in order to be subsequently compared to one another. Therefore, e.g. a position of a first sequence may be compared with the corresponding position of the second sequence. If a position in the first sequence is occupied by the same component (residue) as is the case at a position in the second sequence, the two sequences are identical at this position. If this is not the case, the sequences differ at this position. If insertions occur in the second sequence in comparison to the first sequence, gaps can be inserted into the first sequence to allow a further alignment. If deletions occur in the second sequence in comparison to the first sequence, gaps can be inserted into the second sequence to allow a further alignment. The percentage to which two sequences are identical is then a function of the number of identical positions divided by the total number of positions including those positions which are only occupied in one sequence. The percentage to which two sequences are identical can be determined using a mathematical algorithm. A preferred, but not limiting, example of a mathematical algorithm which can be used is the algorithm of Karlin et al. (1993), PNAS USA, 90:5873-5877 or Altschul etal. (1997), Nucleic Acids Res., 25:3389-3402. Such an algorithm is integrated in the BLAST program. Sequences which are identical to the sequences of the present invention to a certain extent can be identified by this program.As used herein, the term “lipid nanoparticle”, “LNP”, “lipid nanoparticle composition”, or “LNP composition” refers to a carrier or vehicle, formed by one or more lipid components, for payload (e.g., an artificial nucleic acid, protein, peptide, polypeptide, polynucleotide, or oligonucleotide, preferably mRNA) delivery in the context of pharmaceuticals. Further, as used herein the term “formulation” refers to a specific lipid nanoparticle composition of the disclosure. In other words the terms “formulation,” lipid nanoparticle”, “LNP,” “lipid nanoparticle composition,” or “LNP composition” are used herein interchangeably.In the context of the invention, a “composition” refers to any type of composition in which the specified ingredients may be incorporated, optionally along with any further excipients, usually with at least one pharmaceutically acceptable carrier or excipient. In the composition of the invention, the ionizable lipid may be present within, or as part of, lipid nanoparticles (LNPs). In other words, such composition comprises lipid nanoparticles, and the ionizable lipid is present in the lipid nanoparticles.As used herein, “physiological conditions” refers to an aqueous environment having a pH that is within the pH range known from human physiology, including both extra- and intracellular conditions. An approximation of this pH range is from about pH 1 to about pH 9. Depending on the context, physiological conditions may also refer to approximately neutral conditions, such as from about pH 5 to about pH 8.5, or from about pH 5.5 to about pH 8.A “peptide” means an oligomer or polymer of at least two amino acid monomers linked by peptide bonds. The term does not limit the length of the polymer chain of amino acids. A peptide may, for example, contain less than 50 monomer units. Longer peptides are also called polypeptides, typically having 50 to 600 monomeric units, more specifically 50 to 300 monomeric units.A “protein” comprises or consists of one or more polypeptides folded into a 3-dimensional form, facilitating a biological function.“Prevention” or “preventing” refers to inhibiting the onset of a disease in a subject or patient which may be at risk and / or predisposed to the disease but does not yet experience or display any or all of the pathology orCureVac SE / P396WO1 20 / 219symptomatology of the disease, and / or delaying the onset of the pathology or symptomatology of a disease in a subject or patient which may be at risk and / or predisposed to the disease but has not yet experienced or displayed any of the pathology or symptomatology of the disease. Prevention may be complete (no detectable symptoms) or partial, such that fewer symptoms are observed than would likely occur absent treatment.The term “ratio” or “ratios” as used herein when referring to relative amounts of two or more groups, amounts, numbers, quantity, or sizes between two or more things, refers to relative amounts of these groups, amounts, numbers, quantity, or sizes between two or more things, not limited to mole ratios (e.g., mole / mole), weight ratios (w / w, e.g., nanogram / nanogram, pg / pg, ng / pg), volume ratios (v / v, e.g., ml / ml), weight / volume (w / v, e.g., pg / pl, mg / ml), or pg PpLuc / mg tissue 1 / pg PpLuc / mg tissue 2. In essence, the term “ratio” or “ratios” as used herein describes the relationship between two groups or amounts that expresses how much bigger one is than the other. Accordingly, the term “increased ratio” in(a) the lipid nanoparticle is delivered to the spleen tissue in an increased ratio than the liver;(b) the lipid nanoparticle is delivered to draining lymph nodes in an increased ratio than the liver;(c) the lipid nanoparticle is delivered to the muscle tissue of the site of injection in an increased ratio than the liver;(d) the artificial nucleic acid, preferably mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in the spleen tissue than in liver tissue;(e) the artificial nucleic acid, preferably mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in the draining lymph nodes tissue than in liver tissue;(f) the artificial nucleic acid, preferably mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in the muscle tissue of the site of injection than in liver tissue;(g) the peptide or protein encoded by the artificial nucleic acid, preferably mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in the spleen tissue than in liver tissue;(h) the peptide or protein encoded by the artificial nucleic acid, preferably mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in the draining lymph nodes tissue than in liver tissue; and / or(i) the peptide or protein encoded by the artificial nucleic acid, preferably mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in the muscle tissue of the site of injection than in liver tissue;or in(a) the artificial nucleic acid, preferably mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in conventional type 1 dendritic cells (cDC1) as when compared to a reference lipid nanoparticle composition in which the ionizable lipid is replaced by a reference lipid and optionally the phosphatidylserine is replaced by cholesterol;(b) the artificial nucleic acid, preferably mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in macrophages as when compared to a reference lipid nanoparticle composition in which the ionizable lipid is replaced by a reference lipid and optionally the phosphatidylserine is replaced by cholesterol;(c) the peptide or protein encoded by the artificial nucleic acid, preferably mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in conventional type 1 dendritic cells (cDC1 ) as whenCureVac SE / P396WO1 21 / 219compared to a reference lipid nanoparticle composition in which the ionizable lipid is replaced by a reference lipid and optionally the phosphatidylserine is replaced by cholesterol; and / or(d) the peptide or protein encoded by the artificial nucleic acid, preferably mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in macrophages as when compared to a reference lipid nanoparticle composition in which the ionizable lipid is replaced by a reference lipid and optionally the phosphatidylserine is replaced by cholesterol;means, that (preferably intramuscular) administration of the lipid nanoparticle of the invention to a subject in need, the lipid nanoparticle preferably comprising an artificial nucleic acid, preferably mRNA, leads to an increased ratio, i.e. a greater proportion or a higher value of the above quantities that are measured. For example, the artificial nucleic acid, preferably mRNA is detected at an increased ratio in the draining lymph nodes tissue than in liver tissue or at an increased ratio in the muscle tissue of the site of injection than in liver tissue.Stabilized nucleic acid, preferably mRNA: A stabilized nucleic acid, preferably mRNA typically, exhibits a modification increasing resistance to in vivo degradation (e.g. degradation by an exo- or endo-nuclease) and / or ex vivo degradation (e.g. by the manufacturing process prior to vaccine administration, e.g. in the course of the preparation of the vaccine solution to be administered). Stabilization of mRNA can, e.g., be achieved by providing a 5’-CAP-Structure, a polyA-Tail, or any other UTR-modification. It can also be achieved by chemical modification or modification of the G / C content of the nucleic acid. Various other methods are known in the art and conceivable in the context of the invention.“Stability,” “stabilized,” “particle stability” and “stable” in the context of the present disclosure regarding lipid nanoparticles refers to the resistance of lipid nanoparticle compositions and / or pharmaceutical compositions disclosed herein to chemical or physical changes (e.g., degradation, particle size change, aggregation, change in encapsulation, etc.) under given manufacturing, preparation, transportation, storage and / or in-use conditions, e.g., when stress is applied such as shear force, freeze / thaw stress, et cetera. As used herein, “storage” may be understood as a prolonged exposure or containment of a composition in an article, e.g. a syringe or a vial, wherein the duration of storage may be in a range of about 30 minutes to about 6 months. For example, storage may be for at least about 30 minutes, 1 hour, 2 hours, 6 hours, 1 day, 2 days, 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months. The temperature conditions under which storage according to the invention may occur can range from -80°C to about 30°C, preferably in a range from about -20°C to about 30°C, more preferably in a range from about 5°C to about 20°C. Preferred examples of a storage temperature in the context of the invention are -80°C, -20°C, 5°C, or room temperature (about 20°C). Suitably, when reference is made to “storage”, such a storage has to be understood as having a duration of about 30 minutes to about 6 months, and as having a temperature in a range from about 5°C to about 20°C.The term “treatment” or “treating” of a disease includes preventing or protecting against the disease (that is, causing the clinical symptoms not to develop); inhibiting the disease (i.e., arresting or suppressing the development of clinical symptoms; and / or relieving the disease (i.e., causing the regression of clinical symptoms). In a preferred embodiment, the term “subject” refers to a human. “Treating” or “treatment” also broadly includes any approach for obtaining beneficial or desired results in a subject’s condition, including clinical results. Beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of the extent of a disease, stabilizing (i.e., not worsening) the state of disease, prevention of a disease’s transmission or spread, delay or slowing of disease progression, amelioration or palliation of the disease state, diminishment of the reoccurrence of disease, and remission, whether partial or total and whether detectableCureVac SE / P396WO1 22 / 219or undetectable. In other words, "treatment" as used herein includes any cure, amelioration, or prevention of a disease. Treatment may prevent the disease from occurring; inhibit the disease’s spread; relieve the disease’s symptoms, fully or partially remove the disease’s underlying cause, shorten a disease’s duration, or do a combination of these things.The term “therapeutically effective amount” as used herein, refers to an amount of a lipid nanoparticle according to the invention and / or a lipid nanoparticle according to the invention comprising a nucleic acid, preferably an mRNA, sufficient to treat a disease, a disorder, or a condition. For the given parameter, a therapeutically effective amount will show an increase or decrease of at least 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%, 90%, or at least 100% of symptoms in a subject in need. Therapeutic efficacy can also be expressed as “-fold” increase or decrease. For example, a therapeutically effective amount can have at least a 1.2-fold, 1.5-fold, 2-fold, 5-fold, or more effect over a control. The “therapeutically effective amount” can vary depending, for example, but not limited to, on the compound, the disease, or the condition and / or symptoms thereof, severity of the disease or the condition and / or symptoms thereof, the age, weight, and / or health of the subject to be treated, and the judgment of the prescribing physician. An appropriate amount in any given instance can be ascertained by those skilled in the art or capable of determination by routine experimentation.“Vaccine”: a vaccine relates to a pharmaceutical preparation (composition or pharmaceutical composition) or product that upon administration induces an immune response, in particular a cellular immune response and / or a humoral immune response, which is suitable for recognizing and attacking a pathogen or a diseased cell such as a cancer cell. A vaccine may be used for the prevention or treatment of a disease, e.g. a cancer disease. The terms “prophylactic vaccine” or “prophylactic agent”: both terms refer to any agent that, when administered to a subject, has a prophylactic effect and / or elicits a desired biological and / or pharmacological effect. Related, this definition is true for the term “prophylactic vaccination”. The terms “therapeutic vaccine” or “therapeutic agent”: both terms refer to any agent that, when administered to a subject, has a therapeutic, and / or prophylactic effect and / or elicits a desired biological and / or pharmacological effect. Related, this definition is true for the term “therapeutic vaccination”. In this regard, the use of the pharmaceutical composition, prophylactic or therapeutic vaccine or agent is a medicament for therapeutically or prophylactically raising an immune response of a subject in need thereof. Also in this regard, the term “vaccine” is typically understood to be a prophylactic or therapeutic material providing at least one antigen or antigenic function. The antigen or antigenic function may stimulate the body’s adaptive immune system to provide an adaptive immune response. Vaccines are therefore preferably formulated in liquid or solid form. The suitable amount of the vaccine or composition according to the invention to be administered can be determined by routine experiments, e.g. by using animal models. Such models include, without implying any limitation, rabbit, sheep, mouse, rat, dog and non-human primate models. Preferred unit dose forms for injection include sterile solutions of water, physiological saline or mixtures thereof. The pH of such solutions should be adjusted to a physiologically tolerable pH, such as about 7.4. Suitable carriers for injection include hydrogels, devices for controlled or delayed release, polylactic acid and collagen matrices.Variant of a nucleic acid sequence, particularly an mRNA: A variant of a nucleic acid sequence refers to a variant of nucleic acid sequences which forms the basis of a nucleic acid sequence. For example, a variant nucleic acid sequence may exhibit one or more nucleotide deletions, insertions, additions and / or substitutions compared to the nucleic acid sequence from which the variant is derived. Preferably, a variant of a nucleic acid sequence is at least 40%, preferably at least 50%, more preferably at least 60%, more preferably at least 70%, even more preferably at least 80%, even more preferably at least 90%, most preferably at least 95% identical to the nucleic acid sequence the variant is derived from. Preferably, the variant is a functional variant. A “variant” of a nucleic acid sequence mayCureVac SE / P396WO1 23 / 219have at least 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% nucleotide identity over a stretch of 10, 20, 30, 50, 75 or 100 nucleotides of such nucleic acid sequence. Variant nucleic acids or genes may thus preferably comprise, in their nucleic acid sequence, at least one mutation, substitution, insertion or deletion as compared to their respective reference sequence. Preferably, the term “variant” as used herein includes naturally occurring variants, and engineered variants of nucleic acid sequences or genes. Therefore, a “variant” as defined herein can be derived from, isolated from, related to, based on or homologous to the reference nucleic acid sequence.. Variants’ may preferably have a sequence identity of at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, preferably of at least 70%, more preferably of at least 80%, even more preferably at least 85%, even more preferably of at least 90% and most preferably of at least 95% or even 97%, to a nucleic acid sequence of the respective naturally occurring (wild type) nucleic acid sequence or gene, or a homolog, fragment or derivative thereof.Also, the term “variant” as used throughout the present specification in the context of proteins or peptides will be recognized and understood by the person of ordinary skill in the art, and is e.g. intended to refer to a proteins or peptide variant having an amino acid sequence which differs from the original sequence in one or more mutation(s), such as one or more substituted, inserted and / or deleted amino acid(s). Preferably, these fragments and / or variants have the same biological function or specific activity compared to the full-length native protein, e.g. its specific antigenic property. “Variants” of proteins or peptides as defined herein may comprise conservative amino acid substitution(s) compared to their native, i.e. non-mutated physiological, sequence. Those amino acid sequences as well as their encoding nucleotide sequences in particular fall under the term variants as defined herein. Substitutions in which amino acids, which originate from the same class, are exchanged for one another are called conservative substitutions. In particular, these are amino acids having aliphatic side chains, positively or negatively charged side chains, aromatic groups in the side chains or amino acids, the side chains of which can enter into hydrogen bridges, e.g. side chains which have a hydroxyl function. This means that e.g. an amino acid having a polar side chain is replaced by another amino acid having a likewise polar side chain, or, e.g., an amino acid characterized by a hydrophobic side chain is substituted by another amino acid having a likewise hydrophobic side chain (e.g. serine (threonine) by threonine (serine) or leucine (isoleucine) by isoleucine (leucine)). Insertions and substitutions are possible, in particular, at those sequence positions which cause no modification to the three-dimensional structure or do not affect the binding region. Modifications to a three-dimensional structure by insertion(s) or deletion(s) can easily be determined e.g. using CD spectra (circular dichroism spectra). A “variant” of a protein or peptide may have at least 70%, 75%, 80%, 85%, 90%, 95%, 98% or 99% amino acid identity over a stretch of at least 10, 20, 30, 50, 75 or 100 amino acids of such protein or peptide. Preferably, a variant of a protein comprises a functional variant of the protein, which means that the variant exerts the same effect or functionality or at least 40%, 50%, 60%, 70%, 80%, 90%, or 95% of the effect or functionality as the protein it is derived from. Furthermore, variants of proteins or peptides as defined herein, which may be encoded by a nucleic acid molecule, may also comprise those sequences, wherein nucleotides of the encoding nucleic acid sequence are exchanged according to the degeneration of the genetic code, without leading to an alteration of the respective amino acid sequence of the protein or peptide, i.e. the amino acid sequence or at least part thereof may not differ from the original sequence in one or more mutation(s) within the above meaning.Vehicle: An agent, e.g. a carrier that may typically be used within a pharmaceutical composition or vaccine for facilitating administration of the components to an individual (e.g. a buffer solution for solubilizing).CureVac SE / P396WO1 24 / 219BRIEF DESCRIPTION OF THE FIGURESThe figures shown in the following are merely illustrative and shall describe the present invention in a further way. These figures shall not be construed to limit the present invention thereto.Figure 1: mRNA constructs used in the Examples (for more details: Example 5).Figure 2: Luciferase concentration (pg / mg tissue) in homogenized mouse tissues (liver, spleen, lungs, draining lymph nodes (dLNs) and non-draining lymph nodes (ndLNs; inguinal and popliteal) and injected muscle (site of injection; SOI)) after injection of LNPs formulated with the lipid nanoparticles listed herein. Animals received a dose of 5 pg PpLuc mRNA (SEQ ID NO:1) in lipid nanoparticle formulations as described in Example 7. Organs were harvested 4 h after injection. Bars represent the mean of 5 animals and error bars represent standard deviation. Column 1 for each organ / tissue represents “CIL86 - 0.5%’ (black bar)Column 2 for each organ / tissue represents “CIL86 - 1%” (white bar)Column 3 for each organ / tissue represents “LNP SM-102” (striped bar)Figure 3: Luciferase concentration (pg / mg tissue) in homogenized mouse tissues (liver, spleen, lungs, draining lymph nodes (dLNs) and non-draining lymph nodes (ndLNs; inguinal and popliteal) and injected muscle (site of injection; SOI) after injection of LNPs formulated with the lipid nanoparticles listed herein. Animals received a dose of 5 pg PpLuc mRNA (SEQ ID NO:1) in lipid nanoparticle formulations as described in Example 8. Organs were harvested 4 h after injection. Bars represent the mean of 5 animals and error bars represent standard deviation. Column 1 for each organ / tissue represents “Onc1” (black bar)Column 2 for each organ / tissue represents “CIL86 - 0.5%’ (white bar)Column 3 for each organ / tissue represents buffer (striped bar)Figure 4: Frequency of antigen specific polyfunctional TNFa+ IFNg+ CD107a+ CD8+ T cells after three doses of intramuscular vaccination with 5pg of the respective mRNA LNPs in female C57BL / 6 mice (for details: Example 9).Antigen specific activated T cells were detected after restimulation with the relevant peptides, intracellular cytokine staining and detection by flow cytometry. Frequencies are shown here as mean + / - SD and are shown as % of live cells. Each bar represents the data of N=7 mice per group to the respective peptide restimulations shown in the graph. Numbers under x-axis indicate the respective peptides (1 - Pmel, 2 - Trp1, 3 - Obsll, 4 - Dct, 5 - Atp11a, 6 - PSMA-Frag2, 7 - Rif, 8 - Acvrl, 9 - DMSO).Figure 5: Frequency of antigen specific polyfunctional TNFa+ IFNg+ CD4+ T cells after three doses of intramuscular vaccination with 5 g of the respective mRNA LNPs in female C57BL / 6 mice (for details: Example 9). Antigen specific activated T cells were detected after restimulation with the relevant peptides, intracellular cytokine staining and detection by flow cytometry. Frequencies are shown here as mean + / - SD and are shown as % of live cells. Each bar represents the data of N=7 mice per group to the respective peptide restimulations shown in the graph. Numbers in diagram indicate the respective peptides (1 - PADRE, 2 - MAGE-A3, 3 - Zbtb41, 4 - DMSO). Figure 6A. Experimental outline of the antitumoral efficacy study. Naive C57BL / 6 mice were challenged s.c. with 1x105B16.F10 cells; vaccination was started when tumors were palpable (day 7; for more details see Example 10).CureVac SE / P396WO1 25 / 219Figure 6B. Anti-tumor efficacy assessment. T umor size was determined twice per week using a caliper. Survival of mice is plotted with the cut-off-volume for survival set at 1,000 mm3 (for more details see Example 10): • CIL86 - PpLuc (filled squares)• CIL86 - B16-F10 Decatope (filled triangles)• CIL86 - Trp2 (filled circles)• SM-102 - PpLuc (open squares)• SM-102 - B16-F10 Decatope (open triangles)• SM-102 - Trp2 (open circles)Figure 7: Lyophilization data. Size, PDI and Encapsulation Efficiency for fresh LNPs, 1x freeze thawn (FT) LNPs and lyophilized and reconstituted LNPs.Figure 8A / B: Luciferase concentration (pg / mg tissue) in homogenized mouse tissues (liver, spleen, lungs, draining lymph nodes (dLNs) and non-draining lymph nodes (ndLNs; inguinal and popliteal) and injected muscle (site of injection; SOI)) after injection of LNPs formulated with the lipid nanoparticles listed herein. Animals received a dose of 5 g PpLuc mRNA (SEQ ID NO:1) in lipid nanoparticle formulations as described in Example 14. Organs were harvested 4 h after injection. Bars represent the mean of 5 animals and error bars represent standard deviation. Column 1 for each organ / tissue represents “CIL86 - 0.5%’ (black bar)Column 2 for each organ / tissue represents “CIL86 - 1%” (white bar)Column 3 for each organ / tissue represents “LNP SM-102” (striped bar)Figures 9A to 9F: show the frequency of antigen specific polyfunctional TNFa+ IFNg+ CD107a+ CD8+ T cells and the frequency of antigen specific polyfunctional TNFa+ IFNg+ CD4+ T cells after three doses of intramuscular vaccination with 5pg of the respective mRNA LNPs in female C57BL / 6 mice (for details: Example 15). Antigen specific activated T cells were detected after restimulation with the relevant peptides, intracellular cytokine staining and detection by flow cytometry. Frequencies are shown here as mean + / - SD and are shown as % of live cells. Each bar represents the data of N=7 mice per group to the respective peptide restimulations shown in the graph. Numbers under x-axis indicate the respective peptides (1 - Pmel, 2 - Trp1, 3 - Obsll, 4 - Det, 5 - Atp11a, 6 -PSMA-Frag2, 7 - Rif, 8 - Acvrl, 9 - DMSO) or respectively (1 - MAGE-A3, 2 - Zbtb41, 3 - PADRE, 4 - DMSO) (for more details see Example 15).Figure 10A / 10B: Heatmap depicting serum concentrations (pg / mL) of 13 cytokines and chemokines measured 4 hours after intramuscular (IM) administration of lipid nanoparticles (LNPs) formulated with the indicated ionizable lipids (CIL86, CIL139, and CIL140) at 0.5% across independent biodistribution (BD) studies. Cytokine and chemokine levels were quantified using the LEGENDplex™ Mouse Anti-Virus Response Panel (13-plex, BioLegend) according to the manufacturer's protocol. Each column represents an independent BD study replicate. Color intensity corresponds to analyte concentration in pg / mL, ranging from 0 (white) to >6000 (black). Analytes measured include IFN-y, IFN-p, IFN-a, KC, TNF-a, MCP-1, IL-12p70, RANTES, IL-1β, IP-10, GM-CSF, IL-10, and IL-6. IP-10 was identified as the predominant induced chemokine across all formulations. CIL139 and CIL140 exhibited reduced overall cytokine and chemokine induction compared to CIL86, consistent with their distinct pKa profiles (for more details see Example 16).CureVac SE / P396WO1 26 / 219DETAILED DESCRIPTIONAlthough the present disclosure is described in detail below, it is to be understood that this disclosure is not limited to the particular methodologies, protocols and reagents described herein as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the present disclosure which will be limited only by the appended claims. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art.Ionizable lipidIn aIn another embodiment, Y3 and Y4 are independently -(C=O)O-CH2-CH2-, -O(C=O)-CH2-CH2-, -(C=O)O-CH2--O(C=O)-CH2-... -(C=O)NH-CH2-CH2-, -NH(C=O)-CH2-CH2-, -(C=O)NH-CH2-, -NH(C=O)-CH2-, -CH2-CH2-(C=O)NH-, -CH2-CH2-NH(C=O)-, -CH2-(C=O)NH-, or -CH2-NH(C=O)-.CureVac SE / P396WO1 27 / 219CureVac SE / P396WO1 28 / 219CureVac SE / P396WO1 29 / 219In a preferred embodiment, the present invention provides an ionizable lipid having a structure of Formula (I)CureVac SE / P396WO1 30 / 219or a pharmaceutically acceptable salt or stereoisomer thereof, whereinXi is an alkanediyl having 2 to 6 carbon atoms;R1 is independently –OH, –S-OH, or –S-CH3;X2 is an alkanediyl having 2 to 6 carbon atoms;Xs is an alkanediyl having 2 to 6 carbon atoms;Y1 and Y2 are independently -(C=O)O-CH2-CH2-, or -O(C=O)-CH2-CH2-;Ys and Y4 are independently -(C=O)O-CH2-, or -O(C=O)-CH2-; andR2 and Rs are each independently straight or branched, saturated or unsaturated C10-C20 alkyl or C10- C20 alkenyl, wherein the alkyl chain is optionally interrupted by one or more ester bonds.In a further preferred embodiment, the present invention provides an ionizable lipid having a structure of Formulaor a pharmaceutically acceptable salt or stereoisomer thereof, whereinXi is an alkanediyl having 2 to 6 carbon atoms;R1 is –OH;X2 is an alkanediyl having 4 carbon atoms;X3 is an alkanediyl having 4 carbon atoms;Y1 and Y2 are independently -(C=O)O-CH2-CH2-, or -O(C=O)-CH2-CH2-;Ys and Y4 are independently -(C=O)O-CH2-, or -O(C=O)-CH2-; andR2 and Rs are each independently straight or branched, saturated or unsaturated C14, C15 or C16 alkyl, wherein the alkyl chain is optionally interrupted by one or more ester bonds.In a further preferred embodiment, the present invention provides an ionizable lipid having a structure of FormulaCureVac SE / P396WO1 31 / 219In a further preferred embodiment, the present invention provides an ionizable lipid having a structure of Formula (I)or a pharmaceutically acceptable salt or stereoisomer thereof, whereinXi is an alkanediyl having 4 carbon atoms;R1 is –OH;X2 is an alkanediyl having 4 carbon atoms;X3 is an alkanediyl having 4 carbon atoms;Y1 and Y2 are independently -O(C=O)-CH2-CH2-;Y3 and Y4 are independently -(C=O)O-CH2-; andR2 and R3 are each independently straight or branched, saturated or unsaturated C15 alkyl, wherein the alkyl chain is optionally interrupted by one or more ester bonds.In a further preferred embodiment, the present invention provides an ionizable lipid having a structure of FormulaCureVac SE / P396WO1 32 / 219In another embodiment, the present invention provides an ionizable lipid having the structure CIL86(CIL86).In a most preferred embodiment, the present invention provides an ionizable lipid having the structure CIL86 (trans-bis(2-hexyldecyl) O, O'-((1-(4-hydroxybutyl)piperidine-3,5-diyl)bis(butane-4,1-diyl)) disuccinate):CureVac SE / P396WO1 33 / 219In the context of the invention, “CIL86” or“CIL86 trans” is to be considered as CIL86 (racemic mixture).In a most preferred embodiment, the ionizable lipid as comprised in the lipid nanoparticles of the invention is CIL86.In a further most preferred embodiment, the ionizable lipid as comprised in the lipid nanoparticles of the invention is CIL86 (racemic).In a further preferred embodiment, the ionizable lipid as comprised in the lipid nanoparticles of the invention is “CIL86 trans R” (head group optically pure):In a further preferred embodiment, the ionizable lipid as comprised in the lipid nanoparticles of the invention is “CIL86 trans S” (head group optically pure):CureVac SE / P396WO1 34 / 219CureVac SE / P396WO1 35 / 219CureVac SE / P396WO1 36 / 219The compounds as disclosed herein (e.g., lipids in Table 1, lipids according to Formula (I) or Formula (II), or preferably CIL86), or their pharmaceutically acceptable salts, may include an asymmetric center and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms. The present disclosure contemplates various stereoisomers and mixtures thereof and includes “enantiomers,” which refers to two stereoisomers whose molecules are nonsuperimposeable mirror images of one another and “diastereomers,” which refers to stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other. The present disclosure is meant to include all such possible isomers, as well as their racemic and optically pure forms. Optically active (+) and (-), or (R)- and (S)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and fractional crystallization. Conventional techniques for the preparation / isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate using, for example, chiral high pressure liquid chromatography (HPLC).CureVac SE / P396WO1 37 / 219X2 is an alkanediyl having 1 to 8 carbon atoms;X3 is an alkanediyl having 1 to 8 carbon atoms;Y1 and Y2 are independently -(C=O)O-CH2-CH2-, -O(C=O)-CH2-CH2-, -(C=O)O-CH2-, -O(C=O)-CH2-, -CH2-CH2-(C=O)O-, -CH2-CH2-O(C=O)-, -CH2-(C=O)O-, or -CH2-O(C=O)-;Y3 and Y4 are independently -(C=O)O-CH2-CH2-, -O(C=O)-CH2-CH2-, -(C=O)O-CH2-, -O(C=O)-CH2-, -CH2-CH2-(C=O)O-, -CH2-CH2-O(C=O)-, -CH2-(C=O)O-, or -CH2-O(C=O)-; andR2 and R3 are each independently straight or branched, saturated or unsaturated C6–C24 alkyl or C6–C24 alkenyl, wherein the alkyl chain is optionally interrupted by one or more ester bonds.CureVac SE / P396WO1 38 / 219Y1 and Y2 are independently -(C=O)O-CH2-CH2-, -O(C=O)-CH2-CH2-, -(C=O)O-CH2-, -O(C=O)-CH2-, -CH2-CH2-(C=O)O-, -CH2-CH2-O(C=O)-, -CH2-(C=O)O-, or -CH2-O(C=O)-;Y3 and Y4 are independently -(C=O)O-CH2-CH2-, -O(C=O)-CH2-CH2-, -(C=O)O-CH2-, -O(C=O)-CH2-, -CH2-CH2-(C=O)O-, -CH2-CH2-O(C=O)-, -CH2-(C=O)O-, or -CH2-O(C=O)-; andR2 and R3 are each independently straight or branched, saturated or unsaturated C6–C24 alkyl or C6–C24 alkenyl, wherein the alkyl chain is optionally interrupted by one or more ester bonds.CureVac SE / P396WO1 39 / 219CureVac SE / P396WO1 40 / 219CureVac SE / P396WO1 41 / 219CureVac SE / P396WO1 42 / 219CureVac SE / P396WO1 43 / 219CureVac SE / P396WO1 44 / 219In another aspect, the present invention provides an ionizable lipid having a structure of Formula (III-X)CureVac SE / P396WO1 45 / 219CureVac SE / P396WO1 46 / 219CureVac SE / P396WO1 47 / 219or a pharmaceutically acceptable salt or stereoisomer thereof, whereinXi is an alkanediyl having 2 to 6 carbon atoms;R1 is independently -OH, -S-OH, or -S-CH₃;X2 is an alkanediyl having 2 to 6 carbon atoms;Xs is an alkanediyl having 2 to 6 carbon atoms;Y1 and Y2 are independently -(C=O)O-CH2-CH2-, or -O(C=O)-CH2-CH2-;Ys and Y4 are independently -(C=O)O-CH2-, or -O(C=O)-CH2-; andR₂ and R₃ are each independently straight or branched, saturated or unsaturated C10-C20 alkyl or C10- C20 alkenyl, wherein the alkyl chain is optionally interrupted by one or more ester bonds. HEIGHT="480" WIDTH="407" SRC="imgf000047_0001.tif" / >CureVac SE / P396WO1 48 / 219Ys and Y4 are independently -(C=O)O-CH2-, or -O(C=O)-CH2-; andR₂ and R₃ are each independently straight or branched, saturated or unsaturated C10-C20 alkyl or C10- C20 alkenyl, wherein the alkyl chain is optionally interrupted by one or more ester bonds. of the present invention reference is made to a lipid stemming from Formula (I) or Formula (II), for example a lipid selected from the lipids of Table 1, reference may be made to “CIL-lipids”.In most preferred embodiments, CIL86 is prepared as a racemic mixture.In further preferred embodiments, the present invention provides the lipids as shown in Table 1.Table 1: Preferred ionizable lipids according to Formula (I) or Formula (II).CureVac SE / P396WO1 49 / 219Structures Compound numberCureVac SE / P396WO1 50 / 219CureVac SE / P396WO1 51 / 219CureVac SE / P396WO1 52 / 219CureVac SE / P396WO1 53 / 219Compoun Structuresd numberCureVac SE / P396WO1 54 / 219Compoun Structuresd numberCureVac SE / P396WO1 55 / 219Compoun Structuresd numberIn further preferred embodiments, the present invention provides CIL65 cis as shown in Table 1.In further preferred embodiments, the present invention provides CIL66 trans as shown in Table 1In further preferred embodiments, the present invention provides CIL67 cis as shown in Table 1.In further preferred embodiments, the present invention provides CIL68 trans as shown in Table 1In further preferred embodiments, the present invention provides CIL85 cis as shown in Table 1.In further preferred embodiments, the present invention provides CIL87 cis as shown in Table 1.In further preferred embodiments, the present invention provides CIL88 trans as shown in Table 1In further preferred embodiments, the present invention provides CIL89 cis as shown in Table 1.In further preferred embodiments, the present invention provides CIL90 trans as shown in Table 1In further preferred embodiments, the present invention provides CIL91 cis as shown in Table 1.In further preferred embodiments, the present invention provides CIL92 trans as shown in Table 1In further preferred embodiments, the present invention provides CIL93 cis as shown in Table 1.In further preferred embodiments, the present invention provides CIL94 trans as shown in Table 1In further preferred embodiments, the present invention provides CIL95 cis as shown in Table 1.In further preferred embodiments, the present invention provides CIL96 trans as shown in Table 1In further preferred embodiments, the present invention provides CIL98 as shown in Table 1.In further preferred embodiments, the present invention provides CIL129 as shown in Table 1.In further preferred embodiments, the present invention provides CIL129A as shown in Table 1.In further preferred embodiments, the present invention provides CIL134 as shown in Table 1.In further preferred embodiments, the present invention provides CIL134A as shown in Table 1.In further preferred embodiments, the present invention provides CIL134B as shown in Table 1.CureVac SE / P396WO1 56 / 219In further preferred embodiments, the present invention provides CIL111 as shown in Table 1.In further preferred embodiments, the present invention provides CIL112 as shown in Table 1.In further preferred embodiments, the present invention provides CIL114 as shown in Table 1.In preferred embodiments, CIL-lipids of Table 1, when having a chiral atom, are prepared as racemic mixture. In preferred embodiments, CIL-lipids of Table 1, when having a chiral atom, are prepared as separate enantiomers, preferably (R) enantiomer.In preferred embodiments, CIL-lipids of Table 1, when having a chiral atom, are prepared as separate enantiomers, preferably (S) enantiomer.In yet another embodiment of the previous aspects, the present invention provides an ionizable lipid of the above or below aspects and embodiments, the lipid nanoparticle of the above or below aspects and embodiments, the pharmaceutical composition of the above or below aspects and embodiments, or the kit or kit of parts of the above or below aspects and embodiments for use as medicament and / or for use in the prevention or treatment of a cancer disease.In a further preferred embodiment, the present invention provides CIL86, a lipid nanoparticle comprising CIL86, the pharmaceutical composition of the invention comprising a lipid nanoparticle comprising CIL86, or the kit or kit of parts of the invention, for use as medicament and / or for use in the prevention or treatment of a cancer disease. In further embodiments, R2 and R3 for Formula (I) or Formula (II) are each independently optionally substituted CI-30 alkyl, optionally substituted C1-30 alkenyl, or optionally substituted C1-30 alkynyl; optionally wherein one or more methylene units of R2 and R3 are independently replaced with optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, N(RN), O, S, C(O), C(O)N(RN), NRNC(O), -NRNC(O)N(RN), C(O)O, OC(O), OC(O)O, OC(O)N(RN), NRNC(O)O, C(O)S, SC(O), -C(=NRN), C(=NRN)N(RN), NRNC(=NRN), NRNC(=NRN)N(RN), C(S), C(S)N(RN), NRNC(S), NRNC(S)N(RN), S(O), OS(O), S(O)O, OS(O)O, OS(O)2, S(O)2O, OS(O)2O, N(RN)S(O), -S(O)N(RN), N(RN)S(O)N(RN), OS(O)N(RN), N(RN)S(O)O, S(O)2, N(RN)S(O)2, S(O)2N(RN), N(RN)S(O)2N(RN), OS(O)2N(RN), or N(RN)S(O)2O; each instance of RN is independently hydrogen, optionally substituted alkyl, or a nitrogen protecting group;CureVac SE / P396WO1 57 / 219CureVac SE / P396WO1 58 / 219CureVac SE / P396WO1 59 / 219In further embodiments, R2 and R3 for Formula (I) or Formula (II) are each independentlyIn preferred embodiments of the present invention, the ionizable lipids according to Formula (I) or Formula (II) are characterized by the presence of two distinct ester bond-containing linker groups within each alkyl arm extending from the 3- and 5-positions of the piperidine ring to the lipid tail groups R2 and R3, respectively. Specifically, each arm comprises both a first ester-containing linker Y1 or Y2 and a second ester-containing linker Y3 or Y4, such that each arm is a bis-ester arm. This bis-ester arrangement per arm is a critical and distinguishing structural feature ofCureVac SE / P396WO1 60 / 219the present invention. The Y1 / Y2 and Y3 / Y4 linkers together preferably form a dicarboxylic acid diester (e.g., a disuccinate or diglutarate moiety) of the general structure -O-C(O)-(CH2)n-C(O)-O- within each arm, as exemplified by CIL86 (trans-bis(2-hexyldecyl) O, O'-((1-(4-hydroxybutyl)piperidine-3,5-diyl)bis(butane-4,1-diyl)) disuccinate), wherein Y1 / Y2 = -O(C=O)-CH2-CH2- and Y3 / Y4 = -(C=O)O-CH2-, together forming a succinate diester bridge in each arm.Prior art ionizable lipids comprising a piperidine ring at the ionizable nitrogen, wherein each alkyl / alkylene arm at the 3- and 5-positions of the piperidine ring bears only a single carboxylate or ester group per arm, are structurally and functionally distinct from the ionizable lipids of the present invention. In contrast to such prior art compounds, each arm of the ionizable lipids of the present invention necessarily contains two ester bond-containing linkers, i.e., a Y1 or Y2 group and a Y3 or Y4 group, each independently comprising an ester bond. The critical presence of this second ester bond per arm — which together with the first ester bond creates a diester linkage — fundamentally alters the physicochemical properties of the ionizable lipid and the resulting lipid nanoparticle, including but not limited to: pKa, biodegradability, membrane fusogenicity, and in vivo biodistribution. Specifically, as demonstrated in the working examples herein, the bis-ester arms of the ionizable lipids of the invention impart unexpectedly enhanced biodistribution to lymphoid organs (spleen, draining lymph nodes) and injection site muscle tissue, while substantially reducing unwanted liver tropism, properties not demonstrated by prior art ionizable lipids bearing only a single carboxylate group per piperidine-ring arm.Without wishing to be bound by theory, it is believed that the presence of two ester bonds per arm in the ionizable lipids of the present invention contributes to (i) an optimal balance between hydrophilicity and hydrophobicity at physiological and endosomal pH values, (ii) enhanced biodegradability of the ionizable lipid due to the increased number of hydrolysable ester bonds, (iii) a specific molecular geometry and cone-shape of the lipid nanoparticle that promotes endosomal escape and preferential uptake by antigen-presenting cells including macrophages and conventional type 1 dendritic cells (cDC1), and (iv) a reduced propensity for hepatic accumulation. These effects are uniquely achieved by the combination of the piperidine ring core, the hydroxyalkyl substituent at the piperidine nitrogen (R1–X1), and the bis-ester arrangement in each arm (Y1 / Y2 and Y3 / Y4).As used herein, the term 'bis-ester arm' refers to each of the two arms extending from the 3- and 5-positions of the piperidine ring of the ionizable lipids according to Formula (I) or Formula (II), wherein each arm comprises two ester bond-containing linker groups. Specifically, each arm consists of: the alkanediyl spacer X2 or X3 connecting the piperidine ring carbon to the first ester linker Y1 or Y2; the first ester linker Y1 or Y2; the second ester linker Y3 or Y4; and the lipid tail group R2 or R3. The overall connectivity of each arm reads: piperidine(3 or 5)-X2 / X3-Y1 / Y2-Y3 / Y4-R2 / R3. Both Y1 / Y2 and Y3 / Y4 each independently contain an ester bond (-C(O)O- or -OC(O)-). Thus, each arm from the piperidine ring to the lipid tail necessarily contains at least two ester bonds. This structural arrangement is contrasted with ionizable lipids known in the art wherein a piperidine ring is present but wherein the arms extending from the ring positions bear only a single ester bond or carboxylate group per arm.In an aspect, the present invention provides a method of synthesizing trans-bis(2-hexyldecyl) O, O'-((1-(4-hydroxybutyl)piperidine-3,5-diyl)bis(butane-4,1-diyl)) disuccinate (CIL86) according to scheme 1CureVac SE / P396WO1 61 / 219In another embodiment of the previous aspect, the synthesis of trans-bis(2-hexyldecyl) O, O'-((1-(4-hydroxybutyl)piperidine-3,5-diyl)bis(butane-4,1-diyl)) disuccinate (CIL86) is carried out by the steps as shown in Example 2 as disclosed in the Examples section.In an alternative aspect, the present invention provides a method of synthesizing CIL112 according to the descriptions and schemes shown in working example 2.1.In an alternative aspect, the present invention provides a method of synthesizing CIL114 according to the descriptions and schemes shown in working example 2.2.In an alternative aspect, the present invention provides a method of synthesizing CIL130 according to the descriptions and schemes shown in working example 2.3.In an alternative aspect, the present invention provides a method of synthesizing CIL139 according to the descriptions and schemes shown in working example 2.4.In an alternative aspect, the present invention provides a method of synthesizing CIL140 according to the descriptions and schemes shown in working example 2.5.CureVac SE / P396WO1 62 / 219Other preferred ionizable lipids that may be comprised in the lipid nanoparticles of the invention comprises substituents (e.g. R1, R2, R3, R5, R6, R7, R10, M, M1, m, n, o, l) as defined in claims 1 to 13 of US10392341B2; US10392341B2 being incorporated herein in its entirety.In other embodiments, the ionizable lipid of the lipid nanoparticles of the invention is “8-[(2-hydroxyethyl)[6-oxo-6-(undecyloxy)hexyl]amino]-octanoic acid, 1 -octylnonyl ester”, “Heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate”; or Compound 25 as disclosed in WO2017049245A2; WO2017049245A2 being incorporated herein in its entirety.The term “alkanediyl” means any of a series of divalent radicals of the general formula CnH2n derived from aliphatic hydrocarbons. Unless specified otherwise, such alkanediyls include substituted alkanediyls. The term “alkanediyl” when used without the “substituted” modifier refers to a divalent saturated aliphatic group, with one or two saturated carbon atom(s) as the point(s) of attachment, a linear or branched acyclic structure, no carbon-carbon double or triple bonds, and no atoms other than carbon and hydrogen. The groups -CH2- (methylene), -CH2CH2-, and -CH2CH2CH2-are non-limiting examples of alkanediyl groups.In a second aspect, the present invention provides a lipid nanoparticle comprising an ionizable lipid according to the above first aspect and embodiments.In another embodiment of the second aspect, the present invention provides a lipid nanoparticle, wherein the lipid nanoparticle comprises:49 mol% ionizable lipid CIL86O(CIL86);7.5 mol% DSPC;CureVac SE / P396WO1 63 / 219(“PMOZ 4” having 50 PMOZ monomer repeats).In a further embodiment of the second aspect, the present invention provides a lipid nanoparticle, further comprising a nucleic acid, preferably selected from the group consisting of messenger RNA (mRNA), siRNA, RNAi, guide RNA (gRNA), IncRNA (long non-coding RNA), samRNA / saRNA (self-amplifying RNA; SAM vaccines), and circular RNA, most preferably the nucleic acid is messenger RNA (mRNA).In a further embodiment of the second aspect, the present invention provides a lipid nanoparticle, further comprising a messenger RNA (mRNA).In a further embodiment of the second aspect, the present invention provides a lipid nanoparticle, further comprising a messenger RNA (mRNA), wherein the mRNA(a) comprises at least one coding sequence encoding a peptide or protein, or a fragment or variant thereof, wherein the peptide or protein is an antigen, wherein the antigen preferably is, or is derived from, a cancer or tumor antigen, a cancer or tumor epitope, a pathogenic antigen, a viral antigen, a bacterial antigen, a tumor antigen, an allergenic antigen or an autoimmune self-antigen, preferably a cancer or tumor antigen or a cancer or tumor epitope; or(b) comprises at least one coding sequence encoding a therapeutic protein, or a fragment or variant thereof, wherein the therapeutic protein is selected from the group consisting of(i) therapeutic proteins for use in enzyme replacement therapy for the treatment of metabolic, endocrine or amino acid disorders or for use in replacing an absent, deficient or mutated protein;(ii) therapeutic proteins for use in the treatment of blood disorders, diseases of the circulatory system, diseases of the respiratory system, infectious diseases or immune deficiencies;(iii) therapeutic proteins for use in the treatment of cancer or tumor diseases;(iv) therapeutic proteins for use in hormone replacement therapy;(v) therapeutic proteins for use in reprogramming somatic cells into pluri- or omnipotent stem cells; (vi) therapeutic proteins for use as adjuvant or immunostimulation;(vii) therapeutic proteins being a therapeutic antibody;(viii) therapeutic proteins being a gene editing agent; and(ix) therapeutic proteins for use in treating or preventing a liver disease selected from the group consisting of liver fibrosis, liver cirrhosis and liver cancer,CureVac SE / P396WO1 64 / 219preferably wherein the therapeutic protein of (b) is a therapeutic protein for use in the treatment of cancer or tumor diseases.In yet another embodiment of the second aspect, the present invention provides a lipid nanoparticle, further comprising a messenger RNA (mRNA), wherein the mRNA encodes(I) at least one cancer or tumor antigen;(ii) at least one cancer or tumor epitope;(iii) at least one therapeutic protein for use in the treatment or prevention of cancer or tumor diseases; (iv) a multiepitope cancer vaccine, wherein the mRNA comprises an open reading frame encoding at least 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50, or more cancer antigen epitopes or neoepitopes expressed in the tumor in a subject in need; or(v) a personalized cancer vaccine, wherein the mRNA comprises an open reading frame encoding at least 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50, or more cancer antigen epitopes or neoepitopes expressed in the tumor in a subject in need.In the composition of the invention, the ionizable lipid may be present within, or as part of, lipid nanoparticles (LNPs). In other words, such composition comprises lipid nanoparticles, and the ionizable lipid is present in the lipid nanoparticles.In some embodiments, such lipid nanoparticles comprise an ionizable lipid of the invention (e.g., a lipid of Formula (I) or Formula (II), preferably CIL86) and one or more excipients selected from neutral lipids, charged lipids, sterols and polymer conjugated lipids (e.g., a polymer conjugated lipid of formula (X), preferably PMOZ4). As used herein, references to molar amounts of lipidic excipients in the composition of the invention should be understood as also describing the molar amounts of the respective excipients in the lipid nanoparticles comprised in the composition, as the lipid nanoparticles are typically formed by these excipients and reflect the same quantitative ratios of excipients as the overall composition containing the nanoparticles.In most preferred embodiments, the lipid nanoparticles of the invention comprise CIL86, DSPC, DPhyPS, cholesterol, and the polymer conjugated lipid “PMOZ 4” with n = 50 i.e. having 50 monomer repeats.In an aspect, the present invention provides a lipid nanoparticle comprising an ionizable lipid of the present disclosure, e.g., a compound of Formula (I) or Formula (II), preferably CIL86.In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the lipid nanoparticle further comprises a phospholipid.In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the phospholipid is selected from the group consisting of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-diphytanoyl-sn-glycero-3-phospho-L-serine (DPhyPS), 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16.0 PE; DPhyPE), 1,2-diphytanoyl-sn-glycero-3-phosphocholine (DPhyPC), 1,2-dioleoyl-sn-glycero-3-CureVac SE / P396WO1 65 / 219phosphoethanolamine (DOPE), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), and mixtures thereof, preferably wherein the phospholipid is 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC).In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the phospholipid is 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE).In a most preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the phospholipid is 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC).In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the lipid nanoparticle comprises a first and a different second phospholipid, preferably DSPC as first phospholipid and a phosphatidylserine as second phospholipid, more preferably DSPC as first phospholipid and DPhyPS as second phospholipid.In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the lipid component further comprises a sterol lipid.In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the sterol lipid is selected from the group consisting of cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid, alpha-tocopherol, and mixtures thereof, preferably wherein the sterol lipid is cholesterol.In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the sterol lipid is cholesterol.In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the lipid nanoparticle further comprises a polymer conjugated lipid.In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the polymer conjugated lipid is a poly(2-methyl-2-oxazoline) (PMOZ)-conjugated lipid, a poly(2-ethyl-2-oxazoline) (PEOZ)-conjugated lipid, or a polyethyleneglycol (PEG)-conjugated lipid, preferably wherein the polymer conjugated lipid has about 40 to about 60 PMOZ, PEOZ, or PEG monomer repeats.In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the polymer conjugated lipid is a poly(2-methyl-2-oxazoline) (PMOZ)-conjugated lipid, preferably wherein the polymer conjugated lipid has about 40 to about 60 PMOZ monomer repeats, and further preferably wherein the lipid nanoparticle does not comprise polyethyleneglycol, polyethyleneglycol-conjugated lipids, PEG-modified lipids or PEG-lipids.In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the polymer conjugated lipid is a poly(2-methyl-2-oxazoline) (PMOZ)-conjugated lipid, preferably a PMOZ-lipid notCureVac SE / P396WO1 66 / 219comprising a sulphur group (— S— ), more preferably a PMOZ-lipid comprising a linker group [linker] being (C(O)CH₂CH₂C(O)NH).In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the polymer conjugated lipid is “PMOZ 4” having 50 PMOZ monomer repeats(“PMOZ 4” having 50 PMOZ monomer repeats).In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the lipid nanoparticle comprises:20-60 mol% ionizable lipid of the present disclosure;5-25 mol% phospholipid of the present disclosure;25-55 mol% sterol of the present disclosure; and0.1-5 mol% polymer conjugated lipid of the present disclosure.In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the lipid nanoparticle comprises:45-55 mol% ionizable lipid according to any one of claims 1-7;5-15 mol% first phospholipid of the present disclosure;1-5 mol% second phospholipid of the present disclosure;30-50 mol% sterol, preferably cholesterol of the present disclosure; and0.1-2 mol% polymer conjugated lipid of the present disclosure, preferably a poly(2-methyl-2-oxazoline) (PMOZ)-conjugated lipid.In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the lipid nanoparticle comprises:45-55 mol% ionizable lipid according to any one of claims 1-7;5-10 mol% first phospholipid, preferably DSPC;2-3 mol% second phospholipid, preferably DPhyPS;35-45 mol% sterol, preferably cholesterol; and0.1-1 mol% PMOZ-conjugated lipid of the present disclosure, preferably “PMOZ 4” having 50 PMOZ monomer repeats.In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the lipid nanoparticle comprises:40-60 mol% ionizable lipid according to any one of claims 1-7;5-10 mol% first phospholipid, preferably DSPC;2-3 mol% second phospholipid, preferably DPhyPS;35-45 mol% sterol, preferably cholesterol; andCureVac SE / P396WO1 67 / 2190.9-1.1 mol% “PMOZ 4” having 50 PMOZ monomer repeats, preferably 1 mol%.In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the lipid nanoparticle comprises:40-60 mol% ionizable lipid according to any one of claims 1-7;5-10 mol% first phospholipid, preferably DSPC;2-3 mol% second phospholipid, preferably DPhyPS;35-45 mol% sterol, preferably cholesterol; and0.4-0.6 mol% “PMOZ 4” having 50 PMOZ monomer repeats.In a very preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the lipid nanoparticle comprises:40-50 mol% ionizable lipid according to any one of claims 1-7;5-10 mol% first phospholipid, preferably DSPC;2-3 mol% second phospholipid, preferably DPhyPS;35-45 mol% sterol, preferably cholesterol; and0.4-0.6 mol% “PMOZ 4” having 50 PMOZ monomer repeats.For the avoidance of doubt, in case molar ratios of lipid nanoparticles are recited with specific ranges, i.e. 40-60mol% or the like, the mol% of all component sum up to 100 mol%.In some preferred embodiments, the present invention provides a lipid nanoparticle of the present disclosure, wherein the lipid nanoparticle comprises:49 mol% ionizable lipid CIL867.5 mol% DSPC;2.5 mol% DPhyPSCureVac SE / P396WO1 68 / 219(“PMOZ 4” having 50 PMOZ monomer repeats).In a most preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the lipid nanoparticle comprises:49 mol% ionizable lipid CIL86CureVac SE / P396WO1 69 / 219(“PMOZ 4” having 50 PMOZ monomer repeats).In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the lipid nanoparticles further comprise an artificial nucleic acid, preferably selected from the group consisting of messenger RNA (mRNA), siRNA, RNAi, guide RNA (gRNA), IncRNA (long non-coding RNA), samRNA / saRNA (self-amplifying RNA; SAM vaccines), and circular RNA (circRNA), most preferably the artificial nucleic acid is messenger RNA (mRNA).In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the lipid nanoparticles further comprise messenger RNA (mRNA).In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the lipid nanoparticles further comprise messenger RNA (mRNA), wherein the mRNA(a) comprises at least one coding sequence encoding a peptide or protein, or a fragment or variant thereof, wherein the peptide or protein is an antigen, wherein the antigen preferably is, or is derived from, a cancer or tumor antigen, a cancer or tumor epitope, a pathogenic antigen, a viral antigen, a bacterial antigen, a tumor antigen, an allergenic antigen or an autoimmune self-antigen, preferably a cancer or tumor antigen or a cancer or tumor epitope; or(b) comprises at least one coding sequence encoding a therapeutic protein, or a fragment or variant thereof, wherein the therapeutic protein is selected from the group consisting of(i) therapeutic proteins for use in enzyme replacement therapy for the treatment of metabolic, endocrine or amino acid disorders or for use in replacing an absent, deficient or mutated protein;(ii) therapeutic proteins for use in the treatment of blood disorders, diseases of the circulatory system, diseases of the respiratory system, infectious diseases or immune deficiencies;(iii) therapeutic proteins for use in the treatment of cancer or tumor diseases;(iv) therapeutic proteins for use in hormone replacement therapy;(v) therapeutic proteins for use in reprogramming somatic cells into pluri- or omnipotent stem cells; (vi) therapeutic proteins for use as adjuvant or immunostimulation;(vii) therapeutic proteins being a therapeutic antibody;(viii) therapeutic proteins being a gene editing agent; and(ix) therapeutic proteins for use in treating or preventing a liver disease selected from the group consisting of liver fibrosis, liver cirrhosis and liver cancer,preferably wherein the therapeutic protein of (b) is a therapeutic protein for use in the treatment of cancer or tumor diseases.In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the lipid nanoparticles further comprise messenger RNA (mRNA)., wherein the mRNA encodes(i) at least one cancer or tumor antigen;(ii) at least one cancer or tumor epitope;(iii) at least one therapeutic protein for use in the treatment or prevention of cancer or tumor diseases; (iv) a multiepitope cancer vaccine, wherein the mRNA comprises an open reading frame encoding at least 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50, or more cancer antigen epitopes or neoepitopes expressed in the tumor in a subject in need; orCureVac SE / P396WO1 70 / 219(v) a personalized cancer vaccine, wherein the mRNA comprises an open reading frame encoding at least 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50, or more cancer antigen epitopes or neoepitopes expressed in the tumor in a subject in need.In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein (a) the lipid nanoparticle is delivered to the spleen tissue in an increased ratio than the liver;(b) the lipid nanoparticle is delivered to draining lymph nodes in an increased ratio than the liver;(c) the lipid nanoparticle is delivered to the muscle tissue of the site of injection in an increased ratio than the liver;(d) the artificial nucleic acid or the mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in the spleen tissue than in liver tissue;(e) the artificial nucleic acid or the mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in the draining lymph nodes tissue than in liver tissue;(f) the artificial nucleic acid or the mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in the muscle tissue of the site of injection than in liver tissue;(g) the peptide or protein encoded by the mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in the spleen tissue than in liver tissue;(h) the peptide or protein encoded by the mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in the draining lymph nodes tissue than in liver tissue; and / or(i) the peptide or protein encoded by the mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in the muscle tissue of the site of injection than in liver tissue;after administration of the lipid nanoparticle to a subject in need, preferably after intramuscular administration.In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein (a) the artificial nucleic acid or the mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in conventional type 1 dendritic cells (cDC1) as when compared to a reference lipid nanoparticle composition in which the ionizable lipid is replaced by a reference lipid or the phosphatidylserine lipid is replaced by cholesterol;(b) the artificial nucleic acid or the mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in macrophages as when compared to a reference lipid nanoparticle composition in which the ionizable lipid is replaced by a reference lipid or the phosphatidylserine lipid is replaced by cholesterol;(c) the peptide or protein encoded by the mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in conventional type 1 dendritic cells (cDC1) as when compared to a reference lipid nanoparticle composition in which the ionizable lipid is replaced by a reference lipid or the phosphatidylserine lipid is replaced by cholesterol; and / or(d) the peptide or protein encoded by the mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in macrophages as when compared to a reference lipid nanoparticle composition in which the ionizable lipid is replaced by a reference lipid or the phosphatidylserine lipid is replaced by cholesterol; after administration of the lipid nanoparticle to a subject in need, preferably after intramuscular administration.CureVac SE / P396WO1 71 / 219In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein (a) the artificial nucleic acid or the mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in conventional type 1 dendritic cells (cDC1) as when compared to a reference lipid nanoparticle composition in which the ionizable lipid and / or the polymer conjugated lipid is replaced by a reference lipid or the phosphatidylserine lipid is replaced by cholesterol;(b) the artificial nucleic acid or the mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in macrophages as when compared to a reference lipid nanoparticle composition in which the ionizable lipid and / or the polymer conjugated lipid is replaced by a reference lipid or the phosphatidylserine lipid is replaced by cholesterol;(c) the peptide or protein encoded by the mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in conventional type 1 dendritic cells (cDC1) as when compared to a reference lipid nanoparticle composition in which the ionizable lipid and / or the polymer conjugated lipid is replaced by a reference lipid or the phosphatidylserine lipid is replaced by cholesterol; and / or(d) the peptide or protein encoded by the mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in macrophages as when compared to a reference lipid nanoparticle composition in which the ionizable lipid and / or the polymer conjugated lipid is replaced by a reference lipid or the phosphatidylserine lipid is replaced by cholesterol;after administration of the lipid nanoparticle to a subject in need, preferably after intramuscular administration.In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the (i) mRNA or (ii) the peptide or protein encoded by said mRNA can be detected with a ratio of at least about 5:1, at least about 10:1, at least about 20:1, at least about 30:1, at least about 40:1, at least about 50:1, at least about 60:1, at least about 70:1, at least about 80:1, at least about 90:1, at least about 100:1, at least about 150:1, at least about 200:1, at least about 250:1, at least about 300:1, at least about 350:1, at least about 450:1, at least about 500:1, at least about 550:1, at least about 600:1, at least about 650:1, or at least about 700:1, or more in the spleen tissue versus the liver tissue when measured 4 hours post administration of the lipid nanoparticle to a subject in need, preferably after intramuscular administration,wherein the lipid nanoparticles comprise the mRNA at an amount such as to achieve an N / P ratio in the range from about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, or about 12, preferably in the range of about 7.CureVac SE / P396WO1 72 / 219In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the (i) mRNA or (ii) the peptide or protein encoded by said mRNA can be detected with a ratio of at least about 5:1, at least about 10:1, at least about 20:1, at least about 30:1, at least about 40:1, at least about 50:1, at least about 60:1, at least about 70:1, at least about 80:1, at least about 90:1, at least about 100:1, at least about 150:1, at least about 200:1, at least about 250:1, at least about 300:1, at least about 350:1, at least about 450:1, at least about 500:1, at least about 550:1, at least about 600:1, at least about 650:1, or at least about 700:1, or more in the spleen tissue versus the liver tissue when measured 6 hours post administration of the lipid nanoparticle to a subject in need, preferably after intramuscular administration,wherein the lipid nanoparticles comprise the mRNA at an amount such as to achieve an N / P ratio in the range from about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, or about 12, preferably in the range of about 7.In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the (i) mRNA or (ii) the peptide or protein encoded by said mRNA can be detected with a ratio of at least about 5:1, at least about 10:1, at least about 20:1, at least about 30:1, at least about 40:1, at least about 50:1, at least about 60:1, at least about 70:1, at least about 80:1, at least about 90:1, at least about 100:1, at least about 150:1, at least about 200:1, at least about 250:1, at least about 300:1, at least about 350:1, at least about 450:1, at least about 500:1, at least about 550:1, at least about 600:1, at least about 650:1, or at least about 700:1, or more in the spleen tissue versus the liver tissue when measured 24 hours post administration of the lipid nanoparticle to a subject in need, preferably after intramuscular administration,wherein the lipid nanoparticles comprise the mRNA at an amount such as to achieve an N / P ratio in the range from about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, or about 12, preferably in the range of about 7.In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the (i) mRNA or (ii) the peptide or protein encoded by said mRNA can be detected with a ratio of at least about 5:1, at least about 10:1, at least about 20:1, at least about 30:1, at least about 40:1, at least about 50:1, at least about 60:1, at least about 70:1, at least about 80:1, at least about 90:1, at least about 100:1, at least about 150:1, at least about 200:1, at least about 250:1, at least about 300:1, at least about 350:1, at least about 450:1, at least about 500:1, at least about 550:1, at least about 600:1, at least about 650:1, or at least about 700:1, or more(a) in the draining lymph nodes tissue versus the liver tissue; and / or(b) in the muscle tissue of the injection site versus the liver tissuewhen measured 4 hours post administration of the lipid nanoparticle to a subject in need, preferably after intramuscular administration,wherein the lipid nanoparticles comprise the mRNA at an amount such as to achieve an N / P ratio in the range from about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, or about 12, preferably in the range of about 7.In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the (i) mRNA or (ii) the peptide or protein encoded by said mRNA can be detected with a ratio of at least about 5:1, at least about 10:1, at least about 20:1, at least about 30:1, at least about 40:1, at least about 50:1, at least about 60:1, at least about 70:1, at least about 80:1, at least about 90:1, at least about 100:1, at least about 150:1, at leastCureVac SE / P396WO1 73 / 219about 200:1, at least about 250:1, at least about 300:1, at least about 350:1, at least about 450:1, at least about 500:1, at least about 550:1, at least about 600:1, at least about 650:1, or at least about 700:1, or more(a) in the draining lymph nodes tissue versus the liver tissue; and / or(b) in the muscle tissue of the injection site versus the liver tissuewhen measured 6 hours post administration of the lipid nanoparticle to a subject in need, preferably after intramuscular administration,wherein the lipid nanoparticles comprise the mRNA at an amount such as to achieve an N / P ratio in the range from about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, or about 12, preferably in the range of about 7.In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the (i) mRNA or (ii) the peptide or protein encoded by said mRNA can be detected with a ratio of at least about 5:1, at least about 10:1, at least about 20:1, at least about 30:1, at least about 40:1, at least about 50:1, at least about 60:1, at least about 70:1, at least about 80:1, at least about 90:1, at least about 100:1, at least about 150:1, at least about 200:1, at least about 250:1, at least about 300:1, at least about 350:1, at least about 450:1, at least about 500:1, at least about 550:1, at least about 600:1, at least about 650:1, or at least about 700:1, or more(a) in the draining lymph nodes tissue versus the liver tissue; and / or(b) in the muscle tissue of the injection site versus the liver tissuewhen measured 24 hours post administration of the lipid nanoparticle to a subject in need, preferably after intramuscular administration,wherein the lipid nanoparticles comprise the mRNA at an amount such as to achieve an N / P ratio in the range from about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, or about 12, preferably in the range of about 7.In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the (i) mRNA or (ii) the peptide or protein encoded by said mRNA can be detected with a ratio of about 50:1 to about 150:1 in the spleen tissue versus the liver tissue when measured 4 hours post administration of the lipid nanoparticle to a subject in need, preferably after intramuscular administration, wherein the lipid nanoparticles comprise the mRNA at an amount such as to achieve an N / P ratio of about 7.In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the (i) mRNA or (ii) the peptide or protein encoded by said mRNA can be detected with a ratio of about 50:1 to about 150:1 in the spleen tissue versus the liver tissue when measured 6 hours post administration of the lipid nanoparticle to a subject in need, preferably after intramuscular administration, wherein the lipid nanoparticles comprise the mRNA at an amount such as to achieve an N / P ratio of about 7.In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the (i) mRNA or (ii) the peptide or protein encoded by said mRNA can be detected with a ratio of about 50:1 to about 150:1 in the spleen tissue versus the liver tissue when measured 24 hours post administration of the lipid nanoparticle to a subject in need, preferably after intramuscular administration, wherein the lipid nanoparticles comprise the mRNA at an amount such as to achieve an N / P ratio of about 7.CureVac SE / P396WO1 74 / 219In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the (i) mRNA or (ii) the peptide or protein encoded by said mRNA can be detected with a ratio of at least about 50:1, to about 200:1 in the draining lymph nodes tissue versus the liver tissue, when measured 4 hours post administration of the lipid nanoparticle to a subject in need, preferably after intramuscular administration, wherein the lipid nanoparticles comprise the mRNA at an amount such as to achieve an N / P ratio of about 7.In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the (i) mRNA or (ii) the peptide or protein encoded by said mRNA can be detected with a ratio of about 50:1 to about 150:1 in the spleen tissue versus the liver tissue when measured 4 hours post administration of the lipid nanoparticle to a subject in need, preferably after intramuscular administration, wherein the lipid nanoparticles comprise the mRNA at an amount such as to achieve an N / P ratio of about 7.In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the (i) mRNA or (ii) the peptide or protein encoded by said mRNA can be detected with a ratio of at least about 50:1, to about 200:1 in the draining lymph nodes tissue versus the liver tissue, when measured 4 hours post administration of the lipid nanoparticle to a subject in need, preferably after intramuscular administration, wherein the lipid nanoparticles comprise the mRNA at an amount such as to achieve an N / P ratio of about 7.In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the (i) mRNA or (ii) the peptide or protein encoded by said mRNA can be detected with a ratio of at least about 50:1, to about 200:1 in the muscle tissue of the injection site versus the liver tissue, when measured 4 hours post administration of the lipid nanoparticle to a subject in need, preferably after intramuscular administration, wherein the lipid nanoparticles comprise the mRNA at an amount such as to achieve an N / P ratio of about 7.In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the (i) mRNA or (ii) the peptide or protein encoded by said mRNA can be detected with a ratio of at least about 50:1, to about 200:1 in the muscle tissue of the injection site versus the liver tissue, when measured 4 hours post administration of the lipid nanoparticle to a subject in need, preferably after intramuscular administration, wherein the lipid nanoparticles comprise the mRNA at an amount such as to achieve an N / P ratio of about 7.In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the (i) mRNA or (ii) the peptide or protein encoded by said mRNA can be detected with a ratio of at least about 50:1, to about 200:1 in the muscle tissue of the injection site versus the liver tissue, when measured 6 hours post administration of the lipid nanoparticle to a subject in need, preferably after intramuscular administration, wherein the lipid nanoparticles comprise the mRNA at an amount such as to achieve an N / P ratio of about 7.In a preferred embodiment, the present invention provides a lipid nanoparticle of the present disclosure, wherein the (i) mRNA or (ii) the peptide or protein encoded by said mRNA can be detected with a ratio of at least about 50:1, to about 200:1 in the muscle tissue of the injection site versus the liver tissue, when measured 24 hours post administration of the lipid nanoparticle to a subject in need, preferably after intramuscular administration, wherein the lipid nanoparticles comprise the mRNA at an amount such as to achieve an N / P ratio of about 7.In a further preferred embodiment, the composition comprises lipid nanoparticles which comprise:CureVac SE / P396WO1 75 / 219(a) an ionizable lipid, preferably according to Formula (I) or Formula (II), more preferably according to Formula (I), most preferably CIL86, at an amount of 30-70 mol%;(b) a sterol at an amount of about 20-50 mol%, preferably cholesterol;(c) a neutral lipid at an amount of about 5-15 mol%, preferably DSPC;(d) a polymer conjugated lipid, preferably “PMOZ 4” with n = 50 i.e. having 50 monomer repeats at an amount of about 0.1-2 mol%, more preferably at an amount of about 0.4 mol% to about 0.6 mol%, most preferably of about 0.5 mol%; and(e) a phosphatidylserine, preferably DPhyPS, at an amount of about 1-5 mol%;each amount being relative to the total molar amount of all lipidic excipients of the lipid nanoparticles.In another embodiment, the composition comprises lipid nanoparticles comprising:(a) an ionizable lipid, preferably according to Formula (I) or Formula (II), more preferably according to Formula (I), most preferably CIL86, at an amount of 40-60 mol%;(b) a sterol at an amount of 35-45 mol%, preferably cholesterol;(c) a neutral lipid at an amount of 5-10 mol%, preferably DSPC;(d) a polymer conjugated lipid, preferably “PMOZ 4” with n = 50 i.e. having 50 monomer repeats at an amount of about 0.1-2 mol%, more preferably at an amount of about 0.4 mol% to about 0.6 mol%, most preferably of about 0.5 mol%; and(e) a phosphatidylserine, preferably DPhyPS, at an amount of about 2-3 mol%;each amount being relative to the total molar amount of all lipidic excipients of the lipid nanoparticles.In a very preferred embodiment, the composition comprises lipid nanoparticles which comprise:(a) an ionizable lipid, preferably according to Formula (I) or Formula (II), more preferably according to Formula (I), most preferably CIL86, at an amount of about 49 mol%;(b) a sterol at an amount of 40.5 mol%, preferably cholesterol;(c) a neutral lipid at an amount of about 7.5 mol%, preferably DSPC;(d) a polymer conjugated lipid, preferably “PMOZ 4” with n = 50 i.e. having 50 monomer repeats at an amount of about 0.5 mol%; and(e) a phosphatidylserine, preferably DPhyPS, at an amount of about 2.5 mol%;each amount being relative to the total molar amount of all lipidic excipients of the lipid nanoparticles.In a most preferred embodiment, the composition comprises lipid nanoparticles which comprise:(a) CIL86, at an amount of about 49 mol%;(b) cholesterol, at an amount of about 40.5 mol%;(c) 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), at an amount of about 7.5 mol%;(d) “PMOZ 4” with n = 50 i.e. having 50 monomer repeats at an amount of about 0.5 mol%; and(e) DPhyPS, at an amount of about 2.5 mol%;each amount being relative to the total molar amount of all lipidic excipients of the lipid nanoparticles.In some embodiments, the lipids mol% relative to the lipid component will be about ±30%, about ±25%, about ±20%, about ±15%, about ±10%, about ±5%, or about ±2.5% of the specified, nominal, or actual lipid mol%. In some embodiments, the lipid mol% relative to the lipid component will be about ±4 mol %, about ±3 mol%, about ±2 mol%, about ±1.5 mol%, about ±1 mol%, about ±0.5 mol%, about ±0.25 mol%, about ±0.2 mol%, about ±0.1 mol%, about ±0.05 mol%, or about ±0.01 mol% of the specified, nominal, or actual mol%. In certain embodiments, LNP inter-lot variability will be less than about 30%, less than about 25%, less than about 20%, less than about 15%, less thanCureVac SE / P396WO1 76 / 219about 10% or less than about 5%. In some embodiments, the mol% numbers are based on nominal concentration. In some embodiments, the mol% numbers are based on actual concentration.In some embodiments, LNP compositions of the invention are formed by mixing an aqueous RNA solution with an organic solvent-based lipid solution. Suitable solutions or solvents include or may contain water, PBS, Tris buffer, NaCI, citrate buffer, acetate buffer, ethanol, chloroform, diethylether, cyclohexane, tetrahydrofuran, methanol, isopropanol. For example, the organic solvent may be 100% ethanol. A pharmaceutically acceptable buffer, e.g., for in vivo administration of LNP compositions, may be used. In certain embodiments, a buffer is used to maintain the pH of the composition comprising LNPs at or above pH 6.5. In certain embodiments, a buffer is used to maintain the pH of the composition comprising LNPs at or above pH 7.0. In certain embodiments, the composition has a pH ranging from about 7.2 to about 7.7. In additional embodiments, the composition has a pH ranging from about 7.3 to about 7.7 or ranging from about 7.4 to about 7.6. In further embodiments, the composition has a pH of about 7.2, 7.3, 7.4, 7.5, 7.6, or 7.7. The pH of a composition may be measured with a micro pH probe. In certain embodiments, a cryoprotectant is included in the composition. Non-limiting examples of cryoprotectants include sucrose, trehalose, glycerol, DMSO, and ethylene glycol. Exemplary compositions may include up to 10% cryoprotectant, such as, for example, sucrose. In certain embodiments, the composition may comprise tris saline sucrose (TSS). In certain embodiments, the LNP composition may include about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10% cryoprotectant. In certain embodiments, the LNP composition may include about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10% sucrose. In some embodiments, the LNP composition may include a buffer. In some embodiments, the buffer may comprise a phosphate buffer (PBS), a Tris buffer, a citrate buffer, and mixtures thereof. In certain exemplary embodiments, the buffer comprises NaCI. In certain embodiments, the buffer lacks NaCI. Exemplary amounts of NaCI may range from about 20 mM to about 45 mM. Exemplary amounts of NaCI may range from about 40 mM to about 50 mM. In some embodiments, the amount of NaCI is about 45 mM. In some embodiments, the buffer is a Tris buffer. Exemplary amounts of Tris may range from about 20 mM to about 60 mM. Exemplary amounts of Tris may range from about 40 mM to about 60 mM. In some embodiments, the amount of Tris is about 50 mM. In some embodiments, the buffer comprises NaCI and Tris. Certain exemplary embodiments of the LNP compositions contain 5% sucrose and 45 mM NaCI in Tris buffer. In other exemplary embodiments, compositions contain sucrose in an amount of about 5% w / v, about 45 mM NaCI, and about 50 mM Tris at pH 7.5. In some embodiments, the buffer is a PBS / sucrose buffer (pH 7.4, 75 mM NaCI, 10 mM phosphate, 150 mM sucrose). In other embodiments, the buffer is TGS (30mM Tris, 100mM glycerol, 150mM sucrose). In further embodiments, the buffer is 30mM Tris 300mM sucrose. The salt, buffer, and cryoprotectant amounts may be varied such that the osmolality of the overall composition is maintained. For example, the final osmolality may be maintained at less than 450 mOsm / l. In further embodiments, the osmolality is between 350 and 250 mOsm / l. Certain embodiments have a final osmolality of 300 + / - 20 mOsm / l or 310 + / -40 mOsm / l.In one embodiment, the present invention provides the lipid nanoparticle of the invention, wherein the lipid nanoparticles have a lipid to mRNA weight ratio (m / m) in the range of about 20 to about 60, more preferably about 30 to about 50, even more preferably about 40, about 41, about 42, about 43, about 44 or about 45.In one embodiment, the present invention provides the lipid nanoparticle of the invention, wherein the lipid nanoparticle is a sterile solid composition for reconstitution with a sterile liquid carrier, and wherein the lipid nanoparticle further comprises one or more inactive ingredients selected from pH-modifying agents, bulking agents, stabilizers, non-ionic surfactants and antioxidants, and wherein the sterile liquid carrier is an aqueous carrier.CureVac SE / P396WO1 77 / 219In one embodiment, the present invention provides the lipid nanoparticle of the invention, wherein the lipid nanoparticle is a sterile liquid composition, and wherein the lipid nanoparticles have a mean hydrodynamic diameter as determined by dynamic laser scattering from about 50 nm to about 300 nm, or from about 60 nm to about 250 nm, or from about 60 nm to about 200 nm, or from about 70 to 200 nm, or from about 75 nm to about 160, or from about 85 nm to about 140 nm, or from about 90 nm to about 130 nm, or from about 50 nm to about 120 nm. Phospholipid, Neutral lipid, neutral phospholipidA “phospholipid”, “neutral lipid”, also termed “helper lipid” according to the invention preferably is a phospholipid or neutral phospholipid. As used herein, a “neutral phospholipid” is an amphiphilic compound consisting of molecules that typically have two hydrophobic fatty acid “tails” and a hydrophilic “head” comprising a phosphate group. The phosphate group can be modified with simple organic molecules such as choline, ethanolamine or serine. Phospholipids occur abundantly in nature. For example, they represent a significant fraction of the excipients of biological membranes. As used herein, the expression “phospholipid” or “neutral phospholipid” covers both natural and synthetic phospholipids.In a preferred embodiment, the phospholipid is a zwitterionic compound selected from, but not limited to the group of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (DPhyPE; also referred to as 1,2-di-(3,7, 11,15-tetramethylhexadecanoyl)-sn-glycero-3-phosphoethanolamine), 1,2-diphytanoyl-sn-glycero-3-phosphocholine (DPhyPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC; also referred to as dioleoylphosphatidylcholine), 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC, also referred to as dipalmitoylphosphatidylcholine), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), phosphatidylethanolamines, distearoylphosphatidylcholines, dioleoyl-phosphatidylethanolamine (DOPEA), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyl-oleoyl-phosphatidylethanolamine (POPE), 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE), dioleoylphosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1 -carboxylate (DOPE-mal), 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE), 1,2-Dilinoleoyl-sn-glycero-3-phosphoethanolamine (DLoPE), distearoylphosphatidylethanolamine (DSPE), 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE), 1,2-Di-lauroyl-sn-glycero-3-phosphoethanolamine (DLPE), 16-O-monomethylphosphoethanolamine, 16-O-dimethyl phosphatidylethanolamine, 1,2-Dierucoyl-sn-glycero-3-phosphoethanolamine (DEPE), 18-1 -trans phosphatidylethanolamine, 1-stearoyl-2-oleoylphosphatidyethanolamine (SOPE), 1,2-Disqualeoyl-sn-glycero-3-phospho-ethanolamine (DSQPE), 1,2-dielaidoyl-sn-glycero-3-phosphoethanolamine (transDOPE), 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphoethanolamine (SLPE), 1-tridecanoyl-sn-glycero-3-phospho-L-serine (sodium salt), 1-oleoyl-2-hydroxy-sn-glycero-3-phospho-L-serine (sodium salt), 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine (sodium salt) (POPS), 1-1-stearoyl-2-oleoyl-sn-glycero-3-phospho-L-serine (sodium salt), 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (sodium salt) (DOPS), 1,2-distearoyl-sn-glycero-3-phospho-L-serine (sodium salt), 1,2-diphytanoyl-sn-glycero-3-phospho-L-serine (sodium salt), 1-O-hexadecanyl-2-O-(9Z-octadecenyl)-sn-glycero-3-phosphoethanolamine, 1,2-distearoyl-sn-glycero-3-phosphatidylcholine, 1,2-di-O-phytanyl-sn-glycero-3-phosphoethanolamine, 1 -palmitoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (PChemsPC), 1,2-dicholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (DChemsPC), 2-((2,3-bis(oleoyloxy)propyl)dimethylammonio)ethyl hydrogen phosphate (DOCP), 2-((2,3-bis(oleoyloxy)propyl)dimethylammonio)ethyl ethyl phosphate (DOCPe), and 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine (Edelfosine).In one embodiment, the phospholipid according to the invention is 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (DPhyPE), as depicted here:CureVac SE / P396WO1 78 / 219(DPhyPE).In most preferred embodiments, the lipid nanoparticle of the invention comprises 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) as neutral lipid.In various embodiments, the molar ratio of the ionizable lipid to the neutral lipid in the lipid nanoparticle of the invention ranges from about 2:1 to about 8:1.In one embodiment, the lipid nanoparticle of the invention comprises from about 5 mol% to about 20 mol% or from about 7,5 mol% to about 17,5 mol% phospholipid, preferably DSPC, calculated from the total lipid present in the lipid nanoparticle of the invention. In some embodiments, the lipid nanoparticles of the invention comprise about 5 mol% to about 15 mol%, preferably from about 5 mol% to about 10 mol%, more preferably from about 6 mol% to about 9 mol%, or even more preferably about 7 mol% to about 8 mol%, even more preferably about 7,5 mol% phospholipid, preferably DSPC, calculated from the total lipid present in the lipid nanoparticle of the invention. Most preferably the lipid nanoparticle of the invention comprises about 7,5 mol% DSPC, calculated from the total lipid present in the lipid nanoparticle of the invention.CureVac SE / P396WO1 79 / 219In preferred embodiments, the lipid nanoparticles of the invention comprise about 1 mol% to about 5 mol%, about 1.5 mol% to about 4 mol%, about 2 mol% to about 3 mol%, most preferably about 2.5 mol% of a phosphatidylserine, preferably DPhyPS, calculated from the total lipid present in the lipid nanoparticle of the invention.In most preferred embodiments, the lipid nanoparticle of the invention comprises DPhyPS as phosphatidylserine (or respectively second phospholipid).In most preferred embodiments, the lipid nanoparticles of the invention comprise about 2.5 mol% DPhyPS, calculated from the total lipid present in the lipid nanoparticle of the invention. In equally most preferred embodiments, the lipid nanoparticles from the invention comprise about 7.5 mol% DSPC and additionally a about 2.5 mol% DPhyPS, calculated from the total lipid present in the lipid nanoparticle of the invention.Sterols and neutral sterols include both naturally occurring sterols and analogues thereof (e.g. being amphipathic lipid cholesteryl hemisuccinate (CHEMS) which consists of succinic acid esterified to the beta-hydroxyl group of cholesterol as cholesterol derivate). Using the definition for “neutral” as provided herein, the neutral sterol may be a sterol either having no atoms or groups that are ionizable under physiological conditions, or it may be a zwitterionicCureVac SE / P396WO1 80 / 219sterol. In one of the preferred embodiments, the neutral sterol is free of atoms or groups that are ionizable under physiological conditions. In some preferred embodiments, the sterol or sterol analogue is cholesterol. The term “steroid”, “neutral steroid”, “sterol”, “neutral sterol”, “steroid lipid” or “sterol lipid” are used herein interchangeably. In other embodiments, the sterol may be selected from the group consisting of a phytosterol, e.g. [3-sitosterol, campesterol, stigmasterol, fucosterol, stigmastanol, dihydrocholesterol, ent-cholesterol, epi-cholesterol, desmosterol, cholestanol, cholestanone, cholestenone, cholesteryl-2’-hydroxyethyl ether, cholesteryl-4’-hydroxybutyl ether, 3p-[N-(N’N’- dimethylaminoethyl)carbamoyl cholesterol (DC-Chol), 24(S)-hydroxycholesterol, 25-hydroxy cholesterol, 25(R)-27-hydroxycholesterol, 22-oxacholesterol, 23-oxacholesterol, 24-oxacholesterol, cycloartenol, 22-ketosterol, 20-hydroxysterol, 7-hydroxycholesterol, 19-hydroxycholesterol, 22-hydroxycholesterol, 25-hydroxy cholesterol, 7-dehydrocholesterol, 5a-cholest-7-en-3p-ol, 3,6,9-trioxaoctan-1-ol-cholesteryl-3e-ol, dehydroergosterol, dehydroepiandrosterone, lanosterol, dihydrolanosterol, lanostenol, lumisterol, sitocalciferol, calcipotriol, coprostanol, cholecalciferol, lupeol, ergocalciferol, 22-dihydroegocalciferol, ergosterol, brassicasterol, tomatidine, tomatine, ursolic acid, cholic acid, chenodeoxycholic acid, zymosterol, diosgenin, fucosterol, fecosterol, or fecosterol, or a salt or ester thereof, cholesterol, cholesterol succinic acid, cholesterol sulfate, cholesterol hemisuccinate, cholesterol phthalate, cholesterol phosphate, cholesterol valerate, cholesterol acetate, cholesteryl oleate, cholesteryl linoleate, cholesteryl myristate, cholesteryl palmitate, cholesteryl arachidate, cholesteryl phosphorylcholine, and sodium cholate.In a further embodiment, the sterol is an imidazole cholesterol ester or “ICE” as disclosed in paragraphs

[0320] and

[0339] -

[0340] of WO2019226925; which is herein incorporated by reference in its entirety.In other preferred embodiments, the lipid nanoparticle of the invention comprised in the pharmaceutical composition comprise a sterol, sterol analogue or sterol.In a most preferred embodiment, the lipid nanoparticle of the invention comprises cholesterol as sterol lipid. The molar ratio of the ionizable lipid to cholesterol in the lipid nanoparticle of the invention may be in the range from about 2:1 to about 1:1.In some embodiments, the lipid nanoparticle of the invention comprises about 10 mol% to about 60 mol% or about 25 mol% to about 50 mol% sterol, preferably cholesterol (based on 100% total moles of lipids in the lipid nanoparticle of the invention). In a preferred embodiment, the amount of the sterol in the composition is from about 35 mol% to about 45 mol%, calculated from the total lipid present in the lipid nanoparticle of the invention. In a more preferred embodiment, the sterol, preferably cholesterol is about 38 mol%, about 39 mol%, about 40 mol%, about 41 mol%, or about 42 mol%, calculated from the total lipid present in the lipid nanoparticle of the invention.Most preferably the lipid nanoparticle of the invention comprises about 40.5 mol% cholesterol, calculated from the total lipid present in the lipid nanoparticle of the invention.CureVac SE / P396WO1 81 / 219Polymer conjugated lipidThe term "polymer conjugated lipid" or “polymer lipid” refers to a molecule comprising both a lipid portion and a polymer portion. An example of a polymer conjugated lipid is a pegylated lipid, i.e. a molecule comprising both a lipid portion and a polyethylene glycol portion.In a preferred embodiment, the “polymer conjugated lipid” as comprised in the lipid nanoparticles of the invention is a compound according to formula (X):[P]-[linker]-[L] formula (X)or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein[P] is a homopolymer moiety comprising at least one polyoxazoline (POZ) monomer unitwherein R is C1-9 alkyl or C2-9 alkenyl, preferably C1 or C2 alkyl, and n has a mean value ranging from about 45 to about 55, preferably n is about 50 or wherein n is selected such that the [P] moiety has an average molecular weight of about 4.2 kDa to about 4.4 kDa, or most preferably about 4.3 kDa[linker] is an optional linker group, and[L] is a lipid moiety.In another embodiment, the polymer conjugated lipid as comprised in the lipid nanoparticles of the invention comprises as [P] a heteropolymer moiety or homopolymer moiety comprising multiple monomer units selected from the group consisting ofpoly(2-methyl-2-oxazoline) (PMOZ)poly(2-propyl-2-oxazoline) (PPOZ)CureVac SE / P396WO1 82 / 219poly(2-methoxymethyl-2-oxazoline) (PMeOMeOx), andpoly(2-dimethylamino-2-oxazoline) (PDMAOx),preferably wherein [P] is a homopolymer moiety comprising multiple PMOZ or PEOZ monomer units, more preferably wherein [P] comprises or preferably consists of multiple PMOZ monomer units,wherein(i) n has a mean value ranging from about 45 to about 55, preferably n is about 50 or wherein(ii) n is selected such that the [P] moiety has an average molecular weight of about 4.2 kDa to about 4.4 kDa, or most preferably about 4.3 kDa.In another embodiment, the “polymer conjugated lipid” as comprised in the lipid nanoparticles of the invention comprises as [P] a heteropolymer moiety or homopolymer moiety comprising multiple monomer units selected from the group consisting of poly(2-propyl-2-oxazoline) (PPOZ), poly(2-butyl-2-oxazoline) (PBOZ), poly(2-isopropyl-2-oxazoline) (PIPOZ), poly(2-methoxymethyl-2-oxazoline) (PMeOMeOx), and poly(2-dimethylamino-2-oxazoline) (PDMAOx) preferably wherein [P] comprises or preferably consists of multiple PMOZ monomer units, wherein (i) n has a mean value ranging from about 45 to about 55, preferably n is about 50 or wherein(ii) n is selected such that the [P] moiety has an average molecular weight of about 4.2 kDa to about 4.4 kDa, or most preferably about 4.3 kDa.In another embodiment, the “polymer conjugated lipid” as comprised in the lipid nanoparticles of the invention comprises a [P] moiety of about 3.8 kDa to about 4.8 kDa, about 3.9 kDa to about 4.7 kDa, about 4 kDa to about 4.6 kDa, about 4.1 kDa to about 4.5 kDa, about 4.2 kDa to about 4.4 kDa, or most preferably about 4.3 kDa. Other preferred average molecular masses of the [P] moiety are (i) about 3.9 kDa to about 4.4 kDa, about 3.9 kDa to about 4.1 kDa, or about 4.2 kDa to about 4.4 kDa.CureVac SE / P396WO1 83 / 219In another embodiment, the “polymer conjugated lipid” as comprised in the lipid nanoparticles of the invention comprises a [P] moiety having above 4.3 kDa. In other preferred embodiments, the preferred average molecular mass of the [P] moiety is about 4.25 kDa to about 4.675 kDa, about 4.675 kDa to about 5.1 kDa, about 5.1 kDa to about 5.525 kDa, about 5.525 kDa to about 5.95 kDa, about 5.95 kDa to about 6.375 kDa, about 6.375 kDa to about 6.8 kDa, or above 6.8 kDa.In another embodiment, the “polymer conjugated lipid” as comprised in the lipid nanoparticles of the invention comprises a homopolymer moiety according towherein n has a mean value ranging from about 40 to about 80, preferably from about 45 to about 70, more preferably from about 50 to about 60, or most preferably n having a mean value of about 50. In further preferred embodiments, n has a mean value of more than 50. In other preferred embodiments, n has a mean value of about 55, about 60, about 65, about 70, about 75 or about 80.Thus the PMOZ moiety preferably is a PMOZ moiety having a molecular mass of about 4.3 kDa, although also shorter and longer moieties can also be used.In a further most preferred embodiment, the polymer conjugated lipid comprises a lipid moiety [L] comprising ditetradecylamin and a linker group [linker], preferably wherein the linker group [linker] is (C(O)CH₂CH₂C(O)NH). In a further preferred embodiment, the lipid moiety [L] comprises ditetradecylamin, wherein the linker moiety [linker], preferably ( — NHC(O)CH₂CH₂C(O) — ), is forming an amide connection by connection to the N-atom of ditetradecylamin.In a very preferred embodiment, the lipid moiety [L] is the lipid moiety as used in “PMOZ 4” as shown herein below. In a very preferred embodiment, the linker moiety [linker] is the linker moiety as used in “PMOZ 4” as shown herein below.In a most embodiment, the polymer conjugated lipid as comprised in the lipid nanoparticles of the invention is “PMOZ 4” with n = 50 i.e. having 50 monomer repeats as shown herein below:(“PMOZ 4” with n = 50 i.e. having 50 monomer repeats).CureVac SE / P396WO1 84 / 219In further most preferred embodiment, the invention relates to a polymer conjugated lipid having a lipid moiety [L], being the lipid moiety as used in “PMOZ 4”. In another most preferred embodiment, the invention relates to a polymer conjugated lipid having a linker moiety [linker], being the linker as used in “PMOZ 4” with n = 50 i.e. having 50 monomer repeats.In preferred embodiments, the lipid nanoparticle of the invention comprises from about 0.1 mol% to about 1.5 mol% or from about 0.2 mol% to about 1 mol% polymer conjugated lipid, preferably “PMOZ 4”, calculated from the total lipid present in the lipid nanoparticle of the invention. In other preferred embodiments, the lipid nanoparticles of the invention comprise about 0.3 mol% to about 0.7 mol%, preferably from about 0.4 mol% to about 0.6 mol%, more preferably about 0.5 mol% polymer conjugated lipid, preferably “PMOZ 4” with n = 50 i.e. having 50 monomer repeats, calculated from the total lipid present in the lipid nanoparticle of the invention.In some preferred embodiments, the lipid nanoparticle of the invention comprises about 1 mol% “PMOZ 4” with n = 50 i.e. having 50 monomer repeats, calculated from the total lipid present in the lipid nanoparticle of the invention. Most preferably the lipid nanoparticle of the invention comprises about 0.5 mol% “PMOZ 4” with n = 50 i.e. having 50 monomer repeats, calculated from the total lipid present in the lipid nanoparticle of the invention.Lipid nanoparticle compositions ratiosIn a preferred embodiment, the lipid nanoparticles of the invention comprise an ionizable lipid of the invention (e.g., a lipid of Formula (I), preferably CIL86) and one or more excipients selected from neutral lipids (phospholipids), charged lipids, sterols and polymer conjugated lipids (e.g., a polymer conjugated lipid of Formula (X) as described herein below, preferably PMOZ 4). In more preferred embodiments, the lipid nanoparticles of the invention comprise CIL86, DSPC, DPhyPS, cholesterol, and the polymer conjugated lipid “PMOZ 4” with n = 50 i.e. having 50 monomer repeats. In a most preferred embodiment, the present invention provides a lipid nanoparticle, wherein the lipid nanoparticle comprises the ionizable lipid CIL86, DSPC, DPhyPS, cholesterol and “PMOZ 4” having 50 PMOZ monomer repeats with the mol% of 49: 7.5: 2.5: 40.5: 0.5.More specifically, in a further preferred embodiment, the present invention provides a lipid nanoparticle, wherein the lipid nanoparticle comprises:20-60 mol% ionizable lipid of the present disclosure;5-25 mol% phospholipid of the present disclosure;25-55 mol% sterol of the present disclosure; and0.1-5 mol% polymer conjugated lipid of the present disclosure.In other embodiments, the present invention provides a lipid nanoparticle, wherein the lipid nanoparticle comprises:(a) an ionizable lipid, preferably according to Formula (I), more preferably according to Formula (I), most preferably CIL86, at an amount of 30-70 mol%;(b) a sterol at an amount of about 20-50 mol%, preferably cholesterol;(c) a neutral lipid at an amount of about 5-15 mol%, preferably DSPC;(d) a polymer conjugated lipid, preferably “PMOZ 4” with n = 50 i.e. having 50 monomer repeats at an amount of about 0.1-2 mol%, more preferably at an amount of about 0.4 mol% to about 0.6 mol%, most preferably of about 0.5 mol%; and(e) a phosphatidylserine, preferably DPhyPS, at an amount of about 1-5 mol%;CureVac SE / P396WO1 85 / 219each amount being relative to the total molar amount of all lipidic excipients of the lipid nanoparticles.In other embodiments, the present invention provides a lipid nanoparticle, wherein the lipid nanoparticle comprises:(a) an ionizable lipid, preferably according to Formula (I), more preferably according to Formula (I), most preferably CIL86, at an amount of 40-60 mol%;(b) a sterol at an amount of 35-45 mol%, preferably cholesterol;(c) a neutral lipid at an amount of 5-10 mol%, preferably DSPC;(d) a polymer conjugated lipid, preferably “PMOZ 4” with n = 50 i.e. having 50 monomer repeats at an amount of about 0.1-2 mol%, more preferably at an amount of about 0.4 mol% to about 0.6 mol%, most preferably of about 0.5 mol%; and(e) a phosphatidylserine, preferably DPhyPS, at an amount of about 2-3 mol%;each amount being relative to the total molar amount of all lipidic excipients of the lipid nanoparticles.In other embodiments, the present invention provides a lipid nanoparticle, wherein the lipid nanoparticle comprises:(a) an ionizable lipid, preferably according to Formula (I), more preferably according to Formula (I), most preferably CIL86, at an amount of about 49 mol%;(b) a sterol at an amount of 40.5 mol%, preferably cholesterol;(c) a neutral lipid at an amount of about 7.5 mol%, preferably DSPC;(d) a polymer conjugated lipid, preferably “PMOZ 4” with n = 50 i.e. having 50 monomer repeats at an amount of about 0.5 mol%; and(e) a phosphatidylserine, preferably DPhyPS, at an amount of about 2.5 mol%;each amount being relative to the total molar amount of all lipidic excipients of the lipid nanoparticles.In other embodiments, the present invention provides a lipid nanoparticle, wherein the lipid nanoparticle comprises:(a) CIL86, at an amount of about 49 mol%;(b) cholesterol, at an amount of about 40.5 mol%;(c) 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), at an amount of about 7.5 mol%;(d) “PMOZ 4” with n = 50 i.e. having 50 monomer repeats at an amount of about 0.5 mol%; and(e) DPhyPS, at an amount of about 2.5 mol%;each amount being relative to the total molar amount of all lipidic excipients of the lipid nanoparticles.Tumor indications, Tumor antigens, and Cancer disease treatmentIn very preferred aspects and embodiments, the mRNA comprised within the lipid nanoparticles of the invention is an mRNA encoding a tumor antigen as described herein, i.e. being suitable for tumor indications and / or cancer disease treatment.The terms “disease-associated antigen” or "cancer-associated antigen" or equally “cancer antigen” are used in the broadest sense to refer to any antigen associated with a (cancer) disease. A cancer antigen or disease-associated antigen is a molecule which contains epitopes that will stimulate a host's immune system to make a cellular antigenspecific immune response and / or a humoral antibody response against the disease.CureVac SE / P396WO1 86 / 219As used herein, the terms “tumor”, “cancer” or “cancer disease” refer to a malignant disease, which is preferably selected from, but not limited to, the group of malignant diseases disclosed on pages 58-59 in W02018078053; WO2018078053 being incorporated herein by reference in its entirety. I.e., the mRNA used in the lipid nanoparticles of the invention preferably comprises a cancer antigen or a combination of cancer antigens, i.e. the cancer antigen may be any antigen that is associated with cancer or that can elicit an immune response against cancer. Examples of cancer antigens that can be used in the present invention include but are not limited to, melanoma-associated antigen (MAGE), melanoma antigen gene family (MAGE), tyrosinase, glycoprotein 100 (GP100), prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA), carcinoembryonic antigen (CEA), human epidermal growth factor receptor 2 (HER2), epithelial cell adhesion molecule (EpCAM), mesothelin, NY-ESO-1, survivin, Wilms tumor antigen (WT1), PMEL, KLK3, FOLH1, CEACAM5, ERBB2, EpCAM / EPCAM, CTAG1B, BIRC5, and the like.Disease-associated antigens include pathogen-associated antigens, i.e., antigens which are associated with infection by microbes, typically microbial antigens (such as bacterial or viral antigens), or antigens associated with cancer, typically tumors, such as tumor antigens.In a preferred embodiment, the peptide or protein encoded by the mRNA of the invention is a tumor antigen, i.e., a part of a tumor cell, in particular those which primarily occur intracellularly or as surface antigens of tumor cells. In another embodiment, the antigen is a pathogen-associated antigen, i.e., an antigen derived from a pathogen, e.g., from a virus, bacterium, unicellular organism, or parasite, for example a viral antigen such as viral ribonucleoprotein or coat protein. In particular, the antigen should be presented by MHO molecules which results in modulation, in particular activation of cells of the immune system, preferably CD4+ and CD8+ lymphocytes, in particular via the modulation of the activity of a T -cell receptor. The term "tumor antigen" refers to a constituent of cancer cells which may be derived from the cytoplasm, the cell surface or the cell nucleus. In particular, it refers to those antigens which are produced intracellularly or as surface antigens on tumor cells. For example, tumor antigens include the carcinoembryonal antigen, a 1 -fetoprotein, isoferritin, and fetal sulphoglycoprotein, a2-H-ferroprotein and g-fetoprotein, as well as various virus tumor antigens. According to the present disclosure, a tumor antigen preferably comprises any antigen which is characteristic for tumors or cancers as well as for tumor or cancer cells with respect to type and / or expression level.In some embodiments, the mRNA encodes a combination of cancer antigens. The combination of cancer antigens can be selected based on their expression levels in the particular cancer type and / or their ability to elicit an immune response against cancer.In a further embodiment, the mRNA used in the lipid nanoparticles of the invention comprises at least one coding sequence, wherein the at least one coding sequence encodes a peptide or protein, wherein the protein is suitable for cancer disease treatment. In preferred embodiments, the cancer disease is selected from the group consisting of melanoma, breast cancer, lung cancer, colon cancer, prostate cancer, pancreatic cancer, ovarian cancer, and liver cancer. In preferred embodiments, the mRNA comprised within the lipid nanoparticles of the invention, encodes a tumor antigen, preferably as defined herein, or a fragment or variant thereof, wherein the tumor antigen is preferably selected from, but not limited to, the group consisting of tumor antigens disclosed on pages 47-51 in W02018078053; W02018078053 being incorporated herein by reference also from this regard in its entirety. In further preferred embodiments for cancer disease treatment, the mRNA used in the lipid nanoparticles of the invention may be an mRNA encoding a cancer antigen, preferably cytokines, chemokines, suicide enzymes andCureVac SE / P396WO1 87 / 219gene products, apoptosis inducers, endogenous angiogenesis inhibitors, heat shock proteins, tumor antigens, innate immune activators, antibodies directed against proteins associated with tumor or cancer development selected from, but not limited to, the group of cytokines, chemokines, suicide enzymes and gene products, apoptosis inducers, endogenous angiogenesis inhibitors, heat shock proteins, tumor antigens, innate immune activators, antibodies directed against proteins associated with tumor or cancer development as disclosed in Table 1, Table 2, Table 3, Table 4, Table 5, Table 6, Table 7, Table 8, Table 9, Table 10, Table 11 and Table 12 of W02016170176; W02016170176 and especially the content of Tables 1 to 12 being specifically incorporated herein by reference in its entirety.In a particular preferred embodiment of all aspects of the invention, the at least one mRNA comprised within the lipid nanoparticles of the invention comprises at least one open reading frame coding for at least one tumor antigen. In this context tumor antigens are preferably located on the surface of the (tumor) cell. T umor antigens may also be selected from proteins, which are overexpressed in tumor cells compared to a normal cell (e.g. non-tumor cells). Furthermore, tumor antigens also include antigens expressed in cells which are (were) not themselves (or originally not themselves) degenerated but are associated with the supposed tumor. Antigens which are connected with tumor-supplying vessels or (re)formation thereof, in particular those antigens which are associated with neovascularization, e.g. growth factors, such as VEGF, VEGFA, FGF, FGFR1 etc., are also included herein. Antigens associated with a tumor furthermore include antigens from cells or tissues, typically embedding the tumor. Further, some substances (usually proteins or peptides) are expressed in patients suffering (knowingly or not-knowingly) from a cancer disease and they occur in increased concentrations in the body fluids of said patients. These substances are also referred to as “tumor antigens”, however they are not antigens in the stringent meaning of an immune response inducing substance. The class of tumor antigens can be divided further into tumor-specific antigens (TSAs) and tumor-associated-antigens (TAAs). TSAs can only be presented by tumor cells and never by normal “healthy” cells. They typically result from a tumor specific mutation. TAAs, which are more common, are usually presented by both tumor and healthy cells. These antigens are recognized, and the antigen-presenting cell can be destroyed by cytotoxic T cells. Additionally, tumor antigens can also occur on the surface of the tumor in the form of, e.g., a mutated receptor. In this case, they can be recognized by antibodies.Further, tumor associated antigens may be classified as tissue-specific antigens, also called melanocyte-specific antigens, cancer / testis antigens and tumor-specific antigens. Cancer / testis antigens are typically understood to be peptides or proteins of germ-line associated genes which may be activated in a wide variety of tumors. Human cancer / testis antigens may be further subdivided into antigens which are encoded on the X chromosome, so-called CT-X antigens, and those antigens which are not encoded on the X chromosome, the so-called (non-X CT antigens). Cancer / testis antigens which are encoded on the X-chromosome comprise, for example, the family of melanoma antigen genes, the so-called MAGE-family. The genes of the MAGE-family may be characterized by a shared MAGE homology domain (MHD). Each of these antigens, i.e. melanocyte-specific antigens, cancer / testis antigens and tumor-specific antigens, may elicit autologous cellular and humoral immune responses. Accordingly, the tumor antigen encoded by the RNA comprised in the RNA vaccine used in the present invention is preferably a melanocyte-specific antigen, a cancer / testis antigen or a tumor-specific antigen, preferably it may be a CT-X antigen, a non-X CT-antigen, a binding partner for a CT-X antigen or a binding partner for a non-X CT-antigen or a tumor-specific antigen, more preferably a CT-X antigen, a binding partner for a non-X CT-antigen or a tumor-specific antigen.Checkpoint modulators / Checkpoint inhibitorsCureVac SE / P396WO1 88 / 219In the context of the present invention, an immune checkpoint protein, checkpoint modulator or checkpoint inhibitor is typically a molecule, such as a protein (e.g. an antibody), a dominant negative receptor, a decoy receptor, or a ligand or a fragment or variant thereof, which modulates the function of an immune checkpoint protein, e.g. it inhibits or reduces the activity of checkpoint inhibitors (or inhibitory checkpoint molecules) or it stimulates or enhances the activity of checkpoint stimulators (or stimulatory checkpoint molecules). Therefore, checkpoint modulators as defined herein, influence the activity of checkpoint molecules. In this context, inhibitory checkpoint molecules are defined as checkpoint inhibitors and can be used synonymously. In addition, stimulatory checkpoint molecules are defined as checkpoint stimulators and can be used synonymously.In a further preferred embodiment, the mRNA encodes an immune checkpoint protein, checkpoint modulators or checkpoint inhibitor, preferably as defined herein, or a fragment or variant thereof, wherein the immune checkpoint protein, checkpoint modulators or checkpoint inhibitor is preferably selected from, but not limited to, the group consisting of immune checkpoint proteins, checkpoint modulators or checkpoint inhibitors disclosed on pages 51-56 in W02018078053; W02018078053 being incorporated herein by reference in its entirety.Personalized Cancer Vaccine (PCV)In some embodiments, the lipid nanoparticle of the invention comprises a nucleic acid cancer vaccine comprising one or more nucleic acids, wherein each of the nucleic acids encodes at least one suitable cancer antigen such as a personalized antigen specific for a cancer subject. A personalized cancer antigen is a tumor-specific antigen, also referred to as a neoantigen, that is present in a tumor of an individual that is not expressed or expressed at low levels in normal non-cancerous tissue of the individual. The antigen may or may not be present in tumors of other individuals. Herein, a personalized cancer vaccine may also be referred to as a “nucleic acid (cancer) vaccine” and / or an “mRNA (cancer) vaccine”.For instance, the nucleic acid cancer vaccine may include nucleic acids encoding one or more cancer antigens specific for each subject, referred to as neoepitopes. Antigens that are expressed in or by tumor cells are referred to as “tumor associated antigens.” A particular tumor associated antigen may or may not also be expressed in non-cancerous cells. Many tumor mutations are well known in the art. Tumor associated antigens that are not expressed or rarely expressed in non-cancerous cells, or whose expression in non-cancerous cells is sufficiently reduced in comparison to that in cancerous cells and that induce an immune response induced upon vaccination, are referred to as neoepitopes. Neoepitopes are completely foreign to the body and thus would not normally produce an immune response against healthy tissue or be masked by the protective components of the immune system. In some embodiments, personalized vaccines based on neoepitopes are desirable because such vaccines will maximize specificity against a patient’s specific tumor. Mutation-derived neoepitopes can arise from point mutations, non-synonymous mutations leading to different amino acids in the protein; read-through mutations in which a stop codon is modified or deleted, leading to translation of a longer protein with a novel tumor-specific sequence at the C-terminus; splice site mutations that lead to the inclusion of an intron in the mature mRNA and thus a unique tumorspecific protein sequence; chromosomal rearrangements that give rise to a chimeric protein with tumor-specific sequences at the junction of 2 proteins (i.e., gene fusion); frameshift mutations or deletions that lead to a new open reading frame with a novel tumor-specific protein sequence; and / or translocations.In some embodiments, the nucleic acid cancer vaccines and vaccination methods described herein may include peptide epitopes or antigens based on specific mutations (e.g., neoepitopes) and those expressed by cancergermline genes (e.g., antigens common to tumors found in multiple patients, referred to herein as “traditional cancer antigens” or “shared cancer antigens”). In some embodiments, a traditional antigen is one that is known to be foundCureVac SE / P396WO1 89 / 219in cancers or tumors generally or in a specific type of cancer or tumor. In some embodiments, a traditional cancer antigen is a non-mutated tumor antigen. In some embodiments, a traditional cancer antigen is a mutated tumor antigen.In a further preferred embodiment, the mRNA encodes a Personalized Cancer Vaccine as defined on pages 24-30, pages 275-276, or page 300, line 16 to page 301, line 11, in WO2024151811; WO2024151811 being incorporated herein by reference in its entirety.Pathogenic antigens are derived from pathogenic organisms, in particular bacterial, viral or protozoological (multicellular) pathogenic organisms, which evoke an immunological reaction by subject, in particular a mammalian subject, more particularly a human. More specifically, pathogenic antigens are preferably surface antigens, e.g.CureVac SE / P396WO1 90 / 219proteins (or fragments of proteins, e.g. the exterior portion of a surface antigen) located at the surface of the virus or the bacterial or protozoological organism.Accordingly, in some preferred embodiments, the nucleic acid, preferably mRNA, may encode in its at least one coding region at least one pathogenic antigen selected from a bacterial, viral, fungal or protozoal antigen. The encoded (poly-)peptide or protein may consist or comprise of a pathogenic antigen or a fragment, variant or derivative thereof.Pathogenic antigens are peptide or protein antigens preferably derived from a pathogen associated with an infectious disease which are preferably selected from, but not limited to, the group of antigens derived from the pathogens disclosed on pages 21-35 in W02018078053; W02018078053 being incorporated herein by reference in its entirety. Furthermore, pathogenic antigens are peptide or protein antigens preferably derived from a pathogen associated with an infectious disease which are preferably selected from, but not limited to, the group of antigens derived from the pathogens disclosed on page 57 paragraph 3 - page 63, paragraph 2 in W02019077001; WO2019077001 being incorporated herein by reference in its entirety.Even further pathogenic antigens are peptide or protein antigens preferably derived from a pathogen associated with infectious disease which are preferably selected from antigens derived from the pathogens selected from, but not limited to, the group of antigens derived from the pathogens disclosed on pages 32 line 26 - page 34 line 27 in WO2013120628. Furthermore in this regard, the pathogenic antigen (antigen derived from a pathogen associated with infectious disease) may be preferably selected from the antigens preferably selected from antigens selected from, but not limited to, the group of antigens as disclosed on pages 34 line 29 - page 59 line 5 (in brackets is the particular pathogen or the family of pathogens of which the antigen(s) is / are derived and the infectious disease with which the pathogen is associated) in WO2013120628; WO2013120628 being incorporated herein by reference in its entirety.Therapeutic proteins and use for treatment or prophylaxis of any inherited or acquired diseaseIn a further embodiment, the mRNA used in the lipid nanoparticles of the invention is an mRNA encoding a peptide or protein, wherein the protein is a therapeutic protein, or a fragment or variant of a therapeutic protein. In this context, a therapeutic peptide, protein or fragment thereof may be any peptidic compound useful the prevention, management, improvement, treatment or therapy of a disease or condition in a subject, such as an animal, and in particular in a human subject.In one embodiment, the mRNA comprising at least one coding sequence may encode(a) a peptide or protein, or a fragment or variant thereof, wherein the peptide or protein is an antigen, wherein the antigen preferably is derived from pathogenic antigens, cancer or tumor antigens, allergenic antigens or autoimmune self-antigens, or a fragment or variant thereof, preferably cancer or tumor antigens; or(b) a therapeutic protein or a fragment or variant thereof, selected from the group consisting of(i) therapeutic proteins for use in the treatment of cancer or tumor diseases;(ii) therapeutic proteins being a therapeutic antibody;(iii) therapeutic proteins being a gene editing agent; and(iv) therapeutic proteins for use in treating or preventing a liver disease selected from the group consisting of liver fibrosis, liver cirrhosis and liver cancer;preferably wherein the therapeutic protein is a therapeutic protein for use in the treatment of cancer or tumor diseases.CureVac SE / P396WO1 91 / 219In very preferred embodiments and / or aspects of the invention, the mRNA comprising at least one coding sequence encodes a peptide or protein, or a fragment or variant thereof, wherein the peptide or protein is an antigen, wherein the antigen preferably is derived from tumor antigens. In further preferred embodiments and / or aspects of the invention, the mRNA comprising at least one coding sequence encodes a peptide or protein, for use in the treatment of cancer or tumor diseases.In some embodiments, the therapeutic protein encoded by the mRNA comprised within the lipid nanoparticles of the invention, or fragment or variant thereof, is selected from the group consisting of(i) therapeutic proteins for use in the treatment of cancer or tumor diseases, including cytokines, chemokines, suicide gene products, immunogenic proteins or peptides, apoptosis inducers, angiogenesis inhibitors, heat shock proteins, tumor antigens, beta-catenin inhibitors, activators of the STING pathway, checkpoint modulators, innate immune activators, antibodies, dominant negative receptors and decoy receptors, inhibitors of myeloid derived suppressor cells (MDSCs), IDO pathway inhibitors, and proteins or peptides that bind inhibitors of apoptosis; and (ii) therapeutic proteins for use in the treatment of blood disorders, diseases of the circulatory system, diseases of the respiratory system, cancer or tumor diseases, infectious diseases or immune deficiencies, including Alteplase (tissue plasminogen activator; tPA), Anistreplase, Antithrombin III (AT-III), Bivalirudin, Darbepoetin-alpha, Drotrecogin-alpha (activated protein C, Erythropoietin, Epoetin-alpha, erythropoietin, erthropoyetin, Factor IX, Factor Vila, Factor VIII, Lepirudin, Protein C concentrate, Reteplase (deletion mutein of tPA), Streptokinase, Tenecteplase, Urokinase, Angiostatin, Anti-CD22 immunotoxin, Denileukin diftitox, Immunocyanin, MPS (Metallopanstimulin), Aflibercept, Endostatin, Collagenase, Human deoxy-ribonuclease I, dornase, Hyaluronidase, Papain, L-Asparaginase, Peg-asparaginase, Rasburicase, Human chorionic gonadotropin (HCG), Human follicle-stimulating hormone (FSH), Lutropin-alpha, Prolactin, alpha-1 -Proteinase inhibitor, Lactase, Pancreatic enzymes (lipase, amylase, protease), Adenosine deaminase (pegademase bovine, PEG-ADA), Abatacept, Alefacept, Anakinra, Etanercept, Interleukin-1 (IL-1) receptor antagonist, Anakinra, Thymulin, TNF-alpha antagonist, Enfuvirtide, and Thymosin a1.In further, specific preferred embodiments, the mRNA encapsulated in the lipid nanoparticle as described herein, the lipid nanoparticle of the invention preferably comprising the ionizable lipid of the invention, encodes a therapeutic protein for use in the treatment of cancer or tumor diseases, preferably encodes a therapeutic protein selected from the group consisting of cytokines, chemokines, suicide gene products, immunogenic proteins or peptides, apoptosis inducers, angiogenesis inhibitors, heat shock proteins, tumor antigens, beta-catenin inhibitors, activators of the STING pathway, checkpoint modulators, innate immune activators, antibodies, dominant negative receptors and decoy receptors, inhibitors of myeloid derived suppressor cells (MDSCs), IDO pathway inhibitors, and proteins or peptides that bind inhibitors of apoptosis.This invention includes methods for preventing, ameliorating or treating a disease or condition in a subject in need comprising administering to the subject a composition as described herein. The compositions of this invention may be used in the treatment of the human or animal body.In this context, particularly preferred therapeutic proteins which can be used inter alia in the treatment of metabolic or endocrine disorders are selected from those which are disclosed in Table A (in combination with Table C) of WO2017191274. Furthermore, diseases which preferably can be treated with the composition of the invention, preferably selected from infectious diseases, neoplasms (e.g. cancer or tumor diseases), diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, diseases of the nervous system, diseases ofCureVac SE / P396WO1 92 / 219the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, and diseases of the genitourinary system, are disclosed in WO2017191274 on pages 95 line 4 - page 103 line 24. Further particularly preferred therapeutic proteins which can be used inter alia in the treatment of metabolic or endocrine disorders are disclosed in Table 1 of WO2017191274, which also refers to specific target / disease combinations, incorporated herein by reference, and also sequences. WO2017191274 incl. Tables A / C and Table 1 is incorporated herein by reference in its entirety.Lipid nanoparticle biodistributionIn a preferred embodiment, after administration of the lipid nanoparticle of the invention to a subject in need, the (i) mRNA or (ii) the peptide or protein encoded by said mRNA can be detected with a ratio of at least about 2:1, at least about 5:1, at least about 10:1, at least about 15:1, at least about 20:1, at least about 25:1, at least about 30:1, at least about 35:1, at least about 40:1, at least about 45:1, at least about 50:1, at least about 55:1, at least about 60:1, at least about 65:1, at least about 70:1, at least about 75:1, at least about 80:1, at least about 85:1, at least about 90:1, at least about 95:1, at least about 100:1, at least about 125:1, at least about 150:1, at least about 175:1, at least about 200:1, at least about 225:1, at least about 250:1, at least about 275:1, at least about 300:1, at least about 325:1, at least about 350:1, at least about 375:1, at least about 400:1, at least about 425:1, at least about 450: 1, at least about 475: 1, at least about 500: 1, or more, in the spleen tissue versus the liver tissue when measured 4, 6, or 24 hours post administration of the lipid nanoparticle to a subject in need, preferably after intramuscular administration.In yet another embodiment of the second aspect, the present invention provides a lipid nanoparticle, further comprising a messenger RNA (mRNA), wherein(a) the lipid nanoparticle is delivered to the spleen tissue in an increased ratio than the liver;(b) the lipid nanoparticle is delivered to draining lymph nodes in an increased ratio than the liver;(c) the lipid nanoparticle is delivered to the muscle tissue of the site of injection in an increased ratio than the liver;(d) the artificial nucleic acid or the mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in the spleen tissue than in liver tissue;(e) the artificial nucleic acid or the mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in the draining lymph nodes tissue than in liver tissue;(f) the artificial nucleic acid or the mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in the muscle tissue of the site of injection than in liver tissue;(g) the peptide or protein encoded by the mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in the spleen tissue than in liver tissue;(h) the peptide or protein encoded by the mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in the draining lymph nodes tissue than in liver tissue; and / or(i) the peptide or protein encoded by the mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in the muscle tissue of the site of injection than in liver tissue;after administration of the lipid nanoparticle to a subject in need, preferably after intramuscular administration.CureVac SE / P396WO1 93 / 219In yet another embodiment of the second aspect, the present invention provides a lipid nanoparticle further comprising a messenger RNA (mRNA), wherein the (i) mRNA or (ii) the peptide or protein encoded by said mRNA can be detected with a ratio of at least about 5:1, at least about 10:1, at least about 20:1, at least about 30:1, at least about 40:1, at least about 50:1, at least about 60:1, at least about 70:1, at least about 80:1, at least about 90:1, at least about 100:1, at least about 150:1, at least about 200:1, at least about 250:1, at least about 300:1, at least about 350:1, at least about 450:1, at least about 500:1, at least about 550:1, at least about 600:1, at least about 650: 1, or at least about 700: 1, or more in the spleen tissue versus the liver tissue when measured 4, 6, or 24 hours post administration of the lipid nanoparticle to a subject in need, preferably after intramuscular administration.In yet another embodiment of the second aspect, the present invention provides a lipid nanoparticle further comprising a messenger RNA (mRNA), wherein the (i) mRNA or (ii) the peptide or protein encoded by said mRNA can be detected with a ratio of at least about 5:1, at least about 10:1, at least about 20:1, at least about 30:1, at least about 40:1, at least about 50:1, at least about 60:1, at least about 70:1, at least about 80:1, at least about 90:1, at least about 100:1, at least about 150:1, at least about 200:1, at least about 250:1, at least about 300:1, at least about 350:1, at least about 450:1, at least about 500:1, at least about 550:1, at least about 600:1, at least about 650:1, or at least about 700:1, or more(a) in the draining lymph nodes tissue versus the liver tissue; and / or(b) in the muscle tissue of the injection site versus the liver tissuewhen measured 4, 6, or 24 hours post administration of the lipid nanoparticle to a subject in need, preferably after intramuscular administration.In one of the preferred embodiments, the biologically active ingredient is a nucleic acid compound, being a “cargo” within the lipid nanoparticle according to the invention. Examples of nucleic acid compounds that are potentially useful for carrying out the invention include nucleic acid compounds selected from the group consisting of chemically modified or unmodified messenger RNA (mRNA), chemically modified or unmodified RNA, singlestranded or double-stranded RNA, coding or non-coding RNA, viral RNA, replicon RNA, and self-replicating RNA, or any combination thereof; preferably wherein the biologically active ingredient is an mRNA.In preferred embodiments, the nucleic acid compound is complexed or associated with one or more lipids (e.g. ionizable lipids and / or neutral lipids), thereby forming lipid nanoparticles (LNPs). In this context, the terms “complexed” or “associated” refer to the essentially stable combination of nucleic acid compound of the aspects of the invention with one or more lipids into larger complexes or assemblies without covalent binding.In another embodiment, the peptide or protein expressed by the nucleic acid compound is a therapeutic protein, or a fragment or variant thereof, wherein the therapeutic protein is beneficial for the treatment or prophylaxis of any inherited or acquired disease or which improves the condition of an individual. Particularly, therapeutic proteins play a key role in the design of new therapeutic agents that could modify and repair genetic deficiencies, destroy cancer cells or pathogen infected cells, treat, or prevent immune system disorders, or treat or prevent metabolic or endocrine disorders, among other functions.CureVac SE / P396WO1 94 / 219In another embodiment, the peptide or protein expressed by the nucleic acid compound is an antigen. As defined in more detail herein above, an antigen is a compound or material which may be recognized by the immune system, preferably by the adaptive immune system, such as to trigger an antigen-specific immune response.In some embodiments, the biologically active ingredient is siRNA or RNAi.Artificial nucleic acid. mRNAIn a very preferred embodiment, the present invention provides a lipid nanoparticle, wherein the lipid nanoparticles comprise an artificial nucleic acid, preferably selected from the group consisting of messenger RNA (mRNA), RNA, siRNA, RNAi, guide RNA (gRNA), IncRNA (long non-coding RNA), samRNA / saRNA (self-amplifying RNA; SAM vaccines), and circular RNA (circRNA), most preferably the artificial nucleic acid is messenger RNA (mRNA). In some embodiments, the artificial nucleic acid may be chemically modified or chemically unmodified.In preferred embodiments, the present invention provides a lipid nanoparticle, wherein the lipid nanoparticles further comprises an artificial nucleic acid, preferably mRNA. Most preferably, the artificial nucleic acid is a chemically modified mRNA. Also most preferably, the artificial nucleic acid is a chemically unmodified mRNA.Accordingly, in a most preferred embodiment, the present invention provides a lipid nanoparticle, wherein the lipid nanoparticles further comprises mRNA.In a further embodiment, the present invention provides a lipid nanoparticle, further comprising an artificial nucleic acid, preferably selected from the group consisting of mRNA, single-stranded or double-stranded RNA, siRNA, RNAi, guide RNA (gRNA), coding or non-coding RNA, IncRNA (long non-coding RNA), self-replicating RNAs / samRNA / saRNA (self-amplifying RNA; SAM vaccines), viral RNA, replicon RNA, DNA, DNA vectors and circular RNA, wherein each of the nucleic acids may be chemically modified or unmodified.In other embodiments, the present invention provides a lipid nanoparticle, further comprising an artificial nucleic acid, preferably selected from the group consisting viral RNA, retroviral RNA, replicon RNA, small interfering RNA (siRNA), antisense RNA, saRNA (small activating RNA), CRISPR RNA (small guide RNA, sgRNA), ribozymes, aptamers, riboswitches, immunostimulating RNA, transfer RNA (tRNA), plasmids, DNA oligos, ribosomal RNA (rRNA), small nuclear RNA (snRNA), small nucleolar RNA (snoRNA), microRNA (miRNA), Piwi-interacting RNA (piRNA), selfreplicating RNA, and circular RNA.In one embodiment, the present invention provides a lipid nanoparticle, wherein the lipid nanoparticle comprises an artificial nucleic acid that is capable of self-replication, preferably self-replicating RNAs. Thusly, a polynucleotide may be capable of self-replication when introduced into a host cell. Examples of polynucleotides thus include selfreplicating RNAs and DNAs and, for instance, selected from replicons, plasmids, cosmids, phagemids, transposons, viral vectors, artificial chromosomes (e.g., bacterial, yeast, etc.) as well as other self-replicating species. Polynucleotides include those that express antigenic polypeptides in a host cell (e.g., polynucleotide-containing antigens). Polynucleotides include self-replicating polynucleotides within which natural or synthetic sequences derived from eucaryotic or prokaryotic organisms (e.g., genomic DNA sequences, genomic RNA sequences, cDNA sequences, etc.) have been inserted. Specific examples of self-replicating polynucleotides include RNA vector constructs and DNA vector constructs, among others. The term self -replicating RNA as used herein is deemed to be equivalent to self-amplifying RNA (samRNA / saRNA, SAM vaccines).CureVac SE / P396WO1 95 / 219Encapsulation / Complexation in lipid nanoparticles (LNPs):In another aspect, the present invention provides a method of producing a lipid nanoparticle, comprising: providing a mixture comprising the ionizable lipid of any of the above or below aspects and embodiments, at least one helper lipid, and optionally one or more additional excipients, combining said mixture with an aqueous phase comprising a nucleic acid, forming lipid nanoparticles encapsulating said nucleic acid; wherein the nucleic acid is selected from the group consisting of chemically modified or unmodified messenger RNA (mRNA), single-stranded or double-stranded RNA, siRNA, RNAi, guide RNA (gRNA), coding or non-coding RNA, IncRNA (long non-coding RNA), self-replicating RNAs / samRNA / saRNA (self-amplifying RNA; SAM vaccines), viral RNA, replicon RNA, DNA, DNA vectors and circular RNA, preferably the nucleic acid is chemically modified or unmodified messenger RNA (mRNA).In another aspect, the present invention provides the use of the ionizable lipid of any of the above or below aspects and embodiments in the production of a lipid nanoparticle formulation comprising encapsulating a nucleic acid selected from the group consisting of chemically modified or unmodified mRNA, single-stranded or double-stranded RNA, siRNA, RNAi, guide RNA (gRNA), coding or non-coding RNA, IncRNA (long non-coding RNA), self-replicating RNAs / samRNA / saRNA (self-amplifying RNA; SAM vaccines), viral RNA, replicon RNA, DNA, DNA vectors and circular RNA, preferably the nucleic acid is chemically modified or unmodified mRNA.The term “encapsulated”, e.g. incorporated, complexed, encapsulated, encapsulating, partially encapsulated, associated, partially associated, refers to the essentially stable combination of a nucleic acid, preferably mRNA, with one or more lipids into lipid nanoparticle of the invention (e.g. larger complexes or assemblies) preferably without covalent binding of the RNA. The lipid nanoparticles from the invention encapsulated mRNA may be completely or partially located in the interior of the lipid nanoparticle of the invention (e.g. the lipid portion and / or an interior space) and / or within the lipid layer / membrane of the lipid nanoparticle of the invention. The encapsulation of an RNA into lipid nanoparticles from the invention is also referred to herein as “incorporation” as the RNA is preferably contained within the interior of the lipid nanoparticles from the invention. Without wishing to be bound to theory, the purpose of incorporating or encapsulating RNA into lipid nanoparticles from the invention may be to protect the RNA from an environment which may contain enzymes, chemicals, or conditions that degrade the RNA. Moreover, incorporating RNA into lipid nanoparticles from the invention may promote the uptake of the RNA, and hence, may enhance the therapeutic effect of the nucleic acid, preferably mRNA, when administered to a cell or a subject.In preferred embodiments and aspects of the invention, the at least one nucleic acid, preferably the at least one mRNA, is complexed, encapsulated, partially encapsulated, or associated with one or more lipids (e.g. ionizable lipids and / or neutral lipids), thereby forming lipid nanoparticles (LNPs).The lipid nanoparticles (LNPs) incorporated nucleic acid, preferably mRNA, may be completely or partially located in the interior space of the lipid nanoparticles (LNPs), within the lipid layer / membrane, or associated with the exterior surface of the lipid layer / membrane. The incorporation of a nucleic acid into liposomes / LNPs is also referred to herein as "encapsulation" wherein the nucleic acid, e.g., the RNA is entirely contained within the interior space of the lipid nanoparticles (LNPs) of the invention. The purpose of incorporating nucleic acid into lipid nanoparticles (LNPs) is to protect the nucleic acid, preferably mRNA from an environment which may contain enzymes or chemicals or conditions that degrade nucleic acid and / or systems or receptors that cause the rapid excretion of theCureVac SE / P396WO1 96 / 219nucleic acid. Accordingly, incorporating a nucleic acid, preferably a mRNA, into lipid nanoparticles (LNPs) may be particularly suitable for a cancer vaccine, e.g. for intramuscular and / or intravenous administration.The invention further relates to a method of preparing said lipid nanoparticles not limited to the steps of:(i) providing:a) ionizable lipid of the invention as defined herein or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof;b) a polymer conjugated lipid of the invention as defined herein;c) optionally, a sterol lipid; andd) optionally, a neutral lipid;e) optionally, a phosphatidylserine lipid;f) at least one mRNA in an aqueous solution;(ii) solubilizing the lipids in an alcohol such as ethanol;(iii) mixing the alcoholic lipid solution with an aqueous solution comprising the mRNA;(iv) removing the alcohol to purify the lipid nanoparticles; and optionally(v) separating or purifying the lipid nanoparticles.The alcohol may be removed in step iv) by any suitable method which does not negatively affect the lipids or the forming lipid nanoparticles. In one embodiment of the invention the alcohol is removed by dialysis. In an alternative embodiment the alcohol is removed by diafiltration.Preferably, the purifying step v) comprises at least one step selected from precipitation step, dialysis step, filtration step, TFF step. Separation and optional purification of the lipid nanoparticles might also be performed by any suitable method. Preferably the lipid nanoparticles are filtrated, more preferably the lipid nanoparticles are separated or purified by filtration through a sterile filter.Preferably, the mixing means of step iii) is a T-piece connector or a microfluidic mixing device. Suitably, the conditions e.g. for microfluidic mixing or using a T-piece connector are chosen so as to obtain encapsulation of the pharmaceutically active compound at an encapsulation efficiency (EE) of above 80%, preferably above 90%, more preferably above 94%.In other embodiments, microfluidic mixing, T-mixing, or cross-mixing of the aqueous RNA solution and the lipid solution in an organic solvent is used. In certain aspects, flow rates, junction size, junction geometry, junction shape, tube diameter, solutions, and / or RNA and lipid concentrations may be varied. LNPs or LNP compositions may be buffer exchanged, concentrated or purified, e.g., via dialysis, centrifugal filter, tangential flow filtration, chromatography, or gravity size exclusion chromatography. The LNP compositions may be stored as a suspension, an emulsion, or a lyophilized powder, for example. In some embodiments, an LNP composition is stored at 2-8°C, in certain aspects, the LNP compositions are stored at room temperature. In additional embodiments, an LNP composition is stored frozen, for example at -20°C or -80°C. In other embodiments, an LNP composition is stored at a temperature ranging from about 0°C to about -80°C. Frozen LNP compositions may be thawed before use, for example on ice, at room temperature, or at 25°C, preferably at room temperature.Chemically modified artificial nucleic acids and mRNA and unmodified artificial nucleic acids and mRNAIn preferred embodiments, the artificial nucleic acid, preferably mRNA, comprised within the lipid nanoparticles of the invention does not comprise a chemical modification or a base modification, except for a modified base whichCureVac SE / P396WO1 97 / 219serves as Cap-nucleotide (preferably CleanCap, more preferably CleanCap AG). In other words, the nucleic acid used as cargo of the lipid nanoparticle, preferably mRNA, only comprises adenosine, guanosine, cytidine, uridine nucleotides and does not comprise N1MPU.In one embodiment, the present invention provides the lipid nanoparticle of the invention, wherein the mRNA comprises no chemical modification, preferably no base modification, more preferably no base modification selected from the group consisting of N1-methylpseudouridine (m1ψ, N1MPU, N1Mpsi or N1Mψ), pseudouridine (psi or qj), 1-ethylpseudouracil, 2-thiouracil (s2U), 4-thiouracil, 5-methylcytosine, 5-methyluracil, 5-methoxyuracil, most preferably no N1-methylpseudouridine (m1ψ, N1MPU, N1Mpsi or N1Mψ) modification.In another embodiment, the present invention provides the lipid nanoparticle of the invention, wherein the mRNA comprises at least one chemical modification.In another embodiment, the present invention provides the lipid nanoparticle of the invention, wherein the chemical modification is selected from the group consisting of base modifications, sugar modifications, backbone modifications and lipid modifications, preferably wherein the chemical modification is a base modification, more preferably wherein the base modification is selected from the group consisting of pseudouridine (psi or ψ), N1-methylpseudouridine (m1ψ, N1MPU, N1Mpsi or N1Mψ), 1-ethylpseudouracil, 2-thiouracil (s2U), 4-thiouracil, 5-methylcytosine, 5-methyluracil, 5-methoxyuracil, most preferably wherein the chemical modification is N1-methylpseudouridine (m1ψ, N1MPU, N1Mpsi or N1Mψ).In further embodiments, the nucleic acid, preferably mRNA, comprised within the lipid nanoparticles of the invention comprise N1-methylpseudouridine (m1ψ, N1MPU, N1Mpsi or N1Mψ).In another embodiment, the present invention provides a lipid nanoparticle any one of any of the above or below aspects and embodiments comprising at least one artificial nucleic acid, preferably mRNA, wherein the artificial nucleic acid comprises at least one chemical modification.In a preferred embodiment, the present invention provides the lipid nanoparticle of the invention comprising at least one artificial nucleic acid, preferably mRNA, wherein the artificial nucleic acid comprises at least one chemical modification, preferably wherein the chemical modification is N1 -methylpseudouridine.In a preferred embodiment, the present invention provides the lipid nanoparticle of the invention comprising at least one artificial nucleic acid, preferably mRNA, wherein the artificial nucleic does not comprise a chemical modification or a base modification, except for a modified base which serves as Cap-nucleotide (preferably CleanCap, moreCureVac SE / P396WO1 98 / 219preferably CleanCap AG). Notably, a 5’-cap structure as defined herein is typically not considered to be a chemically modified nucleotide). Accordingly, the artificial nucleic acid, preferably mRNA comprises a sequence that consists only of G, C, A and U nucleotides and therefore does not comprise modified nucleotides, and optionally comprises a 5’-cap structure.In some embodiments, however, a polynucleotide molecule of the embodiments does not include any N1-methylpseudouridine substituted positions. In further aspects and embodiments, a polynucleotide molecule of the embodiments does not include any pseudouridine, N1-methylpseudouridine, 5-methylcytosine, and 5-methoxyuridine substituted position. In still further aspects and embodiments, a polynucleotide molecule of the embodiments comprises a coding sequence that consists only of G, C, A and U nucleotides. Thusly, in other preferred embodiments, the RNA comprises a coding sequence that consists only of G, C, A and U nucleotides and therefore does not comprise modified nucleotides (except of the Cap analogue).In one embodiment, the present invention provides the lipid nanoparticle of the invention comprising at least one artificial nucleic acid, preferably mRNA, wherein the artificial nucleic acid comprises no chemical modification, preferably no base modification, more preferably no base modification selected from the group consisting of a N1-methylpseudouridine, pseudouridine, 1 -ethylpseudouracil, 2-thiouracil (s2U), 4-thiouracil, 5-methylcytosine, 5-methyluracil, and 5-methoxyuracil modification, most preferably no N1 -methylpseudouridine modification.Reference lipid nanoparticleIn a preferred embodiment, the present invention provides a lipid nanoparticle, wherein(a) the artificial nucleic acid, preferably mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in conventional type 1 dendritic cells (cDC1) as when compared to a reference lipid nanoparticle composition in which the ionizable lipid is replaced by a reference lipid and optionally the phosphatidylserine is replaced by cholesterol;(b) the artificial nucleic acid, preferably mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in macrophages as when compared to a reference lipid nanoparticle composition in which the ionizable lipid is replaced by a reference lipid and optionally the phosphatidylserine is replaced by cholesterol;(c) the peptide or protein encoded by the artificial nucleic acid, preferably mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in conventional type 1 dendritic cells (cDC1) as when compared to a reference lipid nanoparticle composition in which the ionizable lipid is replaced by a reference lipid and optionally the phosphatidylserine is replaced by cholesterol; and / or(d) the peptide or protein encoded by the artificial nucleic acid, preferably mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in macrophages as when compared to a reference lipid nanoparticle composition in which the ionizable lipid is replaced by a reference lipid and optionally the phosphatidylserine is replaced by cholesterol;after administration of the lipid nanoparticle to a subject in need, preferably after intramuscular administration.In the context of the invention, a “reference lipid” for the ionizable lipid of the invention is for example the ionizable lipid MC3, KC2, DLinDMA (structures are known to a skilled artisan and also indicated below), or SM-102, while a “reference lipid nanoparticle” is a lipid nanoparticle comprising for example MC3, KC2, DLinDMA, or SM-102 as ionizable lipid instead of the ionizable lipid of the invention. Optionally, the “reference lipid nanoparticle” does not comprise phosphatidylserine, i.e. the phosphatidylserine is exchanged by cholesterol. In one embodiment, theCureVac SE / P396WO1 99 / 219“reference lipid nanoparticle” comprises MC3 as ionizable lipid. In another embodiment, the “reference lipid nanoparticle” comprises KC2 as ionizable lipid. In yet another embodiment, the “reference lipid nanoparticle” comprises DLinDMA.(DLinDMA)In yet another embodiment, the “reference lipid nanoparticle” comprises SM-102 as ionizable lipid. In a further embodiment, the “reference lipid nanoparticle” comprises MC3 as ionizable lipid and cholesterol instead of phosphatidylserine. In yet a further embodiment, the “reference lipid nanoparticle” comprises KC2 as ionizable lipid and cholesterol instead of phosphatidylserine. In yet a further embodiment, the “reference lipid nanoparticle” comprises DLinDMA as ionizable lipid and cholesterol instead of phosphatidylserine. In yet a further embodiment, the “reference lipid nanoparticle” comprises SM-102 as ionizable lipid and cholesterol instead of phosphatidylserine.CureVac SE / P396WO1 100 / 219In one embodiment, the “reference lipid nanoparticle” is “LNP SM-102” having the attributes as shown in Table 2. Table 2: attributes of reference lipid nanoparticle “LNP SM-102”CureVac SE / P396WO1 101 / 219In another embodiment, the “reference lipid nanoparticle” is selected from the group consisting of Reference 1, Reference 2, Reference 3, Reference 4, Reference 5, Reference 6, Reference 7, Reference 8, Reference 9 and Reference 10 as shown in Table 3.Table 3: attributes of reference lipid nanoparticles “Reference 1” to “Reference 10”In yet another embodiment, the “reference lipid nanoparticle” comprises SM-102 as ionizable lipid. In a further embodiment, the “reference lipid nanoparticle” comprises MC3 as ionizable lipid and cholesterol instead of phosphatidylserine. In yet a further embodiment, the “reference lipid nanoparticle” comprises KC2 as ionizable lipid and cholesterol instead of phosphatidylserine. In yet a further embodiment, the “reference lipid nanoparticle” comprises DLinDMA as ionizable lipid and cholesterol instead of phosphatidylserine. In yet a further embodiment, the “reference lipid nanoparticle” comprises SM-102 as ionizable lipid and cholesterol instead of phosphatidylserine.CureVac SE / P396WO1 102 / 219In yet another embodiment, the “reference lipid nanoparticle” comprises a PEG-lipid as polymer conjugated lipid instead of a PMOZ comprising polymer conjugated lipid.UTRs and UTR-combinationsA 3’-untranslated region (3’-UTR) is typically the part of an mRNA which is located between the protein coding region (i.e. the open reading frame) and the poly(A) sequence of the mRNA. A 3’-UTR of the mRNA is not translated into an amino acid sequence. The 3’-UTR sequence is generally encoded by the gene which is transcribed into the respective mRNA during the gene expression process. The genomic sequence is first transcribed into pre-mature mRNA, which comprises optional introns. The pre-mature mRNA is then further processed into mature mRNA in a maturation process. This maturation process comprises the steps of 5’-capping, splicing the pre-mature mRNA to excise optional introns and modifications of the 3’-end, such as polyadenylation of the 3’-end of the pre-mature mRNA and optional endo- or exonuclease cleavages etc. In the context of the present invention, a 3’-UTR corresponds to the sequence of a mature mRNA which is located 3’ to the stop codon of the protein coding region, preferably immediately 3’ to the stop codon of the protein coding region, and which extends to the 5’-side of the poly(A) sequence, preferably to the nucleotide immediately 5’ to the poly(A) sequence. The term “corresponds to” means that the 3’-UTR sequence may be an RNA sequence, such as in the mRNA sequence used for defining the 3’-UTR sequence, or a DNA sequence which corresponds to such RNA sequence. In the context of the present invention, the term “a 3’-UTRof a gene”, such as “a 3’-UTRof an albumin gene”, is the sequence which corresponds to the 3’-UTR of the mature mRNA derived from this gene, i.e. the mRNA obtained by transcription of the gene and maturation of the pre-mature mRNA. The term “3’-UTR of a gene” encompasses the DNA sequence and the RNA sequence of the 3’-UTR.A 5’-untranslated region (5’-UTR) is typically understood to be a particular section of mRNA. It is located 5’ of the open reading frame of the mRNA. Typically, the 5’-UTR starts with the transcriptional start site and ends one nucleotide before the start codon of the open reading frame. The 5’-UTR may comprise elements for controlling gene expression, also called regulatory elements. Such regulatory elements may be, for example, ribosomal binding sites or a 5’-Terminal Oligopyrimidine Tract. The 5’-UTR may be post-transcriptionally modified, for example by addition of a 5’-CAP. In the context of the present invention, a 5’-UTR corresponds to the sequence of a mature mRNA which is located between the 5’-CAP and the start codon. Preferably, the 5-UTR corresponds to the sequence which extends from a nucleotide located 3’ to the 5’-CAP, preferably from the nucleotide located immediately 3’ to the 5’-CAP, to a nucleotide located 5’ to the start codon of the protein coding region, preferably to the nucleotide located immediately 5’ to the start codon of the protein coding region. The nucleotide located immediately 3’ to the 5’-CAP of a mature mRNA typically corresponds to the transcriptional start site. The term “corresponds to” means that the 5-UTR sequence may be an RNA sequence, such as in the mRNA sequence used for defining the 5-UTR sequence, or a DNA sequence which corresponds to such RNA sequence. In the context of the present invention, the term “a 5’-UTR of a gene”, such as “a 5’-UTR of a TOP gene”, is the sequence which corresponds to the 5-UTR of the mature mRNA derived from this gene, i.e. the mRNA obtained by transcription of the gene and maturation of the pre-mature mRNA. The term “5’-UTR of a gene” encompasses the DNA sequence and the RNA sequence of the 5’-UTR.In one embodiment, the present invention provides the lipid nanoparticle of the invention comprising at least one mRNA, wherein the at least one coding RNA comprises at least one heterologous 5’-UTR and / or at least one heterologous 3’-UTR, preferably wherein the at least one heterologous 5’-UTR comprises a nucleic acid sequence derived from a 5’-UTR of a gene selected from HSD17B4, RPL32, ASAH1, ATP5A1, MP68, NDUFA4, NOSIP,CureVac SE / P396WO1 103 / 219RPL31, SLC7A3, TUBB4B and UBQLN2, or from a homolog, a fragment or variant of any one of these genes; and / orpreferably wherein the at least one heterologous 3’-UTR comprises a nucleic acid sequence derived from a 3-UTR of a gene selected from PSMB3, ALB7, alpha-globin, CASP1, COX6B1, GNAS, NDUFA1 and RPS9, or from a homolog, a fragment, or a variant of any one of these genes.In some embodiments, the at least one 5’-UTR comprises a nucleic acid sequence derived or selected from a 5’-UTR of gene selected from HSD17B4, AIG1, alpha-globin (HBA1, HBA2), ASAH1, ATP5A1, COX6C, DPYSL2, HHV5, MDR, MP68, NDUFA4, NOSIP, RPL31, RPL32, RPL35A, SLC7A3, synthetic origin, TUBB4B, UBQLN2, or from a homolog, a fragment or variant of any one of these genes.In other embodiments, the at least one 3-UTR comprises or consists of a nucleic acid sequence derived or selected from a 3’-UTR of a gene selected from PSMB3, AES-12S, ALB7 (ALB), alpha-globin (HBA1, HBA2), ANXA4, betaglobin (HBB), CASP1, COX6B1, FIG4, GH1, GNAS, NDUFA1, RPS9, SLC7A3, TUBB4B, or from a homolog, a fragment, or variant of any one of these genes.In another preferred embodiment, the mRNA comprises a 5’-UTR element, which comprises or consists of a nucleic acid sequence which is derived from a cationic amino acid transporter 3 (solute carrier family 7 member 3, SLC7A3) gene, wherein said 5’-UTR element comprises or consists of a DNA sequence according to SEQ ID NO:15 as disclosed in W02019077001 or respectively an RNA sequence according to SEQ ID NO:16 as disclosed in W02019077001; W02019077001 being incorporated herein by reference in its entirety. In another preferred embodiment, the mRNA comprises a 3’-UTR element, which comprises or consists of a nucleic acid sequence which is derived from a proteasome subunit beta type-3 (PSMB3) gene, wherein said 3’-UTR element comprises or consists of a DNA sequence according to SEQ ID NO:23 as disclosed in WO2019077001 or respectively an RNA sequence according to SEQ ID NO:24 as disclosed in WQ2019077001. In further preferred embodiments, the mRNA comprises an UTR-combination as disclosed in WQ2019077001, i.e. both a 5’-UTR element, which comprises or consists of a nucleic acid sequence which is derived from a SLC7A3 gene and a 3’-UTR element, which comprises or consists of a nucleic acid sequence which is derived from a PSMB3 gene.In a preferred embodiment, the present invention provides the lipid nanoparticle of the invention comprising at least one mRNA comprising a (i) HSD17B45-UTR and a PSMB33’-UTR. In another preferred embodiment, the mRNA comprises a 5’-UTR element, which comprises or consists of a nucleic acid sequence which is derived from a 17-beta-hydroxysteroid dehydrogenase 4 gene, wherein said 5’-UTR element comprises or consists of a DNA sequence according to SEQ ID NO:1 as disclosed in WQ2019077001 or respectively an RNA sequence according to SEQ ID NO:2 as disclosed in WQ2019077001; WQ2019077001 being incorporated herein by reference in its entirety. In another preferred embodiment, the mRNA comprises a 3’-UTR element, which comprises or consists of a nucleic acid sequence which is derived from a proteasome subunit beta type-3 (PSMB3) gene, wherein said 3’-UTR element comprises or consists of a DNA sequence according to SEQ ID NO:23 as disclosed in WQ2019077001 or respectively an RNA sequence according to SEQ ID NO:24 as disclosed in WO2019077001. In further preferred embodiments, the mRNA comprises an UTR-combination as disclosed in WQ2019077001, i.e. both a 5’-UTR element, which comprises or consists of a nucleic acid sequence which is derived from a HSD17B4 gene and a 3-UTR element, which comprises or consists of a nucleic acid sequence which is derived from a PSMB3 gene (preferably HSD17B4 as disclosed in SEQ ID NO:12 and SEQ ID NO:13 or PSMB3 as disclosed in SEQ ID NO: 46 and SEQ ID NO:47)).CureVac SE / P396WO1 104 / 219Routes of administrationIn certain embodiments, routes for systemic administration in general include, for example, transdermal, oral, parenteral routes, including subcutaneous, intravenous, intramuscular, intraarterial, intradermal and intraperitoneal injections and / or intranasal administration routes. In other embodiments, routes for local administration in general include, for example, topical administration routes but also intradermal, transdermal, subcutaneous, or intramuscular injections or intralesional, intracranial, intrapulmonal, intracardial, intratumoral and sublingual injections. Administration to the respiratory system can be performed by spray administration or inhalation may in particular be performed by aerosol administration to the lungs, bronchi, bronchioles, alveoli, or paranasal sinuses. In preferred embodiments, routes of administration for lipid nanoparticles of the invention are intramuscular, intravenous, and intratumoral, preferably intramuscular. In most preferred embodiments, route of administration for lipid nanoparticles of the invention is intramuscular.Compositions / vaccines are therefore preferably formulated in liquid or solid form. The suitable amount of the vaccine or composition according to the invention to be administered can be determined by routine experiments, e.g. by using animal models. Such models include, without implying any limitation, rabbit, sheep, mouse, rat, dog and non-human primate models. Preferred unit dose forms for injection include sterile solutions of water, physiological saline or mixtures thereof. The pH of such solutions should be adjusted to a physiologically tolerable pH, such as about 7.4. Suitable carriers for injection include hydrogels, devices for controlled or delayed release, polylactic acid and collagen matrices.The inventors further found that the lipid nanoparticles of the invention have advantageous physiochemical properties after being frozen and thawed or, upon lyophilization and reconstitution, measured with PDI and size measurements and / or the lipid nanoparticles of the invention have an increased short- and / or long-term stability upon storage as compared to a reference lipid nanoparticle composition in which the ionizable lipid is replaced by a reference lipid or the phosphatidylserine lipid is replaced by cholesterol; (ii) as compared to a reference lipid nanoparticle composition in which the ionizable lipid and / or polymer conjugated lipid is replaced by a reference lipid or the phosphatidylserine lipid is replaced by cholesterol; or (iii) as compared to a lipid nanoparticle comprising a reference lipids selected from the group consisting of MC3, KC2, and DLinDMA as ionizable lipid. Herein, the inventors found surprisingly and unexpectedly, that the inventive lipid nanoparticles were superior with regard to size (smaller size) and PDI after putting lipid nanoparticles of the invention under thermal stress, i.e. upon freeze / thaw cycles or lyophilization and reconstitution, respectively. Furthermore, a disadvantageous increase of size and PDI was found for PEG-LNPs for dilutions. I.e. PEG-LNPs had an increasing size and PDI when being diluted. The increase of size and PDI was not found, or respectively not found that pronounced, for LNPs comprising PMOZ as conjugated lipid. Even in cases, in which PMOZ-LNPs show an increase of size upon dilution orCureVac SE / P396WO1 105 / 219freeze / thaw in a similar range as PEG-LNPs, PMOZ-LNPs still were smaller than PEG-LNPs, which would be favorable as findings in that field indicate that smaller particles are more immunogenic (Li et al., 2014, Journal of controlled release, 173, 148-157; Ott et al., Vaccine, 1995 13(16), 1557-1562; Shah et al., 2014. Nanomedicine, 9(17), 2671-2681.“Stability,” “stabilized,” “particle stability” and “stable” in the context of the present disclosure refers to the resistance of lipid nanoparticle compositions and / or pharmaceutical compositions disclosed herein to chemical or physical changes (e.g., degradation, particle size change, aggregation, change in encapsulation, etc.) under given manufacturing, preparation, transportation, storage and / or in-use conditions, e.g., when stress is applied such as shear force, freeze / thaw stress, et cetera.As used herein, "storage" may be understood as a prolonged exposure or containment of a composition in an article, e.g. a syringe or a vial, wherein the duration of storage may be in a range of about 30 minutes to about 6 months. For example, storage may be for at least about 30 minutes, 1 hour, 2 hours, 6 hours, 1 day, 2 days, 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months. The temperature conditions under which storage according to the invention may occur can range from -80°C to about 30°C, preferably in a range from about -20°C to about 30°C, more preferably in a range from about 5°C to about 20°C. Preferred examples of a storage temperature in the context of the invention are -80°C, -20°C, 5°C, or room temperature (about 20°C). Suitably, when reference is made to “storage”, such a storage has to be understood as having a duration of about 30 minutes to about 6 months, and as having a temperature in a range from about 5°C to about 20°C.In a preferred embodiment, the mRNA comprising lipid nanoparticle of the pharmaceutical composition, vaccine or kit of parts according to the invention is provided in lyophilized form. Preferably, the lyophilized mRNA comprising lipid nanoparticles are reconstituted in a suitable buffer, advantageously based on an aqueous carrier, prior to administration, e.g. Ringer-Lactate solution, Ringer solution, a phosphate buffer solution. In a preferred embodiment, the pharmaceutical composition, the vaccine or the kit of parts according to the invention contains at least one, two, three, four, five, six or more mRNAs, which may be provided as a single species of lipid nanoparticles, or separately for each LNP species, optionally in lyophilized form (optionally together with at least one further additive) and which are preferably reconstituted separately in a suitable buffer (such as Ringer-Lactate solution) prior to their use so as to allow individual administration of each of the (monocistronic) mRNAs.In other embodiments, the lipid nanoparticles disclosed herein encapsulating a nucleic acid, preferably mRNA, are lyophilized lipid nanoparticles. A lyophilized lipid nanoparticle is one from which liquid (e.g., water) has been removed by freeze drying, in which a liquid product is frozen and subsequently placed under a vacuum to remove solvent (e.g., water) by sublimation, leaving a composition substantially free of solvent (e.g., water). In some embodiments, a lyophilized lipid nanoparticle as disclosed herein comprises an inventive ionizable lipid according to Formula (I) or Formula (II), DSPC, DPhyPS, cholesterol, and a PMOZ-lipid, e.g. PMOZ 4.Thus, the composition may be a dry composition such as a powder or granules, or a solid unit such as a lyophilized form or a tablet. Alternatively, the composition may be in liquid form, and each excipient may be independently incorporated in dissolved or dispersed (e.g. suspended or emulsified) form. In one of the preferred embodiments, the composition is formulated as a sterile solid composition, such as a powder or lyophilized form for reconstitution with an aqueous liquid carrier. Such formulation is also preferred for those versions of the composition which comprise a nucleic acid as described in further detail below. In this regard, likewise, the term “lipid composition” isCureVac SE / P396WO1 106 / 219used in connection with lipid nanoparticles and the respective lipids which are comprised within a lipid nanoparticle. I.e. a lipid nanoparticle preferably has a lipid composition comprising different lipids, i.e. an ionizable lipid, a phospholipid, a sterol, a polymer conjugated lipid and as disclosed throughout the context of the present application a further phospholipid, preferably being a phosphatidylserine.In one embodiment, the present invention provides a lipid nanoparticle, wherein the lipid nanoparticle has a lower PDI and / or lower size upon (i) freezing and thawing or (ii) freeze-drying (lyophilizing) and reconstitution, as compared to a reference lipid nanoparticle comprising a PEG-lipid instead of a PMOZ comprising polymer conjugated lipid of the invention.In one embodiment, the present invention provides a method of making a frozen lipid nanoparticle of the invention, wherein the lipid nanoparticle upon thawing has a lower PDI and / or lower size as compared to a reference lipid nanoparticle comprising a PEG-lipid instead of a polymer conjugated lipid of the invention.In one embodiment, the present invention provides a method of making a lyophilized lipid nanoparticle of the invention, wherein the lipid nanoparticle upon reconstitution has a lower PDI and / or lower size as compared to a reference lipid nanoparticle comprising a PEG-lipid instead of a polymer conjugated lipid of the invention.In one embodiment, the present invention provides an improved lyophilization process for the preparation of lyophilized lipid nanoparticles of the invention, said process comprising the step of using a PMOZ comprising polymer conjugated lipid of the invention as excipient instead of a PEG-lipid, wherein the lipid nanoparticle upon reconstitution has a lower PDI and / or lower size as compared to a reference lipid nanoparticle comprising a PEG-lipid instead of a PMOZ comprising polymer conjugated lipid of the invention.In one embodiment, the present invention provides a vaccine composition comprising a lipid nanoparticle of the invention, wherein the lipid nanoparticle has an increase in LNP mean size of about 30%, 29%, 28%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less, preferably of about 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less after one or more freeze / thaw cycles as compared to that prior to freeze / thaw cycles.In one embodiment, the present invention provides a vaccine composition comprising a lipid nanoparticle of the invention, wherein the formulation has an increase in LNP mean size of about 30%, 29%, 28%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less, preferably of about 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less after lyophilization as compared to that prior to lyophilization.In one embodiment, the present invention provides a vaccine composition comprising a lipid nanoparticle of the invention, wherein the formulation has an increase in LNP mean size of about 30%, 29%, 28%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less, preferably of about 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less after dilution as compared to that prior to dilution.In one embodiment, the present invention provides a vaccine composition comprising a lipid nanoparticle of the invention, wherein the encapsulation efficiency of the formulation is substantially the same after storage at aboutCureVac SE / P396WO1 107 / 2194°C or lower for at least about one month, about two months, about three months, about four months, about five months, about six months or longer.In one embodiment, the present invention provides a vaccine composition comprising a lipid nanoparticle of the invention, wherein the LNP mean size of the LNPs is substantially the same after storage at about 4°C or lower for at least about one month, about two months, about three months, about four months, about five months, about six months or longer.In one embodiment, the present invention provides a lipid nanoparticle, wherein the lipid nanoparticle has a lower PDI and / or lower size upon (i) freezing and thawing or (ii) freeze-drying (lyophilizing) and reconstitution, as compared to a reference lipid nanoparticle comprising a PEG-lipid as polymer conjugated lipid instead of a PMOZ comprising polymer conjugated lipid of the invention. In yet another embodiment, the “reference lipid nanoparticle” comprises SM-102 as ionizable lipid. In a further embodiment, the “reference lipid nanoparticle” comprises MC3 as ionizable lipid and cholesterol instead of phosphatidylserine. In yet a further embodiment, the “reference lipid nanoparticle” comprises KC2 as ionizable lipid and cholesterol instead of phosphatidylserine. In yet a further embodiment, the “reference lipid nanoparticle” comprises DLinDMA as ionizable lipid and cholesterol instead of phosphatidylserine. In yet a further embodiment, the “reference lipid nanoparticle” comprises SM-102 as ionizable lipid and cholesterol instead of phosphatidylserine. In one embodiment, the “reference lipid nanoparticle” is “LNP SM-102” as shown in Table 2. In another embodiment, the “reference lipid nanoparticle” is selected from the group consisting of Reference 1, Reference 2, Reference 3, Reference 4, Reference 5, Reference 6, Reference 7, Reference 8, Reference 9 and Reference 10 as shown in Table 3.In one embodiment, the present invention provides a method of making a frozen lipid nanoparticle of the invention, wherein the lipid nanoparticle upon thawing has a lower PDI and / or lower size as compared to a reference lipid nanoparticle comprising a PEG-lipid as polymer conjugated lipid instead of a polymer conjugated lipid of the invention.In one embodiment, the present invention provides a method of making a lyophilized lipid nanoparticle of the invention, wherein the lipid nanoparticle upon reconstitution has a lower PDI and / or lower size as compared to a reference lipid nanoparticle comprising a PEG-lipid as polymer conjugated lipid instead of a polymer conjugated lipid of the invention.In one embodiment, the present invention provides an improved lyophilization process for the preparation of lyophilized lipid nanoparticles of the invention, said process comprising the step of using a PMOZ comprising polymer conjugated lipid of the invention as excipient instead of a PEG-lipid, wherein the lipid nanoparticle upon reconstitution has a lower PDI and / or lower size as compared to a reference lipid nanoparticle comprising a PEG-lipid as polymer conjugated lipid instead of a PMOZ comprising polymer conjugated lipid of the invention.In one embodiment, the present invention provides a lipid nanoparticle composition comprising a lipid nanoparticle of the invention, wherein the lipid nanoparticle has an increase in mean size of about 30%, 29%, 28%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less, preferably of about 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less after one or more freeze / thaw cycles as compared to that prior to freeze / thaw cycles.CureVac SE / P396WO1 108 / 219In one embodiment, the present invention provides a lipid nanoparticle composition comprising a lipid nanoparticle of the invention, wherein the formulation has an increase in mean size of about 30%, 29%, 28%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less, preferably of about 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less after lyophilization as compared to that prior to lyophilization.In one embodiment, the present invention provides a lipid nanoparticle composition comprising a lipid nanoparticle of the invention, wherein the formulation has an increase in mean size of about 30%, 29%, 28%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less, preferably of about 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less after dilution as compared to that prior to dilution.In one embodiment, the present invention provides a lipid nanoparticle composition comprising a lipid nanoparticle of the invention, wherein the encapsulation efficiency of the formulation is substantially the same after storage at about 4°C or lower for at least about one month, about two months, about three months, about four months, about five months, about six months or longer.In one embodiment, the present invention provides a lipid nanoparticle composition comprising a lipid nanoparticle of the invention, wherein the LNP mean size of the LNPs is substantially the same after storage at about 4°C or lower for at least about one month, about two months, about three months, about four months, about five months, about six months or longer.In another embodiment, the present invention provides a lipid nanoparticle of any of the above or below aspects and embodiments, wherein the formulation remains stable for at least 6 months at -20°C or 2-8°C, maintaining particle size and encapsulation efficiency.In another embodiment, the present invention provides a lyophilized lipid nanoparticle of any of the above or below aspects and embodiments, wherein reconstitution in aqueous buffer yields a formulation with a polydispersity index (PDI) of less than 0.3, preferably less than 0.2.Size, PDI, zeta potential, and encapsulation efficiency (EE%) of lipid nanoparticles of the inventionThe size of the lipid nanoparticles from the invention is typically described herein as Z-average size. The terms “average diameter”, “mean diameter”, “diameter” or “size” for particles (e.g. lipid nanoparticles from the invention) are used synonymously with the value of the Z-average. The term “Z-average size” refers to the mean diameter of particles as measured by dynamic light scattering (DLS) with data analysis using the so-called cumulant algorithm, which provides as results the so-called Z-average with the dimension of a length, and the polydispersity index (PI), which is dimensionless (Koppel, D., J. Chem. Phys. 57, 1972, pp 4814-4820, ISO 13321).The term “dynamic light scattering” or “DLS” refers to a method for analysing particles in a liquid, wherein the liquid is typically illuminated with a monochromatic light source and wherein the light scattered by particles in the liquid is detected. DLS can thus be used to measure particle sizes in a liquid. Suitable DLS protocols are known in the art. DLS instruments are commercially available (such as the Zetasizer Nano Series, Malvern Panalytical). DLS instruments employ either a detector at 90° (e.g. DynaPro™ NanoStar™ from Wyatt Technology or Zetasizer Nano S90 from Malvern Panalytical) or a backscatter detection system at 173° (e.g., Zetasizer Nano S from Malvern Panalytical) and at 158° (DynaPro™ Plate Reader from Wyatt Technology) close to the incident light of 180°.CureVac SE / P396WO1 109 / 219Typically, DLS measurements are performed at a temperature of about 25°C. DLS is also used in the context of the present invention to determine the polydispersity index (PDI) and / or the main peak diameter of the lipid nanoparticles from the invention incorporating RNA.In preferred embodiments, the lipid nanoparticles from the invention encapsulating RNA have a Z-average size ranging from about 50 nm to about 200 nm. In preferred embodiments, the lipid nanoparticles from the invention encapsulating RNA have a Z-average size in a range from about 50 nm to about 150 nm, more preferably from about 75 nm to about 125 nm, also more preferably about 90 nm to about 110 nm, and also preferably about 91 nm, about 92 nm, about 93 nm, about 94 nm, about 95 nm, about 96 nm, about 97 nm, about 98 nm, about 99 nm, about 100 nm, about 101 nm, about 102 nm, about 103 nm, about 104 nm, about 105 nm, about 106 nm, about 107 nm, about 108 nm, about 109 nm, about 110 nm, about 111 nm, about 112 nm, about 113 nm, about 114 nm, about 115 nm, about 116 nm, about 117 nm, about 118 nm, about 119 nm, about 120 nm, about 121 nm, about 122 nm, about 123 nm, about 124 nm, about 125 nm, about 126 nm, about 127 nm, about 128 nm, about 129 nm, or about 130 nm.In preferred embodiments, the polydispersity index (PDI) of the lipid nanoparticle of the invention is typically in the range of 0.1 to 0.5. In a particular embodiment, a PDI is below 0.3. In a further particular embodiment, a PDI is below 0.2. Typically, the PDI is determined by dynamic light scattering.Preferably, at least about 75%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% of lipid nanoparticles from the invention of the composition have a spherical morphology.The zeta potential of a nanoparticle composition may be used to indicate the electrokinetic potential of the composition. For example, the zeta potential may describe the surface charge of a nanoparticle composition. The lipid nanoparticles according to the invention may, due to the presence of both negatively and positively charged compounds, exhibit a relatively neutral zeta potential. The zeta potential (sometimes abbreviated as “charge”) may be determined along with the particle size of the particles, for example, by dynamic light scattering and Laser Doppler Microelectrophoresis, for example using a Malvern Zetasizer Nano (Malvern Panalytical). Skilled artisans are aware of many suitable methods available for measuring the Zeta potential, for example by diluting LNPs to 0.01 mg / ml mRNA in 0.1X PBS and measuring on a Malvern Zetasizer (Nano ZS) or generally measuring in 0.1 M PBS at pH 7.5.Depending on the amount and nature of charged compounds in the lipid nanoparticles, the nanoparticles may be characterized by a zeta potential. In a preferred embodiment, the zeta potential is in the range from about -50 mV to about +50 mV. In other preferred embodiments, the zeta potential is in the range from about -25 mV to about +25 mV. In some embodiments, the zeta potential of a lipid nanoparticle of the invention may be from about -10 mV to about +20 mV, from about -10 mV to about +15 mV, from about -10 mV to about +10 mV, from about -10 mV to about +5 mV, from about -10 mV to about 0 mV, from about -10 mV to about -5 mV, from about -5 mV to about +20 mV, from about -5 mV to about +15 mV, from about -5 mV to about +10 mV, from about -5 mV to about +5 mV, from about -5 mV to about 0 mV, from about 0 mV to about +20 mV, from about 0 mV to about +15 mV, from about 0 mV to about +10 mV, from about 0 mV to about +5 mV, from about +5 mV to about +20 mV, from about +5 mV to about +15 mV, or from about +5 mV to about +10 mV.Also preferably, the zeta potential of the inventive lipid nanoparticles is in the range of about 0 mV. Also preferably, the zeta potential of the inventive lipid nanoparticles is in the range of about 0 mV to about +10 mV, also preferablyCureVac SE / P396WO1 110 / 219in the range of about +5 mV to +10 mV, further preferably in the range of about +1 mV, further preferably in the range of about +2 mV, further preferably in the range of about +3 mV, further preferably in the range of about +4 mV, or further preferably in the range of about +5 mV.Most preferably, the zeta potential of the inventive lipid nanoparticles is in the range of about -20 mV to about +20 mV, preferably in the range of about -10 mV to about +10 mV, more preferably in the range of about -7.5 mV to about +7.5 mV, most preferably in the range of about -6 mV to about +6 mV.N / P ratioThe amount of lipid comprised in the lipid nanoparticle of the invention may be selected taking the amount of the artificial nucleic acid used in the lipid nanoparticles of the invention, preferably mRNA, into account. The N / P ratio is defined as the mole ratio of the nitrogen atoms (“N”) of the basic nitrogen-containing groups of the lipid to the phosphate groups (“P”) of the artificial nucleic acid, preferably mRNA, which is used as cargo or biologically active ingredient. The N / P ratio may be calculated on the basis that, for example, 1 pg RNA typically contains about 3 nmol phosphate residues, provided that the RNA exhibits a statistical distribution of bases. The “N”-value of the ionizable lipid may be calculated based on its molecular weight and the relative content of permanently cationic and - if present - cationisable groups. If more than one ionizable lipid is present, the N-value should be calculated based on all ionizable lipids comprised in the lipid nanoparticles.In one embodiment, these amounts are selected such as to result in an N / P ratio of the lipid nanoparticle of the invention encapsulating the RNA in the range of about 0.1 to about 20. In another embodiment, these amounts are selected such as to result in an N / P ratio of the nanoparticle(s) or of the composition in the range from about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, or about 12.In preferred embodiments, the amount of the ionizable lipid is selected taking the amount of the artificial nucleic acid, preferably mRNA, which is used as cargo or biologically active ingredient, preferably nucleic acid, into account, at an amount such as to achieve an N / P ratio in the range of about 6 to 8.In most preferred embodiments, the lipid nanoparticles comprise the mRNA at an amount such as to achieve an N / P ratio in the range of about 7.Nucleic acid, artificial nucleic acid, mRNAIn some embodiments, the cargo of the lipid nanoparticles of the invention is a nucleic acid. Preferably, the nucleic acid is messenger RNA (mRNA), siRNA, RNAi, guide RNA (gRNA), IncRNA (long non-coding RNA), samRNA / saRNA (self-amplifying RNA; SAM vaccines), and circular RNA (circRNA), most preferably the nucleic acid is messenger RNA (mRNA).In most preferred embodiments, the nucleic acid is an mRNA. The mRNA according to the invention in encapsulated in or associated with a lipid nanoparticle.The terms “nucleic acid”, “RNA”, “artificial nucleic acid”, “messenger RNA”, “artificial mRNA” in the context of the entire disclosure of the invention herein, are used interchangeably, meaning typically to be understood to be an mRNA molecule, that does not occur naturally. In other words, an “nucleic acid” of the invention typically is an artificial mRNA molecule i.e. a non-natural mRNA molecule. Such mRNA molecule may be non-natural due to its individual sequence (which does not occur naturally) and / or due to other modifications, e.g. structural modificationsCureVac SE / P396WO1 111 / 219of nucleotides which do not occur naturally. Typically, artificial mRNA molecules may be designed and / or generated by genetic engineering methods to correspond to a desired artificial sequence of nucleotides (heterologous sequence). In this context an artificial sequence is usually a sequence that may not occur naturally, i.e. it differs from the wild type sequence by at least one nucleotide. The term “wild type” may be understood as a sequence occurring in nature. Further, the term “artificial nucleic acid molecule” is not restricted to mean “one single molecule” but is, typically, understood to comprise an ensemble of identical molecules. Accordingly, it may relate to a plurality of identical molecules contained in an aliquot.Preferably, the mRNA or the coding sequence (CDS) thereof has a length of about 50 to about 20000, or 100 to about 20000 nucleotides, preferably of about 250 to about 20000 nucleotides, more preferably of about 500 to about 10000, even more preferably of about 500 to about 5000. In certain embodiments, the length the CDS may be about 30, about 40, about 50, about 60, about 70, about 80, about 90, about 100, about 150, about 200, about 250, about 300, about 350, about 400, about 450, about 500, about 600, about 700, about 800, about 900, about 1000, about 1100, about 1200, about 1300, about 1400, about 1500, about 1600, about 1700, about 1800, about 1900, about 2000, about 2100, about 2200, about 2300, about 2400, about 2500, about 2600, about 2700, about 2800, about 2900, about 3000, about 3100, about 3200, about 3300, about 3400, about 3500, about 3600, about 3700, about 3800, about 3900, about 4000, about 4500, about 5000, or about 6000 nucleotides, or more. In some embodiments, the length of the CDS may be in a range of from about 300 to about 2000 nucleotides. In other embodiments, the length of the CDS may be in a range of from about 2000 to about 3000 nucleotides. In other embodiments, the length of the CDS may be in a range of from about 3000 to about 4000 nucleotides.In one embodiment, the present invention provides the lipid nanoparticle of the invention, wherein the mRNA is a mono-, bi-, or multicistronic mRNA.In one embodiment, the present invention provides the lipid nanoparticle of the invention, wherein the mRNA comprises a coding region encoding a peptide or protein, wherein the coding region exhibits a sequence modification.In one embodiment, the present invention provides the lipid nanoparticle of the invention, wherein the sequence modification is selected from a G / C content modification, a codon modification, a codon optimization or a C-optimization of the sequence; preferably wherein, compared with the coding region of the corresponding wild type mRNA, the- G / C content of the coding region is increased;- C content of the coding region is increased;- codon usage in the coding region is adapted to the human codon usage; and / or- codon adaptation index (CAI) is increased or maximized in the coding region.In one embodiment, the present invention provides the lipid nanoparticle of the invention, wherein the mRNA further comprisesa) a 5’-CAP structure, preferably m7GpppN, more preferably CAP1 or m7G(5’)ppp(5’)(2’OMeA)pG;b) optionally at least one miRNA sequence, preferably wherein the microRNA binding site is for a microRNA selected from the group consisting of miR-126, miR-142, miR-144, miR-146, miR-150, miR-155, miR-16, miR-21, miR-223, miR-24, miR-27, miR-26a, or any combination thereof;c) at least one 5'-UTR element;d) a coding sequence;CureVac SE / P396WO1 112 / 219e) at least one 3’-UTR element;f) at least one histone stem-loop (hSL) sequence; and / org) at least one poly(A) sequence;or any combinations of these.Further, as disclosed herein, the mRNA comprised within the lipid nanoparticle of the invention preferably is a miRNA sequence as disclosed on page 18, line 1 to page 22, line 23 in WO2022233880; WO2022233880 being incorporated herein by reference. Further, as disclosed herein, the mRNA comprised within the lipid nanoparticle of the invention preferably is a miRNA sequence as disclosed SEQ ID NO:249 to SEQ ID NO:382 of WO2022233880; again WO2022233880 being incorporated herein by reference.As disclosed herein, in a further embodiment, the lipid nanoparticle of the invention comprises an mRNA compound comprising a histone stem-loop sequence / structure (“hSL”). In said embodiment, the mRNA sequence may comprise at least one (or more) histone stem loop sequence or structure. Such histone stem-loop sequences are preferably selected from histone stem-loop sequences as disclosed in WO2012019780, the disclosure of which is incorporated herewith by reference. A histone stem-loop sequence that may be used within the present invention may preferably be derived from formulae (I) or (II) of W02012019780. According to a further preferred embodiment the coding RNA may comprise at least one histone stem-loop sequence derived from at least one of the specific formulae (la) or (Ila) of the patent application W02012019780. According to a further preferred embodiment the coding RNA may comprise at least one histone stem-loop sequence derived from a Histone stem-loop as disclosed in patent application WO2018104538 under formula (I), formula (II), formula (la) or on pages 49-52 under section “histone stem-loop” and WO2018104538- SEQ ID NO:1451-1452 as disclosed in WO2018104538; WO2018104538 which is herein incorporated by reference in its entirety, also especially SEQ ID NO:1451-1452. In particularly preferred embodiment, the RNA of the invention comprises at least one histone stem-loop sequence, wherein said histone stem-loop sequence comprises a nucleic acid sequence being identical or at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:3 or 4, or fragments or variants thereof. In one embodiment, the present invention provides the lipid nanoparticle of the invention, wherein the least one coding mRNA comprises a 5’-CAP structure, preferably m7G, CAPO, CAP1, CAP2, a modified CAPO or a modified CAP1 structure.In one embodiment, the nucleic acid of the lipid nanoparticles of the invention is capable of self-replication. Thusly, a polynucleotide may be capable of self-replication when introduced into a host cell. Examples of polynucleotides thus include self-replicating RNAs and DNAs and, for instance, selected from replicons, plasmids, cosmids, phagemids, transposons, viral vectors, artificial chromosomes (e.g., bacterial, yeast, etc.) as well as other selfreplicating species. Polynucleotides include those that express antigenic polypeptides in a host cell (e.g., polynucleotide-containing antigens). Polynucleotides include self-replicating polynucleotides within which natural or synthetic sequences derived from eucaryotic or prokaryotic organisms (e.g., genomic DNA sequences, genomic RNA sequences, cDNA sequences, etc.) have been inserted. Specific examples of self-replicating polynucleotides include RNA vector constructs and DNA vector constructs, among others.Pharmaceutical composition and pharmaceutically acceptable carrierThe lipid nanoparticle or pharmaceutical composition according to the invention may typically contain a “pharmaceutically acceptable” carrier or “pharmaceutically acceptable” excipient. Examples of suitable carriers and excipients are known to those skilled in the art and include but are not limited to preserving agents, fillers,CureVac SE / P396WO1 113 / 219disintegrating agents, wetting agents, emulsifying agents, suspending agents, sweetening agents, flavouring agents, perfuming agents, antibacterial agents, antifungal agents, lubricating agents and dispersing agents, depending on the nature of the mode of administration and dosage forms. The term “pharmaceutical composition” in the context of this invention means a composition comprising an active agent and comprising additionally one or more pharmaceutically acceptable carriers. The composition may further contain ingredients selected from, for example, diluents, excipients, vehicles, preserving agents, fillers, disintegrating agents, wetting agents, emulsifying agents, suspending agents, sweetening agents, flavouring agents, perfuming agents, antibacterial agents, antifungal agents, lubricating agents and dispersing agents, depending on the nature of the mode of administration and dosage forms.Thus, in a third aspect, the present invention provides a pharmaceutical composition comprising the ionizable lipid of the above or below aspects and embodiments, or one or more lipid nanoparticles of the above or below aspects and embodiments and a pharmaceutically acceptable carrier, preferably for use in human medicine, more preferably for use in the prophylaxis or treatment of cancer, tumor or infectious diseases in a subject, most preferably for use in the prophylaxis or treatment of cancer or tumor diseases in a subject in need.The choice of a pharmaceutically acceptable carrier is determined, in principle, by the manner, in which the lipid nanoparticle or pharmaceutical composition according to the invention is administered. The lipid nanoparticle of the invention or pharmaceutical composition comprising said lipid nanoparticle can be administered, for example, systemically or locally. Preferred and suitable routes of administration are described herein. Suitable pharmaceutically acceptable carriers for topical application include those which are suitable for use in lotions, creams, gels and the like. If the inventive lipid nanoparticle or pharmaceutical composition is to be administered perorally, tablets, capsules and the like are the preferred unit dose form. The pharmaceutically acceptable carriers for the preparation of unit dose forms which can be used for oral administration are well known in the art. The choice thereof will depend on secondary considerations such as taste, costs and storability, which are not critical for the purposes of the present invention, and can be made without difficulty by a person skilled in the art.CureVac SE / P396WO1 114 / 219content with reference to the specific reference medium, wherein preferably such concentrations of the afore mentioned salts may be used, which do not lead to damage of cells due to osmosis or other concentration effects. Reference media are e.g. in “in vivo” methods occurring liquids such as blood, lymph, cytosolic liquids, or other body liquids, or e.g. liquids, which may be used as reference media in “in vitro” methods, such as common buffers or liquids. Such common buffers or liquids are known to a skilled person.In preferred embodiments, about 80% of artificial nucleic acid, preferably mRNA, comprised in the pharmaceutical composition is encapsulated in lipid nanoparticles from the invention, preferably about 85% of the artificial nucleic acid, preferably mRNA, comprised in the pharmaceutical composition is encapsulated in lipid nanoparticles from the invention, more preferably about 90% of the artificial nucleic acid, preferably mRNA, comprised in the pharmaceutical composition is encapsulated in lipid nanoparticles from the invention, most preferably about 95% of the artificial nucleic acid, preferably mRNA, comprised in the pharmaceutical composition is encapsulated in lipid nanoparticles from the invention. The percentage of encapsulation may be determined by a RiboGreen assay as known in the art.Thusly, the present disclosure provides pharmaceutical compositions comprising lipid nanoparticles of the invention with advantageous properties. The lipid nanoparticles and pharmaceutical compositions described herein may be advantageously used for the delivery of therapeutic and / or prophylactic agents, e.g., mRNAs, to mammalian cells or organs. For example, the ionizable lipids disclosed herein have a higher biodistribution i.e. a higher tropism to the spleen, draining lymph nodes and / or muscle tissue of the injection site as compared to reference lipids (e.g., MC3, KC2, or DLinDMA) or as compared to lipid nanoparticles comprising those reference lipids (e.g., MC3, KC2, or DLinDMA). For example, a formulation comprising an ionizable lipid as disclosed herein and a therapeutic or prophylactic agent, e.g., mRNA, has an increased biodistribution i.e. a higher tropism to the spleen, draining lymph nodes and / or muscle tissue of the injection site as compared to a corresponding formulation which comprises a reference lipid (e.g., MC3, KC2, or DLinDMA) and the same therapeutic or prophylactic agent.In the context of the invention, thusly a “reference lipid” may be for example MC3, KC2, or DLinDMA instead of the ionizable lipid of the invention, while a “reference lipid nanoparticle” may be for example a lipid nanoparticle comprising for example MC3, KC2, or DLinDMA as ionizable lipid instead of the ionizable lipid of the invention.In an aspect, the present invention provides a pharmaceutical composition comprising the ionizable lipid of the invention, or one or more lipid nanoparticles of the invention and a pharmaceutically acceptable carrier, preferably for use in human medicine, more preferably for use in the prophylaxis or treatment of cancer, tumor or infectious diseases in a subject, most preferably for use in the prophylaxis or treatment of cancer or tumor diseases in a subject in need.For purposes of this disclosure, the term “medicine” is intended to include a substance or preparation used in treating disease or a health condition, maintaining health, or treating, preventing, alleviating, or curing of disease or a health condition.In an aspect, the present invention provides the pharmaceutical composition of the present disclosure or the lipid nanoparticle of the present disclosure, for use as a medicament in the prophylaxis or treatment of cancer or tumor diseases in a subject in need, wherein the medicament is a prophylactic vaccine or a therapeutic vaccine, preferably a prophylactic cancer vaccine, a therapeutic cancer vaccine, or a personalized cancer vaccine (PCV).CureVac SE / P396WO1 115 / 219In an aspect, the present invention provides the pharmaceutical composition of the present disclosure, or the lipid nanoparticle of the present disclosure, for use as a medicament in the prophylaxis or treatment of cancer or tumor diseases in a subject in need, wherein the subject in need is a vertebrate, preferably a mammalian subject, more preferably a human subject.Kit, kit of partsAccording to another aspect of the present invention, the present invention also provides a kit, in particular a kit of parts, comprising the lipid nanoparticle of the invention, at least one lipid according to Formula (I) or Formula (II), optionally DSPC, and / or at least one phosphatidylserine, preferably DPhyPS as defined herein.Thus, in a fourth aspect, the present invention provides a kit or kit of parts, comprising the pharmaceutical composition of the above or below aspects and embodiments, the ionizable lipid of the above or below aspects and embodiments, or the lipid nanoparticle of the above or below aspects and embodiments, optionally comprising a liquid vehicle for solubilizing, and, optionally, technical instructions providing information on administration and dosage of the components.In another aspect, the present invention provides a kit or kit of parts, comprising the pharmaceutical composition of the present disclosure, the ionizable lipid of the present disclosure, or the lipid nanoparticle of the present disclosure, optionally comprising a liquid vehicle for solubilizing, and, optionally, technical instructions providing information on administration and dosage of the components.In a further embodiment the kit comprises a lipid nanoparticle as defined above or the pharmaceutical composition comprising a lipid nanoparticle as defined above, optionally a liquid vehicle for solubilizing and optionally technical instructions with information on the administration and dosage of the mRNA comprising lipid nanoparticles, the composition and / or the vaccine. The technical instructions may contain information about administration and dosage of the mRNA comprising lipid nanoparticles, the composition and / or the vaccine. Such kits, preferably kits of parts, may be applied e.g. for any of the above-mentioned applications or uses, preferably for the use of the lipid nanoparticle according to the invention (for the preparation of an inventive medicament, preferably a therapeutic vaccine) for the treatment or prophylaxis of a cancer disease or disorder.The kits may also be applied for the use of the lipid nanoparticle, the composition or the vaccine as defined herein (for the preparation of an inventive vaccine) for the treatment or prophylaxis of a cancer disease, wherein the lipid nanoparticle, the composition and / or the vaccine may be capable of inducing or enhancing an immune response in a mammal as defined above.Such kits may further be applied for the use of the lipid nanoparticle, the composition or the vaccine as defined herein for modulating, preferably for eliciting, e.g. to induce or enhance, an immune response in a mammal as defined above, and preferably for supporting treatment or prophylaxis of a cancer disease or disorder related thereto.Kits of parts, as a special form of kits, may contain one or more identical or different compositions and / or one or more identical or different vaccines as described herein in different parts of the kit. Kits of parts may also contain an (e.g. one) composition, an (e.g. one) vaccine and / or the mRNA comprising lipid nanoparticles according to the invention in different parts of the kit, e.g. each part of the kit containing an mRNA comprising lipid nanoparticles asCureVac SE / P396WO1 116 / 219defined herein, preferably encoding a distinct antigen. Preferably, the kit or the kit of parts contains as a part a vehicle for solubilizing the mRNA according to the invention, the vehicle optionally being Ringer-lactate solution. Any of the above kits may be used in a treatment or prophylaxis as defined above.In another embodiment of this aspect, the kit according to the present invention may additionally contain at least one adjuvant. In a further embodiment, the kit according to the present invention may additionally contain at least one further pharmaceutically active component, preferably a therapeutic compound suitable for treatment and / or prophylaxis of cancer or a related disorder. Moreover, in another embodiment, the kit may additionally contain parts and / or devices necessary or suitable for the administration of the composition or the vaccine according to the invention, including needles, applicators, patches, injection-devices.The term “subject” or “subject in need” refers to a living organism to which any of the compositions as described herein may be administered. The subject may be suffering from or be at risk for a disease or condition that can be treated by administration of pharmaceutical composition as provided herein or by a therapeutic method disclosed herein. Non-limiting examples of subjects include humans, other mammals, bovines, rats, mice, dogs, monkeys, goat, sheep, cows, deer, and other non-mammalian animals. In preferred embodiments, the subject or subject in need is a primate, e.g., a human. In some embodiments, the subject in need has a tumor, a disseminated tumor, multiple myeloma, solid tumor, leukemia, lymphoma, sarcoma, carcinoma, glioma, or a melanoma.The term “therapeutically effective amount” as used herein, refers to an amount of a lipid nanoparticle according to the invention and / or a lipid nanoparticle according to the invention comprising a nucleic acid, preferably an mRNA, sufficient to treat a disease, a disorder, or a condition. For the given parameter, a therapeutically effective amount will show an increase or decrease of at least 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%, 90%, or at least 100% of symptoms in a subject in need. Therapeutic efficacy can also be expressed as “-fold” increase or decrease. For example, a therapeutically effective amount can have at least a 1.2-fold, 1.5-fold, 2-fold, 5-fold, or more effect over a control. The “therapeutically effective amount” can vary depending, for example, but not limited to, on the compound, the disease, or the condition and / or symptoms thereof, severity of the disease or the condition and / or symptoms thereof, the age, weight, and / or health of the subject to be treated, and the judgment of the prescribing physician. An appropriate amount in any given instance can be ascertained by those skilled in the art or capable of determination by routine experimentation.In another aspect, the present invention provides a method for preventing, ameliorating or treating a disease or condition in a subject in need, preferably a cancer or tumor disease, comprising administering to the subject in need (i) the ionizable lipid of the above or below aspects and embodiments, (ii) the lipid nanoparticle of the above or below aspects and embodiments, (iii) the pharmaceutical composition of the above or below aspects and embodiments, or (iv) the kit or kit of parts of the above or below aspects and embodiments.In another aspect, the present invention provides a method of reducing or inhibiting tumor growth in a subject in need, comprising administering to the subject in need (i) the ionizable lipid of the above or below aspects and embodiments, (ii) the lipid nanoparticle of the above or below aspects and embodiments, (iii) the pharmaceutical composition of the above or below aspects and embodiments, or (iv) the kit or kit of parts of the above or below aspects and embodiments.CureVac SE / P396WO1 117 / 219In another embodiment, the present invention provides a method, wherein (i) the ionizable lipid of the present disclosure, (ii) the lipid nanoparticle of the present disclosure, (iii) the pharmaceutical composition of the present disclosure, or (iv) the kit or kit of parts of the present disclosure is administered to the subject in need in combination with one or more immunomodulatory agents.In another embodiment, the present invention provides a method, wherein administration of (i) the ionizable lipid of the present disclosure, (ii) the lipid nanoparticle of the present disclosure, (iii) the pharmaceutical composition of the present disclosure, or (iv) the kit or kit of parts of the present disclosure to a subject in need results in expression of the peptide or protein encoded by mRNA in the spleen, draining lymph nodes and / or muscle tissue of the injection site of the subject in need with a higher spleen, draining lymph nodes and / or muscle tissue of the injection site to liver ratio.In another embodiment, the present invention provides a method, wherein administration of (i) the ionizable lipid of the present disclosure, (ii) the lipid nanoparticle of the present disclosure, (iii) the pharmaceutical composition of the present disclosure, or (iv) the kit or kit of parts of the present disclosure to a subject in need results in expression of the peptide or protein encoded by mRNA in the spleen, draining lymph nodes and / or muscle tissue of the injection site of the subject in need, wherein the (a) mRNA or (b) the peptide or protein encoded by said mRNA can be detected in the spleen, draining lymph nodes and / or muscle tissue versus liver tissue with a ratio of at least about 5:1, at least about 10:1, at least about 20:1, at least about 30:1, at least about 40:1, at least about 50:1, at least about 60:1, at least about 70:1, at least about 80:1, at least about 90:1, at least about 100:1, at least about 150:1, at least about 200:1, at least about 250:1, at least about 300:1, at least about 350:1, at least about 450:1, at least about 500:1, at least about 550:1, at least about 600:1, at least about 650:1, or at least about 700:1, or more when measured 4, 6, or 24 hours post administration of the lipid nanoparticle to the subject in need, preferably after intramuscular administration.In another embodiment, the present invention provides a method, wherein administration of (i) the ionizable lipid of the present disclosure, (ii) the lipid nanoparticle of the present disclosure, (iii) the pharmaceutical composition of the present disclosure, or (iv) the kit or kit of parts of the present disclosure to a subject in need results in an antigenspecific immune response in the subject in need comprising at least one of1. a T cell response;2. a B cell response;3. a CD4 T cell immune response;4. a CD8 T cell immune response;5. an antigen specific antibody response, wherein the antigen specific antibody response is measured by the presence of antigen-specific antibodies in serum;6. an induction of interferon (IFN) production or modulation, preferably production or modulation of IFNa, IFNb, IFNe, IFNk or IFN, most preferably IFNa and / or IFNb; and / or7. an induction of cytokine production or modulation.In another embodiment, the present invention provides a method, wherein administration of (i) the ionizable lipid of the present disclosure, (ii) the lipid nanoparticle of the present disclosure, (iii) the pharmaceutical composition of the present disclosure, or (iv) the kit or kit of parts of the present disclosure to a subject in need results inCureVac SE / P396WO1 118 / 219(a) the artificial nucleic acid or the mRNA comprised in the lipid nanoparticle being detected at an increased ratio in conventional type 1 dendritic cells (cDC1) as when compared to a reference lipid nanoparticle composition in which the ionizable lipid is replaced by a reference lipid or the phosphatidylserine lipid is replaced by cholesterol;(b) the artificial nucleic acid or the mRNA comprised in the lipid nanoparticle being detected at an increased ratio in macrophages as when compared to a reference lipid nanoparticle composition in which the ionizable lipid is replaced by a reference lipid or the phosphatidylserine lipid is replaced by cholesterol;(c) the peptide or protein encoded by the mRNA comprised in the lipid nanoparticle being detected at an increased ratio in conventional type 1 dendritic cells (cDC1) as when compared to a reference lipid nanoparticle composition in which the ionizable lipid is replaced by a reference lipid or the phosphatidylserine lipid is replaced by cholesterol; and / or(d) the peptide or protein encoded by the mRNA comprised in the lipid nanoparticle being detected at an increased ratio in macrophages as when compared to a reference lipid nanoparticle composition in which the ionizable lipid is replaced by a reference lipid or the phosphatidylserine lipid is replaced by cholesterol; preferably after intramuscular administration.In another embodiment, the present invention provides a method, wherein administration of (i) the ionizable lipid of the present disclosure, (ii) the lipid nanoparticle of the present disclosure, (iii) the pharmaceutical composition of the present disclosure, or (iv) the kit or kit of parts of the present disclosure to a subject in need results in (a) the artificial nucleic acid or the mRNA comprised in the lipid nanoparticle being detected at an increased ratio in conventional type 1 dendritic cells (cDC1) as when compared to a reference lipid nanoparticle composition in which the ionizable lipid and / or the polymer conjugated lipid is replaced by a reference lipid, or the phosphatidylserine lipid is replaced by cholesterol;(b) the artificial nucleic acid or the mRNA comprised in the lipid nanoparticle being detected at an increased ratio in macrophages as when compared to a reference lipid nanoparticle composition in which the ionizable lipid and / or the polymer conjugated lipid is replaced by a reference lipid, or the phosphatidylserine lipid is replaced by cholesterol;(c) the peptide or protein encoded by the mRNA comprised in the lipid nanoparticle being detected at an increased ratio in conventional type 1 dendritic cells (cDC1) as when compared to a reference lipid nanoparticle composition in which the ionizable lipid and / or the polymer conjugated lipid is replaced by a reference lipid, or the phosphatidylserine lipid is replaced by cholesterol; and / or(d) the peptide or protein encoded by the mRNA comprised in the lipid nanoparticle being detected at an increased ratio in macrophages as when compared to a reference lipid nanoparticle composition in which the ionizable lipid and / or the polymer conjugated lipid is replaced by a reference lipid, or the phosphatidylserine lipid is replaced by cholesterol;preferably after intramuscular administration.In another embodiment, the present invention provides a method, wherein the method comprises administering to a subject in need (i) the ionizable lipid according of the present disclosure, (ii) the lipid nanoparticle of the present disclosure, (iii) the pharmaceutical composition of the present disclosure, or (iv) the kit or kit of parts of the present disclosure via subcutaneous, intradermal, intravenous, intramuscular, or intratumoral administration, preferably via intramuscular administration.CureVac SE / P396WO1 119 / 219In another embodiment, the present invention provides a method, wherein the method comprises administering to a subject in need (i) the ionizable lipid according of the present disclosure, (ii) the lipid nanoparticle of the present disclosure, (iii) the pharmaceutical composition of the present disclosure, or (iv) the kit or kit of parts of the present disclosure via intramuscular administration.In another embodiment, the present invention provides a method, wherein the method comprises administering to a subject in need (i) the ionizable lipid according of the present disclosure, (ii) the lipid nanoparticle of the present disclosure, (iii) the pharmaceutical composition of the present disclosure, or (iv) the kit or kit of parts of the present disclosure via intravenous administration.In another embodiment, the present invention provides a method, wherein the method comprises administering to a subject in need (i) the ionizable lipid according of the present disclosure, (ii) the lipid nanoparticle of the present disclosure, (iii) the pharmaceutical composition of the present disclosure, or (iv) the kit or kit of parts of the present disclosure via intradermal administration.Allergenic antigens and autoimmune self-antigensIn one embodiment, the mRNA used in the lipid nanoparticles of the invention may, according to some embodiments, be an mRNA, encoding an antigen that represents an allergen, or an allergenic antigen or a selfantigen, also referred to as autoantigen or autoimmune antigen. Such antigens and self-antigens associated with allergy or allergic disease (allergens or allergenic antigens) are derived from or preferably selected from, but not limited to, the group of antigens disclosed on pages 59-73 in WO2018078053; WO2018078053 being incorporated herein by reference in its entirety.Method of treatmentIn yet another aspect, the present invention provides a method for preventing, ameliorating or treating a disease or condition in a subject in need, preferably a cancer or tumor disease, comprising administering to the subject in need (i) the ionizable lipid of any of the above or below aspects and embodiments, (ii) the lipid nanoparticle of any of the above or below aspects and embodiments, (iii) the pharmaceutical composition of any of the above or below aspects and embodiments, or (iv) the kit or kit of parts of any of the above or below aspects and embodiments.In yet another aspect, the present invention provides a method of reducing or inhibiting tumor growth in a subject in need, comprising administering to the subject in need (i) the ionizable lipid of any of the above or below aspects and embodiments, (ii) the lipid nanoparticle of any of the above or below aspects and embodiments, (iii) the pharmaceutical composition of any of the above or below aspects and embodiments, or (iv) the kit or kit of parts of any of the above or below aspects and embodiments.In yet another aspect, the present invention provides a method of inducing an antigen-specific immune response in a subject in need, the method comprising administering to the subject in need (i) the ionizable lipid of any of the above or below aspects and embodiments, (ii) the lipid nanoparticle of any of the above or below aspects and embodiments, (iii) the pharmaceutical composition of any of the above or below aspects and embodiments, or (iv) the kit or kit of parts of any of the above or below aspects and embodiments, in an amount effective to produce an antigen-specific immune response in the subject.CureVac SE / P396WO1 120 / 219In yet another embodiment of the previous aspects, the present invention provides a method, wherein the method comprises administering to a subject in need (i) the ionizable lipid of any of the above or below aspects and embodiments, (ii) the lipid nanoparticle of any of the above or below aspects and embodiments, (iii) the pharmaceutical composition of any of the above or below aspects and embodiments, or (iv) the kit or kit of parts of any of the above or below aspects and embodiments via subcutaneous, intradermal, intravenous, intramuscular, or intratumoral administration, preferably via intramuscular administration.In another embodiment, the present invention provides a method, wherein (i) the ionizable lipid of the present disclosure, (ii) the lipid nanoparticle of the present disclosure, (iii) the pharmaceutical composition of the present disclosure, or (iv) the kit or kit of parts of the present disclosure is administered to the subject in need in combination with one or more immunomodulatory agents.In another embodiment, the present invention provides a method, wherein administration of (i) the ionizable lipid of the present disclosure, (ii) the lipid nanoparticle of the present disclosure, (iii) the pharmaceutical composition of the present disclosure, or (iv) the kit or kit of parts of the present disclosure to a subject in need results in expression of the peptide or protein encoded by artificial nucleic acid, preferably mRNA in the spleen, draining lymph nodes and / or muscle tissue of the injection site of the subject in need with a higher spleen, draining lymph nodes and / or muscle tissue of the injection site to liver ratio.In another embodiment, the present invention provides a method, wherein administration of (i) the ionizable lipid of the present disclosure, (ii) the lipid nanoparticle of the present disclosure, (iii) the pharmaceutical composition of the present disclosure, or (iv) the kit or kit of parts of the present disclosure to a subject in need results in expression of the peptide or protein encoded by artificial nucleic acid, preferably mRNA in the spleen, draining lymph nodes and / or muscle tissue of the injection site of the subject in need, wherein the (a) artificial nucleic acid, preferably mRNA or (b) the peptide or protein encoded by said artificial nucleic acid, preferably mRNA can be detected in the spleen, draining lymph nodes and / or muscle tissue versus liver tissue with a ratio of at least about 5:1, at least about 10:1, at least about 20:1, at least about 30:1, at least about 40:1, at least about 50:1, at least about 60:1, at least about 70:1, at least about 80:1, at least about 90:1, at least about 100:1, at least about 150:1, at least about 200:1, at least about 250:1, at least about 300:1, at least about 350:1, at least about 450:1, at least about 500:1, at least about 550:1, at least about 600:1, at least about 650:1, or at least about 700:1, or more when measured 4, 6, or 24 hours post administration of the lipid nanoparticle to the subject in need, preferably after intramuscular administration.In another embodiment, the present invention provides a method, wherein administration of (i) the ionizable lipid of the present disclosure, (ii) the lipid nanoparticle of the present disclosure, (iii) the pharmaceutical composition of the present disclosure, or (iv) the kit or kit of parts of the present disclosure to a subject in need results in an antigenspecific immune response in the subject in need comprising at least one of1. a T cell response;2. a B cell response;3. a CD4 T cell immune response;4. a CD8 T cell immune response;CureVac SE / P396WO1 121 / 2195. an antigen specific antibody response, wherein the antigen specific antibody response is measured by the presence of antigen-specific antibodies in serum;6. an induction of interferon (IFN) production or modul...

Claims

CureVac SE / P396WO1 08thMay 2026CLAIMS1. An ionizable lipid having a structure of Formula (I) or Formula (II)or a pharmaceutically acceptable salt or stereoisomer thereof, whereinXi is an alkanediyl having 1 to 8 carbon atoms;R1 is independently -OH, -S-OH, -S-CH2-OH, -S-CH2-CH2-OH or-S-CH3;X2is an alkanediyl having 1 to 8 carbon atoms;X3 is an alkanediyl having 1 to 8 carbon atoms;Y1 and Y2are independently -(C=O)O-CH2-CH2-, -O(C=O)-CH2-CH2-, -(C=O)O-CH2-, -O(C=O)-CH2- -CH2-CH2-(C=O)O-, -CH2-CH2-O(C=O)-, -CH2-(C=O)O-, or -CH2-O(C=O)-;Y3and Y4 are independently -(C=O)O-CH2-CH2-, -O(C=O)-CH2-CH2-, -(C=O)O-CH2-, -O(C=O)-CH2- -CH2-CH2-(C=O)O-, -CH2-CH2-O(C=O)-, -CH2-(C=O)O-, or-CH2-0(C=0)-; andR2and R3 are each independently straight or branched, saturated or unsaturated C6–C24 alkyl or C6–C24 alkenyl, wherein the alkyl chain is optionally interrupted by one or more ester bonds.

2. The ionizable lipid according to claim 1 having a structure of Formula (I)or a pharmaceutically acceptable salt or stereoisomer thereof, whereinXi is an alkanediyl having 2 to 6 carbon atoms;Ri is independently -OH, -S-OH, or-S-CH₃;X2is an alkanediyl having 2 to 6 carbon atoms;X3 is an alkanediyl having 2 to 6 carbon atoms;Y1 and Y2are independently -(C=O)O-CH2-CH2-, or -O(C=O)-CH2-CH2-;Y3 and Y4 are independently -(C=O)O-CH2- or -O(C=O)-CH2-; andR2and R3 are each independently straight or branched, saturated or unsaturated C10-C20 alkyl or C10- C20 alkenyl, wherein the alkyl chain is optionally interrupted by one or more ester bonds.

3. The ionizable lipid according to any one of claims 1-2 having a structure of Formula (I)CureVac SE / P396WO1 2 / 15or a pharmaceutically acceptable salt or stereoisomer thereof, whereinXi is an alkanediyl having 2 to 6 carbon atoms;R1 is –OH;X2is an alkanediyl having 4 carbon atoms;X3 is an alkanediyl having 4 carbon atoms;Y1 and Y2are independently -(C=O)O-CH2-CH2-, or -O(C=O)-CH2-CH2-;Y3 and Y4 are independently -(C=O)O-CH2- or -O(C=O)-CH2-; andR2and R3 are each independently straight or branched, saturated or unsaturated C14, C15 or C16 alkyl, wherein the alkyl chain is optionally interrupted by one or more ester bonds.

4. The ionizable lipid according to any one of claims 1-3 having a structure of Formula (I)or a pharmaceutically acceptable salt or stereoisomer thereof, whereinXi is an alkanediyl having 4 carbon atoms;R1 is –OH;X2is an alkanediyl having 4 carbon atoms;X3 is an alkanediyl having 4 carbon atoms;Y1 and Y2are independently -(C=O)O-CH2-CH2-, or -O(C=O)-CH2-CH2-;Y3 and Y4 are independently -(C=O)O-CH2-, or -O(C=O)-CH2-; andR2and R3 are each independently straight or branched, saturated or unsaturated C15 alkyl, wherein the alkyl chain is optionally interrupted by one or more ester bonds.

5. The ionizable lipid according to any one of claims 1-4 having a structure of Formula (I)CureVac SE / P396WO1 3 / 15or a pharmaceutically acceptable salt or stereoisomer thereof, whereinXi is an alkanediyl having 4 carbon atoms;R1 is –OH;X2 is an alkanediyl having 4 carbon atoms;X3 is an alkanediyl having 4 carbon atoms;Y1 and Y2 are independently -O(C=O)-CH2-CH2-;Y3 and Y4 are independently -(C=O)O-CH2-; andR2 and R3 are each independently straight or branched, saturated or unsaturated C15 alkyl, wherein the alkyl chain is optionally interrupted by one or more ester bonds.

6. The ionizable lipid according to any one of claims 1-5 having a structure of Formula (I)or a pharmaceutically acceptable salt or stereoisomer thereof, whereinXi is an alkanediyl having 4 carbon atoms;R1is -OH;X2 is an alkanediyl having 4 carbon atoms;X3 is an alkanediyl having 4 carbon atoms;Y1 and Y2 are independently -O(C=O)-CH2-CH2-;Y3 and Y4 are independently -(C=O)O-CH2-; andR2 and R3 are each branched and saturated C15 alkyl, preferably7. The ionizable lipid according to any one of claims 1-6, having the structure CIL86CureVac SE / P396WO1 4 / 15(CIL86).

8. A lipid nanoparticle comprising an ionizable lipid according to any one of claims 1-7.

9. The lipid nanoparticle according to claim 8, wherein the lipid nanoparticle further comprises a phospholipid.

10. The lipid nanoparticle according to any one of claims 8-9, wherein the phospholipid is selected from the group consisting of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-diphytanoyl-sn-glycero-3-phospho-L-serine (DPhyPS), 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16.0 PE; DPhyPE), 1,2-diphytanoyl-sn-glycero-3-phosphocholine (DPhyPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), and mixtures thereof, preferably wherein the phospholipid is 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC).

11. The lipid nanoparticle according to any one of claims 8-10, wherein the phospholipid is 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC).

12. The lipid nanoparticle according to any one of claims 8-11, wherein the lipid nanoparticle comprises a first and a different second phospholipid, preferably DSPC as first phospholipid and a phosphatidylserine as second phospholipid, more preferably DSPC as first phospholipid and DPhyPS as second phospholipid.

13. The lipid nanoparticle according to any one of claims 8-12, wherein the lipid component further comprises a sterol lipid.

14. The lipid nanoparticle according to any one of claims 8-13, wherein the sterol lipid is selected from the group consisting of cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid, alpha-tocopherol, and mixtures thereof, preferably wherein the sterol lipid is cholesterol.

15. The lipid nanoparticle according to any one of claims 8-14, wherein the sterol lipid is cholesterol.

16. The lipid nanoparticle according to any one of claims 8-15, wherein the lipid nanoparticle further comprises a polymer conjugated lipid.

17. The lipid nanoparticle according to any one of claims 8-16, wherein the polymer conjugated lipid is a poly(2-methyl-2-oxazoline) (PMOZ)-conjugated lipid, a poly(2-ethyl-2-oxazoline) (PEOZ)-conjugated lipid, or a polyethyleneglycol (PEG)-conjugated lipid, preferably wherein the polymer conjugated lipid has about 40 to about 60 PMOZ, PEOZ, or PEG monomer repeats.

18. The lipid nanoparticle according to any one of claims 8-17, wherein the polymer conjugated lipid is a poly(2-methyl-2-oxazoline) (PMOZ)-conjugated lipid, preferably wherein the polymer conjugated lipid has about 40 to about 60 PMOZ monomer repeats, and further preferably wherein the lipid nanoparticle does not comprise polyethyleneglycol, polyethyleneglycol-conjugated lipids, PEG-modified lipids or PEG-lipids.CureVac SE / P396WO1 5 / 1519. The lipid nanoparticle according to any one of claims 8-18, wherein the polymer conjugated lipid is a poly(2-methyl-2-oxazoline) (PMOZ)-conjugated lipid, preferably a PMOZ-lipid not comprising a sulphur group (-S-), more preferably a PMOZ-lipid comprising a linker group [linker] being (C(O)CH₂CH₂C(O)NH).

20. The lipid nanoparticle according to any one of claims 8-19, wherein the polymer conjugated lipid is “PMOZ 4” having 50 PMOZ monomer repeats(“PMOZ 4” having 50 PMOZ monomer repeats).

21. The lipid nanoparticle according to any one of claims 8-20, wherein the lipid nanoparticle comprises:20-60 mol% ionizable lipid;5-25 mol% phospholipid;25-55 mol% sterol; and0.1-5 mol% polymer conjugated lipid.

22. The lipid nanoparticle according to any one of claims 8-21, wherein the lipid nanoparticle comprises:40-60 mol% ionizable lipid according to any one of claims 1-7;5-15 mol% first phospholipid;1-5 mol% second phospholipid;30-50 mol% sterol, preferably cholesterol; and0.1-2 mol% polymer conjugated lipid, preferably a poly(2-methyl-2-oxazoline) (PMOZ)-conjugated lipid.

23. The lipid nanoparticle according to any one of claims 8-22, wherein the lipid nanoparticle comprises:45-55 mol% ionizable lipid according to any one of claims 1-7;5-10 mol% first phospholipid, preferably DSPC;2-3 mol% second phospholipid, preferably DPhyPS;35-45 mol% sterol, preferably cholesterol; and0.1-1 mol% PMOZ-conju gated lipid, preferably “PMOZ 4” having 50 PMOZ monomer repeats.

24. The lipid nanoparticle according to any one of claims 8-23, wherein the lipid nanoparticle comprises:45-55 mol% ionizable lipid according to any one of claims 1-7;5-10 mol% first phospholipid, preferably DSPC;2-3 mol% second phospholipid, preferably DPhyPS;35-45 mol% sterol, preferably cholesterol; and0.4-0.6 mol% “PMOZ 4” having 50 PMOZ monomer repeats.

25. The lipid nanoparticle according to any one of claims 8-24, wherein the lipid nanoparticle comprises:49 mol% ionizable lipid CIL86CureVac SE / P396WO1 6 / 15(CIL86);40.5 mol% cholesterol; and0.5 mol% “PMOZ 4” having 50 PMOZ monomer repeats(“PMOZ 4” having 50 PMOZ monomer repeats).

26. The lipid nanoparticle according to any one of claims 8-25, further comprising an artificial nucleic acid, preferably selected from the group consisting of messenger RNA (mRNA), siRNA, RNAi, guide RNA (gRNA), IncRNA (long non-coding RNA), samRNA / saRNA (self-amplifying RNA; SAM vaccines), and circular RNA, most preferably the artificial nucleic acid is messenger RNA (mRNA).

27. The lipid nanoparticle according to claim 26, wherein the artificial nucleic acid is messenger RNA (mRNA).

28. The lipid nanoparticle according to claim 27, wherein the mRNA(a) comprises at least one coding sequence encoding a peptide or protein, or a fragment or variant thereof, wherein the peptide or protein is an antigen, wherein the antigen preferably is, or is derived from, a cancer or tumor antigen, a cancer or tumor epitope, a pathogenic antigen, a viral antigen, a bacterial antigen, a tumor antigen, an allergenic antigen or an autoimmune self-antigen, preferably a cancer or tumor antigen or a cancer or tumor epitope; orCureVac SE / P396WO1 7 / 15(b) comprises at least one coding sequence encoding a therapeutic protein, or a fragment or variant thereof, wherein the therapeutic protein is selected from the group consisting of(i) therapeutic proteins for use in enzyme replacement therapy for the treatment of metabolic, endocrine or amino acid disorders or for use in replacing an absent, deficient or mutated protein;(ii) therapeutic proteins for use in the treatment of blood disorders, diseases of the circulatory system, diseases of the respiratory system, infectious diseases or immune deficiencies;(iii) therapeutic proteins for use in the treatment of cancer or tumor diseases;(iv) therapeutic proteins for use in hormone replacement therapy;(v) therapeutic proteins for use in reprogramming somatic cells into pluri- or omnipotent stem cells; (vi) therapeutic proteins for use as adjuvant or immunostimulation;(vii) therapeutic proteins being a therapeutic antibody;(viii) therapeutic proteins being a gene editing agent; and(ix) therapeutic proteins for use in treating or preventing a liver disease selected from the group consisting of liver fibrosis, liver cirrhosis and liver cancer,preferably wherein the therapeutic protein of (b) is a therapeutic protein for use in the treatment of cancer or tumor diseases.

29. The lipid nanoparticle according to claim 28, wherein the mRNA encodes(i) at least one cancer or tumor antigen;(ii) at least one cancer or tumor epitope;(iii) at least one therapeutic protein for use in the treatment or prevention of cancer or tumor diseases; (iv) a multiepitope cancer vaccine, wherein the mRNA comprises an open reading frame encoding at least 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50, or more cancer antigen epitopes or neoepitopes expressed in the tumor in a subject in need; or(v) a personalized cancer vaccine (PCV), wherein the mRNA comprises an open reading frame encoding at least 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50, or more cancer antigen epitopes or neoepitopes expressed in the tumor in a subject in need.

30. The lipid nanoparticle according to any one of claims 21-29, for use in delivering a nucleic acid to splenic tissue or lymph-node tissue in a subject in need thereof, wherein the lipid nanoparticle composition is administered intramuscularly..

31. The lipid nanoparticle according to any one of claims 21-29, wherein(a) the artificial nucleic acid orthe mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in conventional type 1 dendritic cells (cDC1) as when compared to a reference lipid nanoparticle composition comprising SM-102 as ionizable lipid at 50 mol%, DSPC at 10 mol%, cholesterol at 38.5 mol%, and PEG-DMG at 1.5 mol%, at an N / P ratio of 6.;(b) the artificial nucleic acid orthe mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in macrophages as when compared to a reference lipid nanoparticle composition comprising SM-102 as ionizable lipid at 50 mol%, DSPC at 10 mol%, cholesterol at 38.5 mol%, and PEG-DMG at 1.5 mol%, at an N / P ratio of 6.;CureVac SE / P396WO1 8 / 15(c) the peptide or protein encoded by the mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in conventional type 1 dendritic cells (cDC1) as when compared to a reference lipid nanoparticle composition comprising SM-102 as ionizable lipid at 50 mol%, DSPC at 10 mol%, cholesterol at 38.5 mol%, and PEG-DMG at 1.5 mol%, at an N / P ratio of 6.; and / or(d) the peptide or protein encoded by the mRNA comprised in the lipid nanoparticle can be detected at an increased ratio in macrophages as when compared to a reference lipid nanoparticle composition comprising SM-102 as ionizable lipid at 50 mol%, DSPC at 10 mol%, cholesterol at 38.5 mol%, and PEG-DMG at 1.5 mol%, at an N / P ratio of 6.;after administration of the lipid nanoparticle to a subject in need, preferably after intramuscular administration.

32. The lipid nanoparticle according to any one of claims 26-31, wherein the (i) mRNA or (ii) the peptide or protein encoded by said mRNA can be detected with a ratio of at least about 5: 1, at least about 10: 1, at least about 20:1, at least about 30:1, at least about 40:1, at least about 50:1, at least about 60:1, at least about 70:1, at least about 80:1, at least about 90: 1, at least about 100:1, at least about 150:1, at least about 200: 1, at least about 250: 1, at least about 300:1, at least about 350:1, at least about 450:1, at least about 500:1, at least about 550:1, at least about 600:1, at least about 650:1, or at least about 700:1, or more in the spleen tissue versus the liver tissue when measured 4 hours post administration of the lipid nanoparticle to a subject in need, preferably after intramuscular administration,wherein the lipid nanoparticles comprise the mRNA at an amount such as to achieve an N / P ratio in the range from about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, or about 12, preferably in the range of about 7.

33. The lipid nanoparticle according to any one of claims 26-31, wherein the (i) mRNA or (ii) the peptide or protein encoded by said mRNA can be detected with a ratio of at least about 5: 1, at least about 10: 1, at least about 20:1, at least about 30:1, at least about 40:1, at least about 50:1, at least about 60:1, at least about 70:1, at least about 80:1, at least about 90: 1, at least about 100:1, at least about 150:1, at least about 200: 1, at least about 250: 1, at least about 300:1, at least about 350:1, at least about 450:1, at least about 500:1, at least about 550:1, at least about 600:1, at least about 650:1, or at least about 700:1, or more in the spleen tissue versus the liver tissue when measured 6 hours post administration of the lipid nanoparticle to a subject in need, preferably after intramuscular administration,wherein the lipid nanoparticles comprise the mRNA at an amount such as to achieve an N / P ratio in the range from about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, or about 12, preferably in the range of about 7.

34. The lipid nanoparticle according to any one of claims 26-31, wherein the (i) mRNA or (ii) the peptide or protein encoded by said mRNA can be detected with a ratio of at least about 5: 1, at least about 10: 1, at least about 20:1, at least about 30:1, at least about 40:1, at least about 50:1, at least about 60:1, at least about 70:1, at least about 80:1, at least about 90: 1, at least about 100:1, at least about 150:1, at least about 200: 1, at least about 250: 1, at least about 300:1, at least about 350:1, at least about 450:1, at least about 500:1, at least about 550:1, at least about 600:1, at least about 650:1, or at least about 700:1, or more in the spleen tissue versus the liver tissue when measured 24 hours post administration of the lipid nanoparticle to a subject in need, preferably after intramuscular administration,CureVac SE / P396WO1 9 / 15wherein the lipid nanoparticles comprise the mRNA at an amount such as to achieve an N / P ratio in the range from about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, or about 12, preferably in the range of about 7.

35. The lipid nanoparticle according to any one of claims 26-31 wherein the (i) mRNA or (ii) the peptide or protein encoded by said mRNA can be detected with a ratio of at least about 5: 1, at least about 10: 1, at least about 20:1, at least about 30:1, at least about 40:1, at least about 50:1, at least about 60:1, at least about 70:1, at least about 80:1, at least about 90: 1, at least about 100:1, at least about 150:1, at least about 200: 1, at least about 250: 1, at least about 300:1, at least about 350:1, at least about 450:1, at least about 500:1, at least about 550:1, at least about 600:1, at least about 650:1, or at least about 700:1, or more(a) in the draining lymph nodes tissue versus the liver tissue; and / or(b) in the muscle tissue of the injection site versus the liver tissuewhen measured 4 hours post administration of the lipid nanoparticle to a subject in need, preferably after intramuscular administration,wherein the lipid nanoparticles comprise the mRNA at an amount such as to achieve an N / P ratio in the range from about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, or about 12, preferably in the range of about 7.

36. The lipid nanoparticle according to any one of claims 26-31, wherein the (i) mRNA or (ii) the peptide or protein encoded by said mRNA can be detected with a ratio of at least about 5: 1, at least about 10: 1, at least about 20:1, at least about 30:1, at least about 40:1, at least about 50:1, at least about 60:1, at least about 70:1, at least about 80:1, at least about 90: 1, at least about 100:1, at least about 150:1, at least about 200: 1, at least about 250: 1, at least about 300:1, at least about 350:1, at least about 450:1, at least about 500:1, at least about 550:1, at least about 600:1, at least about 650:1, or at least about 700:1, or more(a) in the draining lymph nodes tissue versus the liver tissue; and / or(b) in the muscle tissue of the injection site versus the liver tissuewhen measured 6 hours post administration of the lipid nanoparticle to a subject in need, preferably after intramuscular administration,wherein the lipid nanoparticles comprise the mRNA at an amount such as to achieve an N / P ratio in the range from about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, or about 12, preferably in the range of about 7.

37. The lipid nanoparticle according to any one of claims 26-31, wherein the (i) mRNA or (ii) the peptide or protein encoded by said mRNA can be detected with a ratio of at least about 5: 1, at least about 10: 1, at least about 20:1, at least about 30:1, at least about 40:1, at least about 50:1, at least about 60:1, at least about 70:1, at least about 80:1, at least about 90: 1, at least about 100:1, at least about 150:1, at least about 200: 1, at least about 250: 1, at least about 300:1, at least about 350:1, at least about 450:1, at least about 500:1, at least about 550:1, at least about 600:1, at least about 650:1, or at least about 700:1, or more(a) in the draining lymph nodes tissue versus the liver tissue; and / or(b) in the muscle tissue of the injection site versus the liver tissuewhen measured 24 hours post administration of the lipid nanoparticle to a subject in need, preferably after intramuscular administration,CureVac SE / P396WO1 10 / 15wherein the lipid nanoparticles comprise the mRNA at an amount such as to achieve an N / P ratio in the range from about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, or about 12, preferably in the range of about 7.

38. A pharmaceutical composition comprising the ionizable lipid according to any one of claims 1-7, or one or more lipid nanoparticles according to any one of claims 8-37 and a pharmaceutically acceptable carrier, preferably for use in human medicine, more preferably for use in the prophylaxis or treatment of cancer, tumor or infectious diseases in a subject, most preferably for use in the prophylaxis or treatment of cancer or tumor diseases in a subject in need.

39. The pharmaceutical composition according to claim 38 or the lipid nanoparticle according to any one of claims 8-37 for use as a medicament in the prophylaxis or treatment of cancer or tumor diseases in a subject in need, wherein the medicament is a prophylactic vaccine or a therapeutic vaccine, preferably a prophylactic cancer vaccine, a therapeutic cancer vaccine, or a personalized cancer vaccine.

40. The pharmaceutical composition according to any one of claims 38-39, or the lipid nanoparticle according to any one of claims 8-37, for use as a medicament in the prophylaxis or treatment of cancer or tumor diseases in a subject in need, wherein the subject in need is a vertebrate, preferably a mammalian subject, more preferably a human subject.

41. A kit or kit of parts, comprising the pharmaceutical composition according to any one of claims 38-40, the ionizable lipid according to any one of claims 1-7, or the lipid nanoparticle according to any one of claims 8-37, optionally comprising a liquid vehicle for solubilizing, and, optionally, technical instructions providing information on administration and dosage of the components.

42. A method for preventing, ameliorating or treating a disease or condition in a subject in need, preferably a cancer or tumor disease, comprising administering to the subject in need (i) the ionizable lipid according to any one of claims 1-7, (ii) the lipid nanoparticle according to any one of claims 8-37, (iii) the pharmaceutical composition according to any one of claims 38-40, or (iv) the kit or kit of parts according to claim 41.

43. A method of reducing or inhibiting tumor growth in a subject in need, comprising administering to the subject in need (i) the ionizable lipid according to any one of claims 1-7, (ii) the lipid nanoparticle according to any one of claims 8-37, (iii) the pharmaceutical composition according to any one of claims 38-40, or (iv) the kit or kit of parts according to claim 41.

44. A method of inducing an antigen-specific immune response in a subject in need, the method comprising administering to the subject in need (i) the ionizable lipid according to any one of claims 1-7, (ii) the lipid nanoparticle according to any one of claims 8-37, (iii) the pharmaceutical composition according to any one of claims 38-40, or (iv) the kit or kit of parts according to claim 41, in a therapeutically effective amount to produce an antigen-specific immune response in the subject.

45. The method according to any one of claims 42-43, wherein (i) the ionizable lipid according to any one of claims 1-7, (ii) the lipid nanoparticle according to any one of claims 8-37, (iii) the pharmaceutical compositionCureVac SE / P396WO1 11 / 15according to any one of claims 38-40, or (iv) the kit or kit of parts according to claim 41 is administered to the subject in need in combination with one or more immunomodulatory agents.

46. The method according to any one of claims 42-44, wherein administration of (i) the ionizable lipid according to any one of claims 1-7, (ii) the lipid nanoparticle according to any one of claims 8-37, (iii) the pharmaceutical composition according to any one of claims 38-40, or (iv) the kit or kit of parts according to claim 41 to a subject in need results in expression of the peptide or protein encoded by mRNA in the spleen, draining lymph nodes tissue and / or muscle tissue of the injection site of the subject in need with a higher spleen, draining lymph nodes tissue and / or muscle tissue of the injection site to liver ratio.

47. The method according to any one of claims 42-46, wherein administration of (i) the ionizable lipid according to any one of claims 1-7, (ii) the lipid nanoparticle according to any one of claims 8-37, (iii) the pharmaceutical composition according to any one of claims 38-40, or (iv) the kit or kit of parts according to claim 41 to a subject in need results in expression of the peptide or protein encoded by mRNA in the spleen, draining lymph nodes tissue and / or muscle tissue of the injection site of the subject in need, wherein the (a) mRNA or (b) the peptide or protein encoded by said mRNA can be detected in the spleen, draining lymph nodes tissue and / or muscle tissue versus liver tissue with a ratio of at least about 5:1, at least about 10:1, at least about 20: 1, at least about 30:1, at least about 40:1, at least about 50:1, at least about 60:1, at least about 70:1, at least about 80:1, at least about 90:1, at least about 100:1, at least about 150:1, at least about 200:1, at least about 250:1, at least about 300:1, at least about 350:1, at least about 450:1, at least about 500:1, at least about 550:1, at least about 600:1, at least about 650:1, or at least about 700:1, or more when measured 4, 6, or 24 hours post administration of the lipid nanoparticle to the subject in need, preferably after intramuscular administration.

48. The method according to any one of claims 42-47, wherein administration of (i) the ionizable lipid according to any one of claims 1-7, (ii) the lipid nanoparticle according to any one of claims 8-37, (iii) the pharmaceutical composition according to any one of claims 38-40, or (iv) the kit or kit of parts according to claim 41 to a subject in need results in an antigen-specific immune response in the subject in need comprising at least one of1. a T cell response;2. a B cell response;3. a CD4 T cell immune response;4. a CD8 T cell immune response;5. an antigen specific antibody response, wherein the antigen specific antibody response is measured by the presence of antigen-specific antibodies in serum;6. an induction of interferon (IFN) production or modulation, preferably production or modulation of IFNa, I FNb, IFNe, IFNk or IFN, most preferably IFNa and / or IFNb; and / or7. an induction of cytokine production or modulation.

49. The method according to any one of claims 42-48, wherein administration of (i) the ionizable lipid according to any one of claims 1-7, (ii) the lipid nanoparticle according to any one of claims 8-37, (iii) the pharmaceutical composition according to any one of claims 38-40, or (iv) the kit or kit of parts according to claim 41 to a subject in need results in(a) the artificial nucleic acid or the mRNA comprised in the lipid nanoparticle being detected at an increased ratio in conventional type 1 dendritic cells (cDC1) as when compared to a reference lipid nanoparticleCureVac SE / P396WO1 12 / 15composition comprising SM-102 as ionizable lipid at 50 mol%, DSPC at 10 mol%, cholesterol at 38.5 mol%, and PEG-DMG at 1.5 mol%, at an N / P ratio of 6.;(b) the artificial nucleic acid or the mRNA comprised in the lipid nanoparticle being detected at an increased ratio in macrophages as when compared to a reference lipid nanoparticle composition comprising SM-102 as ionizable lipid at 50 mol%, DSPC at 10 mol%, cholesterol at 38.5 mol%, and PEG-DMG at 1.5 mol%, at an N / P ratio of 6.;(c) the peptide or protein encoded by the mRNA comprised in the lipid nanoparticle being detected at an increased ratio in conventional type 1 dendritic cells (cDC1) as when compared to a reference lipid nanoparticle composition comprising SM-102 as ionizable lipid at 50 mol%, DSPC at 10 mol%, cholesterol at 38.5 mol%, and PEG-DMG at 1.5 mol%, at an N / P ratio of 6.; and / or(d) the peptide or protein encoded by the mRNA comprised in the lipid nanoparticle being detected at an increased ratio in macrophages as when compared to a reference lipid nanoparticle composition comprising SM-102 as ionizable lipid at 50 mol%, DSPC at 10 mol%, cholesterol at 38.5 mol%, and PEG-DMG at 1.5 mol%, at an N / P ratio of 6.;preferably after intramuscular administration.

50. The method according to any one of claims 42-49, wherein the method comprises administering to a subject in need (i) the ionizable lipid according to any one of claims 1-7, (ii) the lipid nanoparticle according to any one of claims 8-37, (iii) the pharmaceutical composition according to any one of claims 38-40, or (iv) the kit or kit of parts according to claim 41 via subcutaneous, intravenous, intradermal, intramuscular, or intratumoral administration, preferably via intramuscular administration.

51. The ionizable lipid according to any one of claims 1-7, the lipid nanoparticle according to any one of claims 8-37, the pharmaceutical composition according to any one of claims 38-40, or the kit or kit of parts according to claim 41 for use as medicament and / or for use in the prevention or treatment of a cancer disease.

52. A method of synthesizing CIL86 according to scheme 1CureVac SE / P396WO1 13 / 15(scheme 1);or according to working example 2.

53. The lipid nanoparticle according to any one of claims 8-37, wherein the lipid nanoparticle is in frozen form and wherein the lipid nanoparticle after thawing has a lower PDI and / or lower size as compared to a reference lipid nanoparticle comprising a PEG-lipid instead of a polymer conjugated lipid of the invention after freezing and thawing.

54. The lipid nanoparticle according to claim 53, wherein the lipid nanoparticle has an increase in mean size of about 30%, 29%, 28%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less, preferably of about 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less after thawing as compared to that prior thawing.

55. The lipid nanoparticle according to any one of claims 8-37, wherein the lipid nanoparticle is in lyophilized form and wherein the lipid nanoparticle after reconstitution has a lower PDI and / or lower size as compared to a reference lipid nanoparticle comprising a PEG-lipid instead of a polymer conjugated lipid of the invention after lyophilization and reconstitution.

56. The lipid nanoparticle according to claim 55, wherein the lipid nanoparticle has an increase in mean size of about 30%, 29%, 28%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%,CureVac SE / P396WO1 14 / 1511%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less, preferably of about 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less after reconstitution as compared to that prior lyophilization.

57. A method of freezing the lipid nanoparticle according to any one of claims 8-37, wherein the lipid nanoparticle after thawing has a lower PDI and / or lower size as compared to a reference lipid nanoparticle as shown in Table 2 or Table 3 of the specification, preferably comprising a PEG-lipid instead of a PMOZ-lipid.

58. A method of lyophilizing the lipid nanoparticle according to any one of claims 8-37, wherein the lipid nanoparticle after lyophilization and reconstitution has a lower PDI and / or lower size as compared to a reference lipid nanoparticle as shown in Table 2 or Table 3 of the specification, preferably comprising a PEG-lipid instead of a PMOZ-lipid.

59. A method of producing a lipid nanoparticle, comprising:providing a mixture comprising the ionizable lipid according to any one of claims 1-7, at least one helper lipid, and optionally one or more additional excipients, combining said mixture with an aqueous phase comprising a nucleic acid, forming lipid nanoparticles encapsulating said nucleic acid; wherein the nucleic acid is selected from the group consisting of chemically modified or unmodified mRNA, single-stranded or double-stranded RNA, siRNA, RNAi, guide RNA (gRNA), coding or non-coding RNA, IncRNA (long non-coding RNA), self-replicating RNAs / samRNA / saRNA (self-amplifying RNA; SAM vaccines), viral RNA, replicon RNA, DNA, DNA vectors and circular RNA, preferably the nucleic acid is chemically modified or unmodified mRNA.

60. Use of the ionizable lipid according to any one of claims 1-7 in the production of a lipid nanoparticle formulation comprising encapsulating a nucleic acid selected from the group consisting of chemically modified or unmodified mRNA, single-stranded or double-stranded RNA, siRNA, RNAi, guide RNA (gRNA), coding or non-coding RNA, IncRNA (long non-coding RNA), self-replicating RNAs / samRNA / saRNA (self-amplifying RNA; SAM vaccines), viral RNA, replicon RNA, DNA, DNA vectors and circular RNA, preferably the nucleic acid is chemically modified or unmodified mRNA.

61. The ionizable lipid according to any one of claims 1-6, wherein each arm extending from the 3- and 5-positions of the piperidine ring to R2 and R3, respectively, comprises two ester bonds, wherein the first ester bond is provided by Y1 or Y2, and the second ester bond is provided by Y3 or Y4, such that each arm is a bis-ester arm comprising a dicarboxylic acid diester moiety.

62. The ionizable lipid according to any one of claims 1-6, wherein Y1 and Y3 together, and Y2 and Y4 together, each form a succinate diester moiety of the general structure –O–C(O)–CH2–CH2–C(O)–O– within each arm, providing the ionizable lipid with two bis-succinate ester arms extending from the 3- and 5-positions of the piperidine ring, preferably wherein the ionizable lipid is CIL86.

63. The ionizable lipid according to any one of claims 1-6, wherein Y1 and Y3 together, and Y2 and Y4 together, each form a glutarate diester moiety of the general structure –O–C(O)–CH2–CH2–CH2–C(O)–O– within each arm, providing the ionizable lipid with two bis-glutarate ester arms extending from the 3- and 5-positions of the piperidine ring, preferably wherein the ionizable lipid is CIL114.

64. The ionizable lipid according to any one of claims 1-6, wherein the ionizable lipid comprises a piperidine ring bearing an ionizable nitrogen, and wherein each of the two alkyl / alkylene arms at the 3- and 5-ring positions of theCureVac SE / P396WO1 15 / 15piperidine comprises exactly two ester-containing linker groups (Y1 / Y2 and Y3 / Y4), thereby providing a bis-ester arm per ring position, wherein said ionizable lipid is structurally distinguished from ionizable lipids comprising a piperidine ring in which each arm at the ring positions contains only a single carboxylate or ester group.

65. An ionizable lipid comprising:(a) a piperidine ring bearing an ionizable tertiary amine nitrogen;(b) a hydroxyalkyl group (R1–X1) at the piperidine nitrogen, wherein R1 is –OH and X1 is an alkanediyl having 1 to 8 carbon atoms;(c) two alkanediyl spacer groups X2 and X3 extending from the 3- and 5-positions of the piperidine ring, each independently having 1 to 8 carbon atoms; and(d) in each arm from the piperidine ring to the lipid tail group: a first ester-containing linker Y1 or Y2, followed by a second ester-containing linker Y3 or Y4, followed by a branched saturated or unsaturated C6–C24 alkyl or alkenyl lipid tail R2 or R3;wherein the two ester-containing linkers per arm together form a dicarboxylic acid diester moiety within each arm.